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Abstract 
Vaccination has significantly reduced the rates of mortality and morbidity however the 
adjuvants used in modern vaccines preferentially prime the immune response towards specific 
outcomes that may be disadvantageous. The adjuvant efficiency of the well-established 
cationic liposomal formulation dimethyldioctadecylammonium-salt (DDA) and trehalose-D-(+)-
dibehenate (TDB) with and without encapsulated N-acetyl cysteine (NAC) is explored. The 
antioxidant NAC reduces disulphide bonds and is a precursor of glutathione. This can be used 
to influence the immune response by countering reactive oxygen species (ROS) that are key 
for both innate and adaptive immune responses.  
Dendritic cells (DCs) are specialised antigen-presenting cells (APCs) and are one of the first 
involved in humoral immunity. Herein, a representative mouse bone marrow derived DC model 
for testing the effects of ROS modulators and antigens with DDA:TDB or DDA:TDB-NAC was 
examined. DDA:TDB-NAC with the test antigen ovalbumin was less toxic and increased 
cellular pH and activation markers compared to the DDA:TDB formulation. No difference in 
titre of IgG antibodies to OVA was observed between the two formulations in vivo. 
NADPH oxidase 2 (NOX2) generates ROS in phagosomes alkalinizing the lumen and altering 
the activity of proteolytic processing enzymes cathepsins. This changes the degree of antigen 
processing and potentially immune response. In this study NOX2 deficient DCs did not mature 
as effectively, possibly due to reduced uptake and changes in pH. DDA:TDB adjuvant 
formulations were examined using di-sulphide crosslinked collagen II as an antigen to improve 
a rheumatoid arthritis model. They were more effective than Freund’s regarding cytokine 
release and IgG1 production however arthritic severity scoring was decreased.  
Due to its nature the production of antibodies against lipoarabinomannan from tuberculosis is 
challenging. The possibility of DDA:TDB-Lipoarabinomannan nanoparticles were evaluated 
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and successful binding of LAM to the surface of DDA:TDB was demonstrated along with 
preferential uptake by DCs. 
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ROS Reactive oxygen species 
RSH Reduced form thiols 
RSSR Oxidized form thiols 
SEM Standard error of mean  
SLAMF1 Signalling lymphocytic activation molecule family member 1 
SSC Side scatter  
STAT1 Signal transducer and activator of transcription 1 
STAT4 Signal transducer and activator of transcription 4 
STAT6 Signal transducer and activator of transcription 6 
SUVs Small unilamellar vesicles  
TB Tuberculosis 
TCR T cell receptor 
TDB Trehalose d-(+)-dibehenate 
TDM Trehalose 6,6’-dimycolate 
TGF- β Transforming growth factor-beta  
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Th 1 Helper t cells 1 
Th 2 Helper t cells 2 
Th 17 Helper t cells 17 
TLR Toll-like receptors  
TNF Tumour necrosis factor 
Trx Thioredoxin 
WHO World health organisation  
WT Wild type 
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Executive Summary 
Improving human vaccines  
Although vaccinations have proven to be the most effective method of maintaining public 
health much work still needs to be done to effectively deliver vaccines to those most in need. 
This has been demonstrated of late with vaccinatable diseases such as measles and polio 
making a global comeback. Some groups within these populations such as the elderly and 
the immunosuppressed are also particularly susceptible to disease, have longer-lasting 
effects and unfortunately respond relatively poorly to vaccination.  
Most modern vaccines are subunit based and have excellent safety profiles but suffer from 
reduced immunogenicity relative to live vaccines, this is particularly pronounced in 
susceptible groups. This problem is only likely to worsen in future as life expectancy is 
increasing globally, with the number of people over 60 predicted to double by 2050. 
Strategies to improve vaccination in these groups have included higher antigen dose, 
alternative routes of administration, and the use of adjuvants. The development of more 
effective adjuvants is of interest due to the relatively small number approved for use in 
humans and the reduced scope of immune responses they illicit. Approval of adjuvants is 
challenging due to the necessarily strict guidelines for approval in humans and a poor 
understanding of the exact modes of action of current adjuvants. New adjuvants have the 
potential to improve vaccination responses especially in groups that would ordinarily respond 
poorly. However, these new adjuvants must not only prove their efficiency at eliciting a 
strong long-lasting immune response but also low toxicity, that they are upscalable and are 
compatible with a range of antigens. 
Improving animal models of immune diseases 
Rheumatoid arthritis (RA) is a major cause of disability and is the most prevalent form of 
inflammatory arthritis. It primarily affects the joints of the hands and feet and symptoms 
include inflammation, oxidative stress, pain and bone erosion of the joints. It is estimated 
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that between 0.5 to 1.0% of the adult population worldwide is affected and this is only set to 
increase with progressively larger ageing populations. 
The causative reasons behind RA is believed to primarily stem from a loss of self-tolerance 
by the immune system however many questions remain unanswered. To further develop an 
understanding of this disease several mouse models have been developed, of which the 
collagen-induced RA model is the most prevalent. This method uses collagen in combination 
with a potent adjuvant in order to develop an immune response to the animal’s own collagen 
resulting in RA like symptoms. The development of better adjuvants to help bring about RA 
symptoms could lead to a better understanding of the disease and future treatments. 
Production of antibodies for use in clinical testing 
Tuberculosis (TB) is estimated to have been responsible for 1.6 million deaths in 2017 
making it one of the top ten causes of death worldwide. The number of cases continues to 
grow with 10 million new cases being reported that year. It is estimated 1.7 billion people 
globally may have a latent TB infection and could consequently develop TB later in life. An 
exact number is difficult to determine however as tuberculosis is challenging to monitor and 
improved point of care tests are needed particularly in developing countries where the 
disease is more prevalent.  
The World Health Organization has promoted the development of high sensitivity, low cost, 
point of care testing methods for the detection of TB specific markers. Lipoarabinomannan 
(LAM) which is a glycoprotein derived from the cell wall of Mtb is of interest as it is present in 
the urine and thus easily and safely accessible. Due to the requirements of this assay, 
antibodies are used for detection, however, existing anti-LAM antibodies lack high avidity 
and so current urine-based LAM testing kits lack the sensitivity required for effective 
diagnosis. The use of better more appropriate adjuvants in combination with LAM could be 
used to develop novel antibodies with the potential for higher affinity which is necessary for 
future point of care testing kits.  
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Chapter 1: Introduction 
1.1 Immunity and inflammation 
The immune system can be broadly separated into innate and adaptive arms. These two 
systems work in conjunction with the development of an effective immune response to 
eradicate harmful stimuli (1). Stimuli from invading pathogens may include pathogen-
associated molecular pattern (PAMPs), lipopolysaccharides (LPS) and endotoxin e.g LPS. 
The interaction of these stimuli with the host results in an immune response designed to 
counter the pathogen and clear it from the hosts’ system. This often involves inflammation 
which is associated with pain, heat, swelling and redness which can result in loss of function 
of the inflamed tissue. This is orchestrated by cells of the immune system in combination with 
a complex system of signalling and regulatory mediators produced by the host and pathogen 
(1).  
1.2 The innate immune response  
The innate immune response functions as the first response of the host to foreign materials 
such as pathogens. It is made up of a range of cells including natural killer (NK) cells, 
macrophages, dendritic cells (DCs), neutrophils, basophils and eosinophils. Neutrophils are 
recruited within minutes along chemotactic gradients e.g. of leukotrienes. Upon contact and 
uptake of pathogens by phagocytosis, cells such as neutrophils begin to produce reactive 
oxygen species (ROS) and release soluble signalling molecules, cytokines and chemokines, 
which in turn activate signalling pathways and recruit more cells to the site of inflammation (2).  
Common cytokines and chemokines found at inflammatory sites include tumour necrosis 
factor- α (TNF-α), interleukins- IL-1β, IL-4, IL-6, IL-10, IL- 12, IL-18 and interferon- ɣ (IFN-ɣ) 
(2).  
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1.3 The adaptive immune response  
The adaptive immune response is different from the innate immune response in that it is more 
targeted and prolonged than the more non-specific innate response, appearing several days 
after the first challenge. The recruitment and presentation of antigen by antigen-presenting 
cells (APCs) such as DCs and macrophages are vital in initiating the cell-mediated immune 
response by T cells (1). Some APCs are resident in tissues, and many are recruited to the site 
of inflammation after neutrophil activation. APCs phagocytose foreign materials and present 
peptides on their surface via the major histocompatibility complexes (MHC). The T cell 
receptor (TCR) is then able to interact with the peptide from the APCs in an antigen-specific 
manner. This triggers the differentiation of naive into effector T cells. The effector T cell is then 
able to deliver the antigen along with other activation signals to B cells leading to their 
maturation to plasma cells and production of antibodies. Antibodies opsonise pathogen and 
target it for destruction by innate immune cells through immune complex uptake via the 
fragment crystallizable (Fc) receptors (1,3).  
Once the pathogen is cleared the majority of T and B cells are removed through apoptosis 
however a minority differentiate into memory cells. If these cells are then subsequently 
exposed to the antigen again, they are able to produce a rapid and robust immune response 
(1,3). 
1.4 Reactive oxygen species 
ROS encompass a group of chemically reactive molecules able to modify biomolecules 
reversibly and irreversibly. Excess ROS are traditionally associated with oxidative stress and 
damage such as DNA-protein crosslinks, peroxidation of lipids, proteins dysfunction through 
amino acid modification (4–7). 
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Since the original characterisation of ROS as mediators of oxidative stress, ROS have been 
demonstrated to play a critical role in immunity both directly in the respiratory burst and 
through signalling by modulating APC, T cell and B cell response (8–10). ROS have been 
demonstrated to be important in intracellular signalling pathways, cell cycle regulation and 
inflammation (11–14). The immune cells primarily produce ROS from mitochondrial, 
peroxisomal and various nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 
(NOX) complexes. The first radical to be formed is the superoxide anion. Hydrogen peroxide 
(H2O2) is formed from the dismutation of superoxide anion, is the most stable and can be 
metabolised to form hypochlorous acid and hydroxyl radical which are also important reactive 
species involved in inflammation (15,16). H2O2 is reactive with protein thiol (-SH) groups in a 
reversible manner (see Figure 1.1). 
 
Figure 1.1: The roles of NADPH generated by the pentose phosphate pathway (PPP) on thiol-
dependent redox systems. Glucose is oxidised producing NADPH which is then available for oxidation 
forming NADP+. This reaction provides the reduction necessary for the regeneration of glutathione 
(GSH) and Thioredoxin (Trx). Disulfides in oxidized Trxs and GSH oxidise NADPH and are transformed 
into thiols by TrxR and GR. NADPH establishes the pathways necessary for the production of other 
ROS reducing molecules such as Peroxiredoxin (Prx) and glutaredoxin (Grx) and the removal of 
oxidising molecules such as glutathionylated protein (RSSG) and protein sulphenate (RSOH). This 
ultimately culminates in the protection from excess ROS. 
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1.5 Nicotinamide adenine dinucleotide 
phosphate oxidase 2 
The NOX complex has a large influence on the cellular redox state and exists in a variety of 
forms that affect function. Pathogens often cause the activation of the NADPH oxidase in host 
innate immune cells that produce ROS to counter pathogen growth. However, this can be 
damaging to surrounding cells (e.g. after time, and damaged cells will become inactive and 
go through apoptosis) (17–24). Infected tissues are often oxidising environments, so T cells 
upregulate thiol production as a countermeasure to escape ROS induced inactivation (17,25–
28). This upregulation may be triggered by antigen presented DCs during antigen presentation 
which causes antigen-specific T cell survival and allows them to escape apoptosis (17,29,30). 
In murine models, it has been shown that ROS production is linked to the number of reduced 
surface thiols on T cells. Increased numbers of reduced surface thiols cause increased 
proliferation and lowering the activation threshold which could play a role in autoimmunity (31). 
For example, NOX2-derived ROS have been shown to inhibit antigen-dependent T cell 
reactivity reducing arthritic symptoms in animal models (32). 
Phagocytes like DCs primarily express NOX2 which is responsible for amongst other things 
the respiratory burst. Like other NOX complexes, it is composed of subunits both intracellularly 
and in the membrane. gp91phox which is the catalytic element, located in the membrane 
dimerises with p22phox to form the flavocytochrome b558 complex. Once activated, Ncf1 is 
phosphorylated changing its conformation, allowing it to translocate to the membrane with 
(p47phox), Ncf2 (p67phox) and Ncf4 the cytosolic components where it binds to the p22phox 
(15,33,34). In the absence of Ncf1 (p47phox) as is the case in some knockout (KO) strains of 
mice such as C57BLK6 Ncf1-/-, the NOX2 complex is no longer functional causing drastically 
reduced ROS upon phagocyte activation (see Figure 1.2) (31,35). 
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Figure 1.2: NOX2 activation in wild type and Ncf1-/-. NOX2 is made up of p47phox, p67 phox, p40 phox 
and Rac in the cytosolic compartment and gp91 phox bound to p22 phox in the membrane. Once activated 
of Ncf1 becomes phosphorylated changing its conformation, causing it to translocate to the membrane 
and bind GP91phox where it allows for the production of superoxide anion (O2–.). In the Ncf1-/- knockout, 
the cytosolic components are no longer able to translocate and so NOX2 is not functional. 
  
Page 26 of 212 
 
 
1.6 Dendritic cells  
DCs are a type of phagocyte that constantly sample their environment whilst traveling through 
the periphery. Phagocytosis of pathogenic materials by DCs is the first step on the path to 
adaptive immunity due to their specialisation in antigen presentation, as they constitutively 
express CD80. Macrophages and neutrophils also use phagocytosis as part of the innate 
immune response to immediately counter pathogens and are principally involved in killing. 
Pattern recognition receptors (PRRs) such as CD14 and Toll-like receptors (TLR), on the cell 
surface, recognise a range of PAMP ligands and upon recognition, the DC begins to mature. 
In the periphery DCs show relatively poor antigen presentation capabilities but upon 
recognition of CCL19 and CCL21 produced by lymph tissue and upregulation of CCR7, they 
migrate to the lymph node and MHC-II upregulation occurs enhancing antigen presentation. 
(8,36). APCs have developed ROS production through the NADPH oxidase NOX2, as an 
antimicrobial mechanism in a process called the respiratory burst which is critical for their 
function (8,37). DCs also produce ROS in response to pathogen uptake however they focus 
on antigen presentation and activation of naïve T cells (8). 
1.7 The role of reactive oxygen species in 
antigen processing by dendritic cells 
NOX2 once recruited to phagosomes for antigen processing produces the superoxide anion 
radical and protons in the reaction NADPH + 2O2 ↔ NADP+ + 2O2−. + H+. The production of 
ROS resulted in consumption of protons in the lumen and their translocation from the cytosol 
by proton permeable channels such as V-ATPase causing sustained alkalinisation of the 
phagosomal lumen (38). In DC models lacking NOX2, this cannot take place and so the lumen 
becomes acidified causing increased antigen degradation resulting in impaired processing 
and cross-presentation (38–40). ROS such as superoxide (and hydrogen peroxide) only 
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interact with molecules in the immediate vicinity of where it is produced as it is extremely 
unstable within the cellular environment with a half-life of milliseconds (41). NOX2 localisation 
to the phagosome ensures a high ROS environment to kill the engulfed pathogen. This has 
the potential to alter the functions of proteins by changing functional groups on proteins like 
hydroxyls and carbonyls or by adding oxygen as well as change protein turnover, cause 
fragmentation, unfolding and crosslinking. These changes may also then influence antigen 
processing, cross-presentation and the immune response (41–44). 
1.8 Antigen presenting cell-T cell interaction 
At the immunological synapse, the interaction between APCs and naive T cells is a critical 
starting point for the humoral immune response. This interaction depends on APC and T cells 
interacting through MHCs and TCR respectively along with several other co-stimulatory 
molecules and chemical mediators expressed by APCs. This interaction helps to define the T 
cell subset that will differentiate as a result (45,46). On the surface of APCs CD80 and CD86 
receptors are expressed. These interact with either CD28 or CTLA4 on naïve T cell triggering 
proliferation and survival (Figure 1.3). The absence of these signals causes peripheral 
tolerance and anergy of the T cell causing it to become incapable of responding to self and 
non-self-antigen. Chemical mediators like IFNα, IL-2, 4, 5 and 12 released by the APC and 
the T cells themselves cause the naive T cell to differentiate into effector cells (47).  
The lymph nodes are spread throughout the body to increase the potential of antigen 
introduction to T cells and are structured in such a way as to maximise the chances of 
pathogen antigen presentation by APCs to T cells. The lymph introduces APCs to areas of 
densely populated with T cells in the paracortex. T cells then mature to effector T cells and 
migrate to the follicle rich cortex area to interact with B cells. Primary follicles then form 
secondary follicles which are made up of germinal centres in which memory T and B cells can 
form. Other areas of the lymph node-like the medulla are rich in plasma cells for antibody 
production (48,49).  
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Figure 1.3: The innate to adaptive immune response. APC are recruited to the site of infection as 
first responders where they phagocytose foreign antigens. Upon activation the secrete chemokines to 
recruit immune cells to the site of infection induces CD4+ or CD8+ T cells. CD4+ T cells then 
differentiate into Th1 or Th2 T cells and interact with B cells which subsequently produce antibodies 
against the pathogenic antigen in the humoral response. Antigen uptake by B cells is mediated by the 
association of the B cell receptor (BCR), a surface-bound membrane IgM antibody (mIgM). 
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1.9 T cell differentiation 
APC-secreted IL-12 is the driving factor behind the Th1 differentiation of CD4+ T cells and 
triggers natural killer cells (NK) cells to release IFNɣ, suppressin Th2 differentiation. Th1 cells 
are primarily involved in the cell-mediated immune response and secrete IL-2, LT-α, and 
IFN-γ. This is dependent on STAT1, STAT4 and T-bet transcription factors which are 
activated by IL-12 and IFNɣ (50). 
Th2 differentiation is primarily dependent on IL-4 and IL-2 secretion, through STAT6 which 
increases GATA3, c-MAF and NFATp expression. IL-4 also serves to regulate transcription 
factors suppressing Th1 differentiation. Through the secretion of B cell growth factors, T helper 
(Th2) cells drive the humoral response (51,52). IL-6 has also been shown to cause NFAT 
upregulation in CD4+ T cells causing the release of additional IL-4 and Th2 differentiation/ Th1 
suppression (53). 
TGF- β, IL-6, IL-21 and IL-23 cytokines result in the transcription of the RAR-related orphan 
nuclear receptor RORɣt which produces IL-17. This culminates in differentiation into Th17 
which is used in response to bacterial infections as well as being associated with rheumatoid 
arthritis (RA) and other autoimmune disorders (5). Th2 and Th17 cells can mediate B cell 
activation.  
RA induced chronic inflammation is associated with the accumulation of inflammatory cells in 
the synovial membrane, oxidative stress, pain and bone erosion of the joints. This is often due 
to the loss of self-tolerance; T cells that recognise self-antigens are not eliminated during 
selection. DCs, macrophages, monocytes, T cells and synovial-like fibroblasts are activated 
and, interleukins and other pro-inflammatory cytokines are released along with the production 
of ROS and RNS (54–56). 
Establishing models to study RA is necessary in order to better understand the disease and 
develop new treatments. For this, the collagen-induced arthritis mouse model is one of the 
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most commonly used. Type II collagen makes up the majority of collagen in cartilage is used 
in combination with Freund's adjuvant to stimulate immunogenicity in this model resulting in 
clinical symptoms within 2-3 weeks (57–59). Collagen-induced arthritis is primarily a T cell-
driven, receptor-independent disease. Activation of T cells requires glycosylated type II 
collagen to be presented by APCs (60). Anti-collagen type II antibodies are detectable a few 
weeks after immunisation and have been shown to induce arthritis in non-immunised mice 
(61,62). 
 
1.10 Reactive oxygen species in B cell 
development 
B cells, once activated, go through changes in gene and protein expression necessary for 
immunoglobulin (Ig) maturation in plasma cells. This involves upregulation of cell metabolism 
and an increase in antioxidant systems for intracellular signalling and to defend against 
oxidative stress (49,63–66). Lymph nodes involved in an immune response show an increase 
in the production of non-protein thiols. Monocytes, DCs and activated B cells have been 
demonstrated to produce low molecular weight thiols (29,49,67). 
The interplay between ROS and antioxidant systems serve an important role in signalling 
(66,68). In B cells, thioredoxin (Trx) an oxidoreductase controls the transcription factor Pax 5 
(67,69). A cycle of early oxidation by ROS and reduction by Trx-related antioxidant proteins is 
evident in B lymphocytes and is necessary for T-cell activation and DC antigen presentation 
(29,63). B cell activation, differentiation and IgM secretion are dependent on ROS production 
with H2O2 acting as a second messenger for the initiation and increase of signalling following 
BCR activation (63,70). The antioxidant response to the oxidative burst that occurs upon 
activation is necessary for B cell activation and initial survival. However, IgM secretion later in 
cell development favours a more reducing microenvironment in order to take advantage of the 
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exocytic pathway (63,71,72). In vivo it has been suggested that ROS from mature B cells 
(possibly derived from NADPH oxidase, mitochondria or cytochrome P450s) may be blocked 
in the spleen and lymph by antioxidant enzymes such as Trx reductase from the red pulp 
macrophage which serves to segregate the immature B cells from oxidative stress (63). 
1.11 Reductase enzymes, thiols and N-acetyl 
cysteine 
The intracellular redox state is regulated by a series of interconnected enzymes including Trx 
reductase and the low molecular weight tripeptide, GSH (see Figure 1.1). GSH synthesis is 
catalysed in a series of two reactions linking glutamate-cysteine and glycine. The glutamyl 
cysteine synthetase step is the slowest. N-acetyl cysteine (NAC) is a low molecular mass 
molecule and is the acetylated precursor of the amino acid L-cysteine and precursor of the 
antioxidant GSH (Figure 1.4). NAC can be rapidly hydrolysed within cells to form cysteine 
which is a limiting factor in GSH production by γ-glutamyl-cysteine synthetase. NAC itself is 
an antioxidant with the acetyl group attached to a nitrogen atom allowing it to be oxidized by 
a range of radicals serving as an electron-pair donor. NAC is able to change some protein 
structures and inhibit ligand binding by reducing disulphide bonds. Because of its small size, 
NAC is able to compete with larger antioxidants in sterically less accessible areas. The thiol 
and carboxyl groups allow NAC to bind transition metal ions at two coordination sites allowing 
it to act a chelating agent (73).  
NAC has been used clinically for decades for a range of conditions and purposes including to 
modulate ROS and prevent oxidative modification or damage (74,75). It is Food and Drug 
Administration approved. 
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Figure 1.4: Structure of NAC and its medical uses. A) NAC has the linear formula 
HSCH2CH(NHCOCH3) CO2H and a molecular weight of 163.19. B) Due to its range of activities from 
metal chelation to reducing disulphide bonds to break up mucus and antioxidant activities NAC has 
been used in the treatment of a variety of medical treatments.  
1.12 Vaccination 
With regards to the immune response to vaccination, there is a great deal of overlap between 
immunisation by vaccination and infection with a pathogen. In both circumstances, the immune 
system will attempt to produce an effective immune response that will ultimately clear the 
immunogen and result in immune memory to it. They differ in that pathogen exposure is most 
often unwanted and pathogens compete with the host for resources in order to propagate 
themselves and so rapid clearance is desirable. Vaccinations are not given with the intention 
to compete, instead, they exist to drive host immunity to the pathogen they are targeted 
against without causing the disease itself. The host's immune response may be unable to 
distinguish an antigen and so measures must be taken to ensure that the antigen is first 
recognised as a threat by the immune system and secondly that the immune system has time 
to mount sufficient response as to cause immune memory to form.  
Diseases treated in part with NAC
Acetaminophen (paracetamol) intoxication
Acute respiratory distress syndrome
Bronchitis
Chemotherapy-induced toxicity
Doxorubicin-induced cardiotoxicity
Heavy metal toxicity
HIV/AIDS
Ischemia–reperfusion cardiac injury
Psychiatric disorders
Radio-contrast-induced nephropathy
Stable angina pectoris
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1.13 Vaccine origins 
The first records of smallpox date back to 1122 BC in China, however, it is a disease that was 
found around the globe until it was finally eradicated completely in 1980 due to a massive 
global vaccination campaign. Smallpox is a highly infectious disease and spreads quickly with 
those who do not die becoming disfigured and/or blind. Although Edward Jenner is credited 
as the father of vaccination the concept of “inoculation” had existed in different forms for 
hundreds of years. This involved transferring pus from the infected to the skin of those not 
infected with the hopes of inducing what is now known as immunity. Edward Jenner was born 
in 1749 in Gloucestershire, UK and is credited as the father of vaccination. As a child, he 
himself was inoculated against smallpox using the method described above. During his time 
as a General Practitioner (GP), he became aware of a belief held by dairymaids that if they 
became infected with cowpox were immune to smallpox. He subsequently tested this idea by 
transferring infectious material from lesions of a dairymaid suffering from cowpox to a young 
boy and then exposing him to smallpox two months later. This was the beginning of what is 
now recognised as vaccination (76).  
1.14 Why vaccination is important 
Immunisation using vaccination is considered the most effective public health invention ever 
created and has inarguably reduced the rates of morbidity and mortality for over 200 years 
(77,78). Currently, the World Health Organisation (WHO) delivers vaccines against twenty-
five diseases that cause life-threatening disease with twenty-four under development. It aims 
to make vaccinations available for everyone worldwide by 2030. As of 2017, the number of 
children immunized was the highest ever reported at 116.2 million with 113 countries adding 
new vaccinations to their health regimes. This has led to twenty million more children being 
vaccinated worldwide with immunization programmes now reaching over 80 percent of 
children before their first birthday (79,80). 
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Despite these positive figures from the WHO, 20 million children worldwide still miss out on 
potentially life-saving vaccinations. With diseases like yellow fever only being vaccinated for 
in less than half the countries where there is a risk of developing the disease. Since 1980 there 
has been an upward trend in vaccine converge however in some cases this has only increased 
by as little as 5% in the last decade and in some cases has completely plateaued. More 
alarmingly cases of vaccinatable diseases such as diphtheria, measles, polio, rubella, tetanus 
and yellow fever have all increased globally between 2017 and 2018 (79,80). This highlights 
the need for better coverage and the development of newer, cheaper more effective vaccines.  
Disease control on a population-wide scale is dependent on long-lasting mass protective 
immunity, also known as herd immunity. This is best achieved by taking advantage of adaptive 
immunity with vaccinations inducing what is termed herd immunity in a population (81). 
Vaccines have the potential to eradicate many diseases such as polio, measles and tetanus 
as it did with smallpox previously. However, the WHOs crusade to eradicate such diseases is 
often set back by outside measures such as political instabilities causing poor vaccination 
campaigns and reduced coverage (81).  
Adaptive immunity is dependent on the upkeep of antigen-specific immune effectors and the 
induction of immune memory cells that are able to quickly reactivate into effectors upon 
recognition of a previously exposed specific pathogen (78,82). Preventing through vaccination 
rather than treating the symptoms has proven the most cost-effective method for dealing with 
disease and is now standard in many national health programs. This knowledge has led to the 
further development of new vaccinations and which contributed to the vaccine market being 
estimated to be worth $24 billion (78,82). 
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• Cholera 
• Dengue 
• Diphtheria 
• Hepatitis A 
• Hepatitis B 
• Hepatitis E 
• Haemophilus influenza type b 
(Hib) 
• Human papillomavirus (HPV) 
• Influenza 
• Japanese 
encephalitis 
• Malaria 
• Measles 
• Meningococcal 
meningitis 
• Mumps 
• Pertussis 
• Pneumococcal 
disease 
• Poliomyelitis 
 
 
• Rabies 
• Rotavirus 
• Rubella 
• Tetanus 
• Tick-borne encephalitis 
• Tuberculosis 
• Typhoid 
• Varicella 
• Yellow Fever 
• Campylobacter jejuni 
• Chagas Disease 
• Chikungunya 
• Dengue 
• Enterotoxigenic Escherichia 
coli 
• Enterovirus 71 (EV71) 
• Group B Streptococcus 
(GBS) 
• Herpes Simplex Virus 
• HIV-1 
• Human Hookworm 
Disease 
• Leishmaniasis 
Disease 
• Malaria 
• Nipah Virus 
• Nontyphoidal 
Salmonella Disease 
• Norovirus 
• Paratyphoid fever 
• Respiratory Syncytial Virus 
(RSV) 
• Schistosomiasis Disease 
• Shigella 
• Staphylococcus aureus 
• Streptococcus pneumonia 
• Streptococcus pyrogens 
• Tuberculosis 
• Universal Influenza Vaccine 
 
Table 1.1: Vaccines available or from the WHO or under development. A) Vaccines currently 
available from WHO B) Vaccines being developed and overseen by WHO’s Product Development for 
Vaccines Advisory Committee (PDVAC). Some vaccines such as Malaria and tuberculosis (Tb) have 
existing vaccines although better more effective vaccines are required to ultimately eradicate the 
disease. 
 
Table 1.2: The rise in the number of reported cases of disease with available vaccines as 
reported by the WHO in 2017 and 2018. A) The number of reported cases of diphtheria, measles, 
polio, rubella, tetanus and yellow fever in 2017 and 2018. B) A comparison of the increase of incidences 
of reported vaccinatable diseases between 2017 and 2018 shown as a normalised ratio to 2017 
numbers. 
B 
A 
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1.15 Vaccination and the immune system 
The immunity gained through vaccination can be T cell or antibody-mediated. Both responses 
require the vaccine antigens to be relocated to draining lymph nodes for immune cell 
activation. Most approved vaccines confer protection by antibody-based methods, these 
antibodies bind in an epitope-specific fashion to antigens native to the pathogen or toxin 
vaccinated against (82,83). Cytotoxic CD8+ T lymphocytes are another form of immune 
effector elicited by vaccination, these serve to kill infected cells or secrete antiviral cytokines 
and thus inhibit the spread of pathogens. TLRs control the “danger signal” which in turn 
activates the host immune response and are a requirement for differentiation and proliferation 
of B cells (84). C-type lectin receptors (CLR) are pathogen-associated receptors which 
regulate gene transcription to endocytosis and antimicrobial activity in response to pathogen 
recognition. Interactions between TLRs and CLRs may be present during antigen presentation 
and may affect the outcome; for example, it was shown that when foreign fungal antigen is 
presented to the CLR dectin, it suppressed LPS induced TLR innate immune system with high 
levels of interaction favouring a Th2 response and low levels of a Th1 response (85–88). The 
preferential selection of TLRs or CLRs and subsequent preferential could potentially be 
influenced with vaccine adjuvants. 
T cell activation is dependent on major histocompatibility complex (MHC) of which there are 
two major classes MHC I and MHC II; both present foreign antigens to the matching receptor 
on the T cell. MHC I uses either cytosolic or phagocytosed antigens to activate CD8+ T cells 
inducing a cytotoxic response (cross-presentation) and MHC II-peptide complexes are created 
intracellularly, expressed on the surface and activate CD4+ T cells (8,89–93). 
These vaccine-induced immune effectors are dependent on signals and growth factors from 
CD4+ Th cells. Th cells are described according to their cytokine secretion profile and exist in 
many subsets. The major subtypes are Th1 (cellular immunity) which aid in differentiation and 
activation for macrophages, B cells and CD8+ T cell and Th2 (humoral immunity) which assist 
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in B cell activation. The antibody response is sustained through the production of plasma cells 
in the germinal centres of lymphoid organs. Immune tolerance is regulated by Tregs and DCs 
to ensure that the immune system does not raise a response to a self-antigen. This can 
prevent autoimmune disease in the case of self-antigens and help to manage the immune 
system (94–96). The majority of vaccines cause both an antibody and a CD8+ T cell response. 
However, guiding an immune response towards a Th1 or Th2 response has shown beneficial 
in specific vaccination types such as tuberculosis and HIV (82,97). 
Although the majority of antibodies are produced by B cells via helper T cells as discussed 
above some are produced through direct B cell stimulation in what is known as thymus 
independent antibody production. This is characterised by the absence of immune memory 
and is an antigen specific response. These antigens can be divided into TI-1 and TI-2 with the 
former (e.g. LPS) activating B cells directly and the latter which causes simultaneous cross-
linking of mature B cell’s BCRs due to its repetitive nature e.g. capsular polysaccharides(98).  
The thymus independent antibodies produced are usually limited to low affinity IgM. This 
combined with the poor immune memory make this type of immune response for vaccinations 
unfavourable, particularly in those with reduced immune response. Therefore efforts are made 
to avoid this when developing vaccines(98).  
1.16 Types of vaccination  
Vaccines are traditionally separated into three groups based on the nature of the antigenic 
material used. Killed vaccines like the polio vaccine use heat or chemically killed/ inactivated 
organisms causing their genetic components to lose functionality. These organisms are no 
longer able to propagate or produce toxins but retain a structure similar to the living version 
allowing for immune recognition. Attenuated vaccines like the tuberculosis vaccine are altered 
physically or chemically to diminish growth capabilities or present less danger to the host. 
These types of vaccines are by far the most immunogenic however they are not suitable for 
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everyone. Those with less developed immune systems or those that are immune weakened 
like infants and the elderly are more likely to develop complications and so alternative 
vaccination strategies are necessary (99).  
Subunit vaccines like influenza are made up of the antigenic unit of the pathogen being 
immunised against. This renders them incapable of reverting to a pathogenic form and 
significantly decreases toxicity whilst allowing for the targeting of a specific antigen. However, 
the absence of other biomolecules that would ordinarily be present and alert the host's immune 
system to the presence of a pathogen results in a severely inhibited immune response. This 
is primarily because they are unable to cause maturation in DCs the most significant of APCs. 
This results in multiple vaccinations being necessary in order to induce sufficient immune 
response due to reduced T cell and antibody induction levels (77,100–105). Adjuvants can 
thus be added to counter these shortcomings by reducing the dose necessary to elicit an 
immune response in a more rapid manner with the potential of stimulating a guided or broader 
response depending on the adjuvant (104,106,107). 
1.17 Adjuvants 
The word adjuvant comes from the Latin word adjuvare meaning to aid, they are substances 
that enhance the immune response when combined with an antigen. Despite their benefits, 
only a handful of approved vaccine adjuvants exist to date (See table 1.3). This is because of 
poor upscaling and lack of scope with regards to compatible antigens compared to more 
traditional alum-based adjuvants. This is why adjuvants are licenced in individual vaccines 
rather than as a standalone product (108,109). Adjuvants are often made of a combination of 
compounds and vary significantly between adjuvant types. Oil, virosomes, TLR-related 
monophosphoryl lipid A (MPL), unmethylated CpG dinucleotides and tuftsin have all been 
shown to be effective (78).  
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Upon introduction, adjuvants; depending on their formulation may help to induce an effective 
immune response via a range of methods as laid out in Figure 1.5. Some adjuvants cause the 
release of non-specific pro-inflammatory cytokines and upregulation of the presenting and 
costimulatory molecules required for antigen presentation e.g. MHCII and B7-1/2. This allows 
for better antigen presentation to the adaptive immune system with better activation and clonal 
expansion of T cells (78).  
Another well-documented method by which adjuvants work is through the formation of a depot 
at the site of injection. This enhances antigen persistence reducing the need for boosters by 
stabilising the antigen. This reduces the rate of antigen release allowing for increased APC - 
vaccine antigen interaction times, thus increasing the amount of antigen presented in the 
lymph nodes. The duration of the depot at the site of injection has been demonstrated to have 
a direct bearing on the effectiveness of the immune response. This is likely representative of 
what would be normal host response to a pathogen forming a foothold. Depot effectiveness is 
based on numerous factors such as the formulation of the adjuvant used such as viscosity, 
particulate size and charge as well as the tissue it is introduced to (110,111).  
Chemokines are small secreted proteins that take advantage of the receptors expressed on 
immune cells to recruit them to areas of inflammation. Adjuvants taking advantage of this 
mechanism can use high concentrations of chemokines to attract specific immune cells to the 
point of injection thus enhancing the immune response (82,110–112). Several bacterial 
species are used as PAMPs to boost adjuvant efficiency such as TLR agonists. These include 
Mycobacterium spp., Corynebacterium parvum and C. granulosum, with the muramyl 
dipeptide (MDP) being used in place of the whole bacteria (106,113,114).  
Soluble antigens may also be converted into particulates and increase their size and immune 
recognition. This is dependent on antigen adjuvant association, antigen should also remain 
associated with the adjuvant in order to confer protection from the hostile extracellular 
compartment. Subunit vaccines like those composed of nucleic acids and small peptides are 
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particularly susceptible to rapid degradation by extracellular enzymes. As these subunit 
antigens are themselves inert, they are often broken down and removed via the circulatory or 
lymphatic system without antigen presentation occurring. The antigen-adjuvant association is 
therefore vital until antigen uptake by APC in order to produce effective vaccination (115).  
Localised tissue damage as a result of the insertion of the adjuvant itself results in the release 
of intracellular alarmins which signal the host immune system in the form of damage-
associated molecular patterns (DAMPS). These are biomolecules released by cells upon 
unintentional death and include mitochondria, uric acid and heat shock proteins (HSPs). 
Alarmins have been referred to as the first action of adjuvanticity due to their immediate nature 
(116). 
Adjuvants, therefore, are able to reduce the need for further booster vaccinations and reduce 
the antigenic load as they increase antigen recognition and uptake at the site of injection 
through stabilising of the antigen, DAMPs, PAMPs, release of proinflammatory cytokines, 
protection of the antigen and the formation of a depot.  
The reduction in the number of boosters is particularly important as the WHO estimates that 
for diseases like diphtheria, tetanus, and pertussis (covered by the DTPcv-3 vaccine) 16.6% 
fail to receive their final booster vaccination. This leaves up to 19.4 million children worldwide 
vulnerable to preventable diseases like this (80). 
1.18 Classic adjuvants 
Aluminium salts often referred to as alum encompass aluminium hydroxide, aluminium 
phosphate and aluminium potassium sulphate that are used in half of the licenced vaccines in 
the US. Alum is widely regarded as a benchmark adjuvant from which to compare newly 
developed formulations. It has an excellent safety profile with few side effects reported and 
improves Th2 vaccine immune responses as demonstrated by IgG1 titres and IL-4 secretion 
from splenocytes, however, it works in an antigen-specific fashion and is not suitable for all 
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vaccines (e.g. tuberculosis). This limits the scope of alum where a Th1 response would be 
more effective. Th2 modulators have been added in an attempt to balance the Th1 and Th2 
responses as with Adjuvant System 04 (AS04) which includes monophosphoryl lipid A (MPL) 
Alum works by creating a strong depot prolonging antigen presentation and reducing 
degradation as well as causing cell death which releases alarmins and inflammatory mediators 
DAMPS (65,116).  
Oil in water emulsions most famously Freund's adjuvant induce a varied immune response 
depending on the exact composition. Complete Freund's adjuvant (CFA) is made up of the 
non-metabolizable oils paraffin oil and mannide monooleate, trehalose 6,6’ dimycolate to 
stimulates Mincle, ligands for TLR2, TLR4, and TLR9 and heat-killed Mycobacterium 
tuberculosis (Mtb). It is associated with pain at the site of injection, abscesses, chronic 
granulomas ulceration, tissue necrosis, the formation of fistulous tracts and spread to other 
muscles and organs in the animal. Incomplete Freund's adjuvant (IFA) which lacks the Mtb 
component is less detrimental however it is also associated with severe local inflammation. 
Both CFA and IFA have been banned from use in humans however they are still frequently 
used in animal testing for which they are considered the gold standard (117).  
MF59 is another oil in water emulsion composed of 5 % squalene, Span 85 and Tween 80 
however it is far less toxic and licenced for use in human vaccines like influenza. It has been 
demonstrated to produce greater antigen uptake at the site of injection and transport to the 
lymph node (117).  
 MPL is a synthetic version of lipid A it is derived from the LPS which makes up part of the cell 
wall of gram-negative bacteria. It is a type of PAMP and strong TLR-4 agonist and 
subsequently drives a strong Th1 response. MPL is used as a component of many vaccine 
adjuvants like in AS01 where it was combined with a liposomal formulation (118). 
Vesicular based adjuvants that allow for the delivery of vaccines either entrapped within or 
associated with the surface exist in numerous forms and can be lipid or polymer-based. They 
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work at least in part by protecting the antigen from degrative extracellular compounds and 
form a depot to prolong presentation. These include microspheres, nanoparticles, virosomes, 
immune-stimulating complexes, liposomes and bilosomes. Vesicles are available with a range 
of properties meaning they can be tailored to a degree to maximise effectiveness by for 
example changing the size to ensure endocytosis (119–122).   
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Table 1.3: A history of adjuvants 1885 – Current. Vaccine adjuvants have existed for over 130 years 
with the first known use being in the rabies vaccine in around 1885 which inadvertently took advantage 
of ssRNA to stimulate TLRs. Subsequent vaccine adjuvants have taken advantage of LPS and its 
derivative MPL, virosomes and oil-in-water emulsions and Freund’s adjuvant immunogenic nature to 
raise an enhanced immune response. Aluminium salt vaccines take advantage of strong depot effects.  
Page 44 of 212 
 
  
 
Figure 1.5: Adjuvanticity modes of action. A) Antigen translocation to the lymph nodes for T cell 
interactions. B) Prolonged antigen presentation (depot effect). C) Pathogen recognition receptor 
signalling causes the upregulation of costimulatory molecules through innate immature cells cytokine 
release. D) Improved local reaction through danger signals from dead or stressed cells causing APCs 
to upregulate costimulatory molecules. E) The release of inflammatory cytokines and costimulatory 
molecules.  
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1.19 Liposomal adjuvants 
Discovered by Alex Bangham in 1961, liposomes are vesicles made up of lipid bilayers which 
may include lipophilic components which form in response to an aqueous media (123). 
Liposomes have been used for drug delivery because of their ability to not only encapsulate a 
range of different pharmaceutical compounds but also to associate them with their surface 
depending on their properties or through modifications. However, problems with drug leakage, 
liposome instability and rapid clearance by phagocytes led to further work to better understand 
liposome clearance and stability (124–128).  
Liposomal adjuvants usually work by either activating the innate immune response or by 
enhancing antigen delivery. Because of their synthetic nature, the strength and pathway of 
immune responses can also be tailored based on the type of lipid used and any other 
additional mechanisms incorporated (e.g. PAMPs). This is also where features like particle 
size, charge, type of antigen and entrapment homogeneity come into play (110,129–132). The 
properties of the antigenic material and adjuvant being incorporated into the liposome dictate 
the location they will be found in the liposomal structure. Nucleic acids, protein peptides and 
other water-soluble compounds are found encased in the inner aqueous region. Lipophilic 
compounds like antigens and adjuvants are trapped in the lipid bilayer. Compounds may also 
be joined to the surface of liposomes via a stable chemical linker (129,133).  
Liposomal charge is another key factor, liposomes may be either anionic, neutral or cationic 
surface charge depending on the lipids used. This will affect which type of antigen becomes 
associated and how they interact with the host environment when introduced. Neutral and 
ionic liposomes favour a Th1 immune response and have a non-rigid structure allowing for 
easier integration of adjuvants and antigens through encapsulation or covalent surface 
attachments (see Figure 1.6 & 1.7). The cationic liposome can encourage a Th1 or Th17 
response depending on the factors mentioned above (129,133,134).  
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Cationic liposomes produce long-lasting depots at the site of injection due to their strong 
electrostatic attraction to plasma and extracellular matrix proteins. This force also helps to 
bring in APCs to further enhance the depots and immune response and reduces the need for 
subsequent boosters. The anionic lipids phosphatidylserine and phosphatidylinositol and the 
zwitterionic lipids phosphatidylcholine and sphingomyelin give cell bilayers an overall anionic 
surface charge. This allows for electrostatic interactions between the liposome and the cell 
surface in a cell receptor-independent fashion (See figure 1.6) (111,135).  
 
 
Figure 1.6: Strategies of antigen liposome incorporation. Antigens and immune-stimulating drugs 
may be added to liposomes in a manner dependent on their nature and that of the liposome itself. 
Electrostatic binding of antigens is possible when the lipids and antigen have opposite charges. 
Antigens and drugs like NAC may be encapsulated into the aqueous interior during lipid hydration. 
Antigens with lipid anchors or that can be covalent conjugation to lipid anchors can be used to 
incorporate them into the liposomal membrane. Similarly, glycolipids may also be incorporated into the 
lipid membrane directly. 
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Figure 1.7: Forms of liposome following lipid hydration. Multilamellar vesicles (MLVs) containing 
multiple layers of lipid bilayers, small unilamellar vesicles (SUVs), large unilamellar vesicles (LUVs) 
which allow for more uniform delivery of antigens or pharmaceuticals and dehydration-rehydration 
vesicle (DRV) which forms after freeze-drying and is used to encapsulate some antigens. 
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1.20 Dimethyldioctadecylammonium D-(+)-
trehalose 6,6'-dibehenate liposomes 
The adjuvanticity of DDA was first discovered when used in guinea pigs with the diphtheria-
tetanus toxoids (136). It is a quaternary ammonium lipid (providing charge) with two saturated 
18-carbon lipophilic tails (See figure 1.8). This head group is small relative to other cationic 
lipids used to make liposome-based vaccine adjuvants like Dioleoyl-3-trimethylammonium 
propane (DOTAP), 3ß-[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol DC-Chol. The 
use of DDA only liposomes have shown to produce a strong immune response as an adjuvant 
to TB, malaria and tetanus amongst other diseases (137–139).  
DDAs potent adjuvanticity is known to be due to multiple factors including its strong charge 
causing interacting with the surrounding tissue at the point of injection forming a sturdy depot 
effect. Antigen protection, better uptake by APCs and improving antigen delivery to the lymph 
nodes have also been demonstrated. Unlike alum which is also able to turn soluble antigens 
into particulates, DDA is not associated with the same levels of tissue damage and uric acid 
production at the site of injection (140,141).  
DDA-only liposomes are not stable, however, and so investigations into increasing their 
stability using other lipids have been explored. Early experiments included cholesterol as a 
non-immunogenic common component of cell membranes. This served to increase stability 
and improve lipid packing which reduced the transition temperature and increased bilayer 
fluidity. This led to many early experiments involving DDA adjuvants also including cholesterol 
(124,142,143). However, it was demonstrated that the addition of cholesterol also resulted in 
decreased phagocytic uptake due to reduced plasma protein association with the liposome 
surface (127,144). 
The immunogenicity of DDA liposomes was subsequently explored by adding MPL which 
demonstrated effective immune response against TB (145). Another bacterial wall derived 
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component incorporated into DDA liposomes was trehalose 6,6’-dimycolate (TDM) which was 
known for inducing strong humoral immunity (146).  
TDM is a large molecule with a weight of 2970 and the formula C186H366O17 ± 10CH2. It takes 
advantage of the receptor, macrophage inducible Ca2+-dependent lectin receptor (mincle), 
known to recognise fungal pathogens as well as the scavenger receptor MARCO and TLR 2 
to promote immune recognition and causes a strong Th1/Th17 polarization (147,148). The 
similarity of TDM to the cell wall of TB from which it is derived makes it toxic in vivo and so 
unsuitable for a vaccine adjuvant despite its positive immunogenic properties (149).  
Trehalose 6,6’-dibehenate (TDB) is a synthetic analogue of TDM that has the same glucose 
disaccharide head groups but the number of mycolate chains is decreased in number and 
length shortened. This makes TDB much smaller than TDM with a molecular weight of 987 
and far less toxic whilst still retaining its immune-stimulating properties (See figure 1.8) (150). 
TDB can be incorporated into DDA liposomes to around a 5:1 molar ratio before it begins to 
affect liposome size and immunogenicity. The addition of TDB also serves to increase stability 
because of interaction between the glucose head-groups the water in the hydration fluid. The 
ideal ratio of DDA:TDB is determined to be around a 9:1 ratio yielding the best antibody titres. 
(151,152). 
Liposomal adjuvants have a number of advantages such as better flexibility of formulation 
during design and the ability to incorporate a range of different immunomodulators. DDA:TDB 
is particularly good at this as due to the possibility of electrostatic binding to the surface. This 
along with its high stability and proven results high antibody titers make it an ideal adjuvant 
under the correct circumstances (153,154). 
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Figure 1.8: Lipid structure of DDA and TDB. A) The cationic lipid DDA which gives DDA:TDB 
liposomes there charge allowing antigen electrostatic binding and depot formation. B) TDB non- toxic 
analogue of the mycobacterial cell wall which provides stability and increased immunity to the DDA:TDB 
formulation. 
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1.21 Dimethyldioctadecylammonium D-(+)-
trehalose 6,6'-dibehenate vaccine antigens 
Ovalbumin (OVA) is cheap and easily available as such it is a popular choice of antigen to 
study humoral and cell-mediated immunity with the wealth of existing literature further adding 
to the benefits of this choice. It is 68 kDa soluble protein and has an isoelectric point of 4.6 
allowing it to bind to the surface of cationic liposomes. This stabilises it and converts it into 
particulates which increases immune recognition (115,155–157). This makes it a popular 
choice when examining the efficacy of new DDA:TDB based liposomes.  
Other subunit vaccines like those based on DNA and glycolipids have also been explored in 
the literature. DNA vaccines use pathogen-derived DNA to produce antigens within cells 
themselves. They are often associated with other proteins to mediate uptake and have been 
approved for animal vaccinations but not in humans. Despite their many benefits such as a 
varied immune response and long-term persistence, they have other downsides like their 
inability to produce non-protein based antigens, for example, bacterial polysaccharides and 
the possibility of immune regulatory issues. The use of cationic lipids for DNA delivery has 
been demonstrated to deliver DNA directly into the cytoplasm previously however DNA 
vaccines are outside the remit of this project (158,159).  
Glycolipids are essentially carbohydrates (monosaccharide or oligosaccharide) bound to a 
lipid moiety via a covalent bond and are found in the cell membranes. This makes them easily 
incorporated in the surface of liposomes. TDB, for example, is glycolipid that as discussed 
above provides added stability and immunogenicity in an antigen-specific manner (151,152). 
This makes the use of liposomes as adjuvant carriers for glycolipid vaccines ideally suited for 
each other.  
Due to their amphiphilic structure liposomes enable a diverse range of hydrophilic and 
lipophilic antigens. Cationic liposomes allow for peptides/proteins, including soluble ones to 
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be surface adsorbed or encapsulated in unilamellar or multilamellar vesicles s depending on 
preparation and antigen charge. Lipophilic glycolipids such as those derived from bacterial 
walls are also able to be inserted in the liposomal membrane. For these reasons DDA:TDB 
liposomes are ideal candidates to evaluate the efficacy of a range of vaccine antigens.  
1.22 Project aims  
Although we have a good understanding of the general mechanisms behind the interactions 
between the immune system and vaccine adjuvants, a great deal is still unknown. Work in 
particular need to be done on how specific adjuvants interact with the host immune cells (i.e. 
which pathways and receptors are involved). This and other factors that are known to be 
immune critical but have not yet been fully explored such as redox state could be taken 
advantage of. This knowledge of adjuvants would allow for the development of better suited 
or even antigen tailored vaccine adjuvants designed to maximise immune response to subunit 
vaccines. This ability to raise a strong immune response against a wider range of small 
peptides, proteins and nucleic acids through a well characterised structural approach would 
be invaluable in the development of new vaccines against new and existing diseases.  
Because of its well characterised immunogenic properties as an adjuvant, a cationic liposome 
formulation consisting of DDA and TDB was evaluated as a possible adjuvant vesicle for the 
delivery of the redox modulating small molecule NAC. It was hypothesised that by changing 
the redox state at the site of antigen presentation, the immune response to test antigens could 
modulate in such a way as to enhance antibody production for both the prevention of diseases 
and the production of antibodies against specific antigens for industrial purposes. The latter 
for example could be used to develop immunoassay based diagnostic testing. With these aims 
in mind several projects were carried out with the goals to: 
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1. Establish and characterise the mouse DC model for use in in vitro testing for examining 
common DC markers and ability to take up model antigens. Evaluate the effectiveness 
of the in vitro immune response of DCs when supplemented with the redox modulators 
H2O2 and NAC. 
2. Characterise the differences in properties between DDA:TDB and DDA:TDB-NAC and 
compare the effectiveness of DDA:TDB and DDA:TDB-NAC liposomes in vitro and in 
vivo with a range of antigens in generating an immune response.  
3. Determine the differences in response to antigen using DDA:TDB and DDA:TDB-NAC 
in WT and Ncf1-/- DCs and in vivo to discern the importance of ROS. Establish a better 
understanding of the role of ROS in the development of the rheumatoid arthritis 
autoimmunity model. 
4. Evaluate the possibility of using DDA:TDB liposomes to create suitable immunogens 
that may ultimately be used to generate antibodies against epitopes from TB, 
Lipoarabinomannan (LAM). To be developed in future for use in diseases detection 
assays as a point of care testing method for disease diagnosis.  
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Chapter 2: Materials and methods 
2.1 Materials 
All chemicals were purchased from Sigma (Poole, UK) or Fisher Scientific (Loughborough, 
UK) unless stated otherwise. Cell culture and general plastic ware were obtained from Thermo 
Fisher Scientific (Loughborough, UK). Recombinant mouse GMCSF was purchased from R&D 
(UK). Rat collagen type II was purchased from Chondrex, Inc, (Redmond, USA). DDA and 
TDB were purchased from Avanti Polar Lipids (Alabaster, Alabama, USA), LAM from 
Mycobacterium tuberculosis (Mtb) strain H37Rv was from BEI Resources (Washington, USA). 
2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 Bone marrow progenitor cell extraction 
Containing the closely related progenitors for macrophages, monocytes and DCs, bone 
marrow is often used as a cell source to generate DCs ex-vivo (160). C57BLK6 mice which 
show a strong Th1 preference were used as a source of bone marrow (161). Mice unless 
otherwise stated were sacrificed in accordance with schedule 1 and donated from the Sir 
William Dunn School (Oxford). Tissue was cleared from the femur of C57BLK6 hind legs and 
the bone was removed, then the femurs were sterilised with 70% ethanol solution. The 
proximal and distal ends of the femur were then removed, and the marrow was flushed out 
using sterile phosphate-buffered solution (PBS). The marrow was then centrifuged at 200 xg 
for 5mins and the supernatant removed. The pellet was treated with 2 mL Gibco™ ACK Lysing 
Buffer (Ammonium-Chloride-Potassium lysis buffer) from ThermoFisher (Loughborough, UK) 
containing ammonium chloride, potassium bicarbonate and EDTA for 10mins at 37°C (162). 
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2.2.1.2 Granulocyte macrophage colony-stimulating factor induced 
differentiation of mouse bone marrow progenitor cells to generate 
immature dendritic cells 
Mouse bone marrow cells were seeded in 10 mL RPMI 1640 media supplemented with 0.4 
ng/mL GMCSF at a concentration of 2x105 cells/mL in a 100 x 21mm petri dish. Cells were 
incubated for three days at 37°C in a humidified atmosphere with 5% CO2 in air. An additional 
10 mL RPMI 1640 media supplemented with 0.4 ng/mL GMCSF was added to each dish and 
incubation was continued as before for a further three days. On day six 10 mL was removed 
from each petri dish and the cells pelleted at 200 xg for 5mins at room temperature. The pellet 
was then resuspended in fresh 10 mL RPMI 1640 media supplemented with 0.4 ng/mL 
GMCSF and returned to the same dish. Following a further two days of incubation as before, 
the day six protocol was repeated and incubation continued for a further two days. On day ten 
immature DCs were harvested by removing cells in suspension without disturbing adherent 
cells (162). DC generation was confirmed by surface expression of CD11c, CD86 and MHC II 
using flow cytometry. 
2.2.2 In vitro treatments 
The mouse DC model was used to determine the effectiveness of different redox modulating 
treatments and liposome formulations using OVA or LPS from Escherichia coli O26:B6 (LPS) 
(Sigma). OVA is a 42.7kDA glycoprotein that makes up the majority of chicken egg whites; its 
size and complexity make it slightly immunogenic. It is frequently used as a model antigen for 
immunisation research (163,164). LPS are components of Gram-negative bacteria cell walls 
and through TLR-4 are potent activators of the innate immune system (165).  
In the methods below, OVA (0.8 mg/mL), LPS (100 ng/mL), NAC (50-500 µM), H2O2 (2.2-17.6 
µM), OVA-coated DDA:TDB liposomes or OVA-coated DDA:TDB-NAC (12 µg/mL) liposomes 
were all used as treatments where indicated. To coat DDA:TDB or DDA:TDB-NAC with OVA 
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the inherent electrostatic binding between OVA and the cationic DDA was taken advantage 
of. OVA (0.8 mg/mL) was added to 12 µg/mL DDA:TDB or 12 µg/mL DDA:TDB-NAC 
liposomes and mixed by pipetting before being left overnight at 2-8°C. Concentrations were 
determined based on previous data & published material or data shown in this study (166,167) 
2.2.3 Flow cytometry analysis of dendritic cell cultures 
2.2.3.1 Propidium iodide staining 
Flow cytometry was used to analyse cell viability using a propidium iodide exclusion method. 
Propidium iodide is a fluorescent molecule which is excluded from viable cells but binds to 
double-stranded nucleic acid in membrane-permeable cells (168). Fluorescence can, 
therefore, be used to determine the viability of cells by indicating if they are permeable; further 
analysis of nucleoids can be used to determine whether cells have entered cell cycle arrest 
(169).  
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Figure 1: Example histograms and accompanying dot plots of propidium iodide staining. DCs 
were seeded at 1x106cell/mL. A: Dot plot showing DC gate highlighted by the white line. B: Histogram 
showing 2% gating of the healthy control. C: Dot plot showing the increased side scatter and propidium 
iodide stain (yellow associated with cell death) following 20min incubation at 60°C. D: Histogram 
showing +ve gating of DCs following 20min incubation at 60°C. 
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Non-adhesive bone marrow derived DCs were centrifuged at 200 xg in a microfuge for 5mins 
and resuspended to 1x106 cells/mL in RPMI and 10% FCS. Cells were either left untreated or 
treated with 0.2 µg/mL propidium iodide at room temperature and analysed immediately. 
10,000 cells were then examined using BD FACSCelesta and BD FACSDiva analysis software 
at excitation 535 nm, emission 617 nm. 
Propidium iodide levels were as percent (%) of positive cells, after gating for 2% positive 
fluorescence of the non-stained cells.  
2.2.3.2 Cell surface marker analysis 
Flow cytometry was used to analyse the dendritic cell surface markers CD11c, CD86 and 
MHC-II. For all surface antigen expression analysis using flow cytometry, an analysis was 
undertaken in propidium iodide-negative cells as shown in figure 2. 
  
Figure 2.1: Example histogram showing 2% isotype control gating. This histogram is 
representative of at least three independent experiments. 
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2.2.3.3 Mouse bone marrow derived dendritic cell markers 
Anti-mouse monoclonal antibodies (mAbs) specific to these targets conjugated to 
fluorophores: anti-CD11c Alexa Fluor 647, anti-CD86 Fluorescein isothiocyanate 
(FITC) and anti-MHC-II Phycoerythrin (PE) and their respective isotype controls were from 
AbD Serotec Biorad (Oxford, UK) or BioLegend (London, UK). DCs were centrifuged at 200 
xg for 5mins at room temperature and re-suspended to the required cell density in RPMI, 10% 
FCS and 0.1% BSA. Cells (2x105 in 200 µl) were incubated on ice for 20mins. Following this, 
they were treated with the manufacturer’s recommended volume of targeted mAbs or with 
appropriate isotype controls and incubated for a further 30mins. 10,000 cells were then 
examined for antigen expression using BD FACSCelesta and BD FACSDiva analysis 
software.  
Antigen Clone 
Fluorophore 
(Excitation/ 
Emission nm) 
Species 
Antibody 
Class 
Volume 
per sample 
(µl) 
MHC class II (I-A/I-
E) 
M5/114.15.2 PE (496/578) Rat IgG2b, κ 10 
CD86 GL-1 FITC (490/525) Rat IgG2a, κ 0.2 
CD11c N418 
Alexa Flour 647 
(650/668) 
Rat IgG 0.125 
Table 2.1: Antibodies used for analysing DC activation surface markers by flow cytometry. 
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2.2.4 Protein quantification by bicinchoninic assay  
The bicinchoninic assay (BCA) assay from ThermoFisher (Loughborough, UK) was used to 
determine the total protein concentration of cell extracts and protein encapsulation within 
liposomes (170). Unknown protein concentration was determined by adding 200 µl of CuSO4 
and BCA solution (1:50 - v/v) to 10 µl of either the unknown sample or BSA standards ranging 
from 0-1 mg/mL.  
The plate was then incubated for 30mins at 37°C before the absorbance was read at 570 nm. 
A standard curve dependent on sample concentration was generated plating BSA standards 
in triplicates and sample concentration calculated. 
2.2.5 Lipid film hydration method & zeta analysis 
DDA:TDB liposomes were prepared by lipid film hydration. DDA and TDB lipids purchased 
from Avanti Polar Lipids (Alabaster, Alabama, USA) were dissolved in 5 mL 
chloroform/methanol (9/1 v/v) at 5/1 w/w and the solvent was removed using rotary 
evaporation at 37°C resulting in thin lipid film formations. The film was then purged with N2 to 
remove remaining solvents. The film was rehydrated with 10mM Tris-buffer with or without 
10mM NAC at pH 7.4 which was heated to 60°C (above the transition temperature 47°C) for 
30mins with interspersed periods of vigorous mixing. The mixture was left to cool at room 
temperature for 30mins before a portion was diluted 1:10 in 10mM Tris-buffer at pH 7 for 
analysis. Determination of liposome size (z-average diameter) and surface charge (zeta 
potential) was carried out. For this, a ZetaSizer (Malvern Instruments, Worcestershire, UK) 
was used to carry out photon correlation spectroscopy (PCS) and dynamic light scattering 
analysis.  
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Liposome Purpose 
DDA 
used 
(mg) 
TDB 
used 
(mg) 
Resuspension 
Volume (mL) 
NAC 
wash? 
Final concentration 
(mg/mL) 
In vitro 2.5 0.5 3 Yes 1 
OVA immunisations 2.5 0.5 0.5 No 6 
Rat collagen type II 
immunisations 
2.5 0.5 1 No 3 
Table 2.2: NAC liposomes specifications upon hydration developed for testing in vitro and vivo. 
Values are representative of the quantity needed for ten 100 µl in vivo mice injections.  
 
2.2.6 Encapsulation efficiency 
2.2.6.1 N-acetyl cysteine encapsulation measurement  
NAC encapsulation efficiency into liposomes was determined by measuring the removal of 
NAC from the supernatant after pelleting liposomes. Liposomes were centrifuged at 20800 xg 
for 1.5hours at 4°C, the supernatant containing any remaining free NAC was then removed 
without disturbing the pellet. The supernatant (25 µl) was added to a 96 well plate in triplicate 
along with 6mM DTNB (5’, 5’ – dithio-bis (2-nitrobenzoic acid) and the absorbance at 410 nm 
was measured using a SpectraMax iD3 spectrometer. Values were then compared to 
appropriate fresh NAC TRIS standards (0-7.5mM). Encapsulation efficiency was then 
calculated using the equation: 
𝐸𝑛𝑡𝑟𝑎𝑝𝑚𝑒𝑛𝑡 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (%) =
(𝑇𝑜𝑡𝑎𝑙 𝑁𝐴𝐶 –  𝐹𝑟𝑒𝑒 𝑁𝐴𝐶)
𝑇𝑜𝑡𝑎𝑙 𝑁𝐴𝐶
𝑥100 
2.2.6.2 Ovalbumin loading measurements  
A BCA assay was used to determine OVA loading efficiency by measuring free OVA the 
supernatant of liposomes centrifuged at 20800 xg for 1.5 hours. The supernatant containing 
OVA was removed without disturbing the pellet and 10 µl was added to a 96 well plate in 
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triplicate. BSA standards (1 mg/mL) equivalent to 0.25, 0.5, 0.75, 1, 1.25 and 1.5 µg/m of 
protein were added in triplicate (10 µl) and methods were carried out as stated above. 
 
Protein 
concentration 
BSA (µl) 
Water 
(µl) 
Final 
volume (µl) 
0 µg/mL 0 10 10 
25 µg/mL 0.25 9.75 10 
50 µg/mL 0.5 9.5 10 
75 µg/mL 0.75 9.25 10 
100 µg/mL 1 9 10 
125 µg/mL 1.25 8.75 10 
150 µg/mL 1.5 8.5 10 
Table 2.3: Reagent volumes required to prepare the standard curve to determine the protein 
concentration of non-liposome associated rat collagen type II . 
A standard curve was generated using BSA standards in triplicates and OVA concentration in the 
supernatant was then calculated.  
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Figure 2.2: Example BCA standard curve used to determine OVA loading. Figure representative 
of at least three independent experiments. 
Total OVA concentration was based on initial quantities added.  
OVA Loading Efficiency was then calculated using the equation: 
𝐿𝑜𝑎𝑑𝑖𝑛𝑔 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (%) =
(𝑇𝑜𝑡𝑎𝑙 OVA –  𝐹𝑟𝑒𝑒 OVA)
𝑇𝑜𝑡𝑎𝑙 OVA
𝑥100 
2.2.7 Antigen uptake 
Bovine serum albumin–fluorescein isothiocyanate (FITC) conjugate from Sigma (UK, 
Gillingham) was used to monitor antigen uptake in the presence of free NAC, H2O2 and/or 
DDA/TDB based liposomes with and without NAC. For the free NAC (50-500 µM) and H2O2 
(2.2-17.6 µM) treatments, DCs were seeded at 1x105 cell/mL in 4 mL volumes and treated 
with NAC or H2O2 for one hour at 37°C, 5% CO2. FITC-conjugated albumin (10 mg/mL in PBS 
pH 7.4) solution was made up freshly and following treatment, 0.4mg was added to each well 
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and incubated for a further 4hours at 37°C, 5% CO2 or at ~5°C as a negative control. Following 
incubation cells were washed and analysed by flow cytometry.  
FITC-conjugated albumin was added to liposomes post-lipid-film hydration at a ratio of 1mg of 
FITC-albumin to 15mg of DDA:TDB (based on pre-hydration weights). DCs were seeded at 
1x106 cell/mL and treated with 15 µg/mL DDA:TDB or DDA:TDB encapsulated NAC for one 
hour at 37°C, 5% CO2 or at ~5°C as a negative control. 10,000 cells were then examined using 
BD FACSCelesta and BD FACSDiva analysis software at excitation 490 nm, emission 525 
nm. Albumin-FITC uptake levels were reported as MdX of the fluorescence intensity after 
positive gating for 2% fluorescence of the equivalent no FITC-albumin negative no stain 
control.  
Alternatively, cells treated as above were imaged by confocal microscopy then examined 
using Nikon Ti-Eclipse with A1M Confocal and NIS-Elements Acquisition software. Cells were 
resuspended in PBS to 1x106 cell/mL and (20 µl) were mounted onto glass slides. To this 2 µl 
of Vectashield Antifade Mounting Medium with DAPI from Vector laboratories (Peterborough, 
UK) was added and coverslipped. DAPI excitation 358 nm, emission 461 nm. 
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2.2.8 Intracellular pH measurements 
pHrodo™ from Invitrogen (Loughborough, UK) was used to determine relative intracellular pH. 
They are a group of pH-sensitive dyes which fluoresce intensely in acidic environments but 
are non-fluorescent at neutral pH. Cells (1x105cell/mL) were washed in PBS then resuspended 
in 1 mL pHrodo™ Red AM staining solution (1 µl of pHrodo™ AM Ester, 10μl of PowerLoad 
per mL in PBS) and incubated for 30mins at 37°C, 5% CO2. Treatments, as stated in “In vitro 
treatments” above were then incubated for a further 30mins at 37°C, 5% CO2 or at ~5°C as a 
control. 10,000 cells were then examined using BD FACSCelesta and BD FACSDiva analysis 
software at excitation 596 nm, emission 615 nm. pHrodo™ Red AM expression levels were 
reported as MdX after positive gating for 2% fluorescence of the negative no stain control. 
2.2.9 Phagosomal pH measurements 
pHrodo™ Red E. coli BioParticles™ Conjugate for Phagocytosis (Loughborough, UK) are 
extracellularly non-fluorescent outside the cell, but fluoresce bright red in phagosomes. These 
bioparticles were used to determine relative phagosomal pH in response to 50-500 µM NAC, 
2.2-17.6 µM H2O2 or 12 µg/mL DDA:TDB and DDA:TDB-NAC liposomes. pHrodo Red E. coli 
Bio Particles were suspended in PBS at 1 mg/mL in PBS and mixed by a vortex. DCs were 
seeded at 1x106 cell/mL in 200 µl resuspended homogenised bioparticles and treated with 
NAC, H2O2, DDA:TDB or DDA:TDB-NAC for 1.5 hours at 37°C in a 96 well plate from Thermo 
Fisher Scientific. 10,000 cells were then examined using BD FACSCelesta and BD FACSDiva 
analysis software at excitation 596 nm, emission 615 nm. pHrodo™ Red expression levels 
were reported as MdX after positive gating for 2% fluorescence of the negative no stain 
control. 
2.2.10 Intracellular oxidation measurements 
Dihydroxy (H2) 2′,7′-dichlorofluorescin diacetate (DCF-DA) is a non-fluorescent cell-permeable 
probe that is de-esterified intracellularly and becomes fluorescent on oxidation (171). 
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Dihydroxy (H2) DCF-DA was used to determine changes in intracellular peroxides. DCs were 
seeded at 1x106 cell/mL and 200 µl were treated as described in “In vitro treatments” above 
for 30mins at 37°C, 5% CO2 before adding 50 µM H2DCF-DA. Cells were then immediately 
analysed using BD FACSCelesta and BD FACSDiva analysis software 10,000 cells were 
examined. DCF intensity levels were reported as MdX after positive gating for 2% fluorescence 
of the negative no stain control. 
2.2.11 GSH-Glo™ glutathione assay 
The GSH-Glo™ (from Promega UK) is a luminescent plate-based assay catalysed by 
glutathione S-transferase (GST) enzyme and is used to detect GSH in cells through the 
release of luciferin. This is then converted to light proportional to GSH content by Ultra-Glo™ 
Recombinant Luciferase.  
The assay was carried out as per manufacturer’s instructions. Following treatment, cells were 
washed and suspended in PBS to a concentration of 4x105cell/mL and 50 µl of each treatment 
aliquoted in triplicate into a 96 well Thermo Scientific Microlite™ White Microtiter™ Plate. The 
GSH top standard was made by diluting GSH standard solution (GSH, 5mM) 1:100 in water. 
Other standards were made up by 1:1 serial dilution of the top standard using deionized water 
(DI) water. Standard values were 5, 2.5, 1.25, 0.62, 0.31, 0.15, 0.07 & 0 µM, 10 µl of each was 
added in duplicate to the 96 well plate.  
Luciferin-NT substrate and GST diluted 1:50 in GSH-Glo™ Reaction Buffer to make GSH-
Glo™ Reagent 2X, 50μl was added to each well and the plate was shaken and incubated for 
30mins at room temperature. Following this 100μl of Luciferin Detection reagent was added 
per well, the plate was shaken and incubated for 15mins in the dark. Luminescence at all 
wavelengths was then measured using SpectraMax iD3 spectrometer. A standard curve after 
removing background was then made and sample values calculated. 
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Figure 2.3: Example GSH-Glo assay standard curve used to determine the GSH content of 
samples. (R2=0.9951). Figure representative of at least three independent experiments. 
 
2.2.12 Ovalbumin immunisation 
Ten C57BLK6 mice were immunised with liposomes consisting of 250 µg DDA and 50 µg TDB 
with or without 10mM NAC during hydration and coated with 50 µg OVA. Immunisations (100 
µl) took place on days 0 and 14 and serum was obtained from tail bleeds (50 µl) withdrawn on 
days 7, 21 and 49. Blood was collected in a heparinised micro-centrifuge tube (1% w/v 
heparin) and centrifuged for 10mins at 10,000 xg to separate plasma. Plasma was frozen until 
analysis.  
2.2.13 Collagen immunisation and induction of arthritis  
For eliciting collagen-induced arthritis C57B6N.Q wild types and C57B6N.Q.Ncf1-/- developed 
by in-house breeding at Redoxis (Lund, Sweden) were used.  
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C57B6N.Q.Ncf1-/- mice lack a functional NOX2 complex due to the inability of Ncf1 (p47phox) 
protein to locate to the membrane upon activation.  
Mice were immunised (100 µl) with liposomes consisting of 250 µg DDA and 50 µg TDB with 
100 µg of rat collagen type II and with or without 10mM NAC, added during hydration. For 
comparison, complete Freund’s’ adjuvant (CFA) with equivalent amounts of rat collagen type 
II was used. CFA is made up of mineral oils, emulsifier and mycobacterial components. It is 
frequently used in current arthritis models (172,173).  
The aim of the collagen-induced arthritis study was to establish whether a more reducing 
environment during antigen presentation (by co-delivery of NAC with antigen) enhances the 
immune response. For this 20 wild type C57B6N.Q (10 females, 6-8 weeks old and 10 males, 
6-8 weeks old) and 21 C57B6N.Q.Ncf1-/- mice (6 females, 10 weeks old and 15 males, 6-8 
weeks old) were injected (100 µl s.c) at the base of the tail with 100 µg of rat collagen type II 
in groups of six using DDA:TDB, DDA:TDB-NAC or IFA as an adjuvant. On day 29 boosters 
were given made according to the same procedure as used in the original immunisation. Blood 
was collected from tail bleeds on days 7, 28 and 40 for further analysis. Mice were weighed 
on days 0, 10, 20 30 and 40 and then sacrificed (day 41). 
2.2.14 Ex vivo re-stimulation of splenocytes and lymph nodes 
To determine the efficacy of immunisation splenocytes and lymph nodes cells were presented 
with their vaccine antigen or Con A in order to determine cytokine release. Spleens were 
homogenised to single-cell suspension using a 40μm cell strainers into 50 mL of Dulbecco’s 
Hanks balanced salt solution (HBSS) (Gibco, Life Technologies). Pharmlyse (BD Bioscience) 
diluted 1:10 in HBSS was used to lyse RBCs and the cells were then washed with and 
resuspended in HBSS. Cell counts were then carried out using a ScepterTM cell counter 
(Merck, Millipore). 
Page 69 of 212 
 
Cells were resuspended at 2x106 cells/mL in complete RPMI (10% FBS and 1% 
penicillin/streptomycin) and 100μl was plated in a 96well plate coated with or without 1 
μg/mL of anti-CD3ε (Biolegend; 145-2C11). To stimulate rat collagen type II (100 μg/mL) 
(Chondrex), OVA (5 μg/mL) (Sigma) antigens or Concanavalin A (ConA) (5 μg/mL) were 
added to wells and incubated for 24h at 37°C, 5% CO2 to stimulate activationon and 
subsequent cytokine release.  
2.2.15 Mouse Th1/Th2 cytokine kit multiplex 
BD Cytometric Bead Array Mouse Th1/Th2 Cytokine Kit (New Jersey, US) was used to 
determine the serum concentrations of IL-2, IL-4, IL-5, IFN- γ & TNF-α as per manufacturer’s 
instructions. Standards consisting of each cytokine were made up in assay diluent to the 
concentration of 5000 pg/mL. The top standard (5000 pg/mL) was then serially diluted in assay 
diluent as shown below. 
Cytokine standard 
dilution 
Concentration 
(pg/mL) 
N/A (Assay Diluent Only) 0 
1:256 20 
1:128 40 
1:64 80 
1:32 156 
1:16 312.5 
1:8 625 
1:4 1250 
1:2 2500 
1:1 (Top Standard) 5000 
Table 2.4: Standard dilutions required for the standard curve for the cytometric bead array 
Th1/Th2 Cytokine assay. 
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Capture bead suspension for each cytokine was vortexed for 30secs immediately before 5 µl 
per sample was mixed in a single mixed bead solution. Mouse serum samples were diluted at 
a 1:5 ratio in assay diluent and 25 µl of each sample and standard was added individually to 
each tube in duplicate. 25 µl of the mixed bead solution and 25 µl PE Detection Reagent was 
then added to each tube and incubated for 2hours at room temperature in darkness. 1 mL of 
wash buffer was added to each sample and standards which were then centrifuged at 200 xg 
for 5mins. The supernatant was removed and the beads were re-suspended in 200μl of Wash 
Buffer.  
To establish appropriate gating and voltages, cytometer setup beads were used as per 
manufacturer’s instructions. Briefly, 100 µl of cytometer setup beads were diluted in 400 µl of 
wash buffer. The digital instrument cytometric bead array template provided by BD was then 
used to adjust voltages so as to bring test beads within parameters as established in the 
manual as shown  
1. Majority of beads in P1 
2. Mean APC voltage of P2 = ~70,000 
3. Mean PE voltage of P3 = ~75 
4. Mean FITC voltage of P4 = ~75 
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Figure 2.4: cytometric bead array setup beads showing appropriate gating and voltages as 
described in the manufacturer’s instructions. 
2.2.16 Antibody titre determination by ELISA 
An ELISA using goat polyclonal IgG anti-mouse IgG1 horseradish peroxidase-conjugated 
(HRP) from Biorad (Oxford, UK) was used to determine antibody titre following DDA:TDB OVA 
and DDA:TDB-NAC OVA immunisation or after rat collagen type II immunisation. 
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OVA or TYPE II COLLAGEN was coated at 50 µl/well onto Nunc MAXISORB 96 well plates 
in 5 µg/mL Sodium Carbonate Buffer pH 9.6 buffer and incubated at 37°C for 1hr. The plates 
were then washed three times in washing buffer (PBS/Tween 20 0.05%) and blocked 
overnight with PBS/Tween 20 (0.1%), 200 µl/well at 4°C. The plates were then washed three 
times in washing buffer and 100 µl PBS/Tween 20 (0.05%) was added to all rows except B. 
To row B 100 µl of serum which was pre-diluted 1:400 in PBS was added in duplicate. From 
row, A 50 µl of serum was then serially diluted as shown below. Wells at the edge of the plate 
was not used for analysis. 
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B Not used 1:400 1:400 
C Not used 1:1600 1:1600 
D Not used 1:6400 1:6400 
E Not used 1:12800 1:12800 
F Not used 1:25600 1:25600 
G Not used 0 0 
H Not used Not used Not used 
Table 2.5: Plate layout of serum dilutions used for determining antibody titter. 
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The plates were then incubated for 2 hours at 37°C and then washed three times in washing 
buffer. Goat polyclonal HRG-conjugated IgG antibodies against mouse IgG1 were then added 
to all wells at a 1:4000 dilution using blocking buffer as a diluent (Tween-20 1% v/v in PBS, 
50 µl/well). The plates were then incubated for 1hr at 37°C and washed three times. Substrate 
solution (10 mL citrate-phosphate buffer (0.15M, pH 5), 8 µl hydrogen peroxide, and 1 o-
phenyldiamine tablet (Sigma) were added per at 50 µl/well. The plates were then incubated 
for 30mins to allow colour development before 50 µl of 2M sulphuric acid stop solution was 
used to quench the reaction. The absorbance at 490 nm was measured using a SpectraMax 
iD3 spectrometer and the maximum dilution that signal could still be detected was assessed. 
2.2.17 Lipid hydration of Dimethyldioctadecylammonium D-(+)-
trehalose 6,6'-dibehenate- Lipoarabinomannan liposomes 
stained with Bodipy 
To visualise liposome uptake, DDA:TDB liposomes were stained with Bodipy ((diaza-s-
indacene-3-propionyl)-1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine, 
triethylammonium salt) from ThermoFisher (Loughborough, UK) and were made up in the ratio 
5:1:0.01 respectively. Lipid film hydration was then carried out as described above using 
10mM Tris-buffer at pH 7 with 50 µg/mL LAM from Mtb strain H37Rv from BEI Resources 
(Washington, USA). 
2.2.18 Dimethyldioctadecylammonium D-(+)-trehalose 6,6'-
dibehenate- Lipoarabinomannan flow cytometry analysis 
A Coulter EPICS Elite ESP was used to determine liposome homogeneity and to establish the 
availability of surface LAM. The size of Bodipy stained DDA:TDB-LAM liposomes was 
compared to green fluorescent bead stock of 390 nm diameter. To determine the presence of 
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surface LAM, APC-labelled monoclonal anti-LAM antibodies derived from humans infected 
with TB were used.  
2.2.19 Dimethyldioctadecylammonium D-(+)-trehalose 6,6'-
dibehenate- Lipoarabinomannan uptake 
wild type derived DCs (2x105) were treated with DDA/TDB-LAM or DDA-TDB coated in OVA 
(12 µg liposomes /mL) stained with Bodipy in the presence and absence of NAC for 24hours 
at 37°C, 5% CO2. They were then imaged by confocal microscopy using Nikon Ti-Eclipse with 
A1M Confocal and NIS-Elements Acquisition software. Cells were resuspended in PBS to 
1x106 cell/mL and (20 µl) were mounted onto glass slides. To this 2 µl of Vectashield Antifade 
Mounting Medium from Vector laboratories (Peterborough, UK) was added and coverslipped. 
Bodipy was detected using excitation 503 nm, emission 512 nm. Alternatively, treated cells 
were studied by flow cytometry, 10,000 cells were examined using BD FACSCelesta and BD 
FACSDiva analysis software at excitation 503 nm, emission 512 nm. DDA:TDB-LAM uptake 
levels were reported as MdX or %+ve of the fluorescence intensity of Bodipy after positive 
gating for 2% fluorescence of the equivalent no negative no stain control. 
2.2.20 Data analysis 
Unless specified, all data obtained were analysed using GraphPad Prism v6/7 as mean and 
standard error of mean (SEM). Experiments were performed in at least duplicate with at least 
three independent repeats. Comparison between more than two columns was performed 
using one-way analysis of variance (ANOVA) followed by Tukey’s/Sidak’s multiple comparison 
tests. Tukey’s multiple comparison was used where appropriate to compare every mean to 
every other mean and determine the confidence intervals for every comparison. Sidak’s was 
used to compare selected pairs of means, for example, to compare every mean to a control 
mean. For all other data a T-test was used.   
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Chapter 3: Establishing the model 
systems 
Preface 
The 3Rs are part of UK legislation on the humane use of animals for scientific experimentation. 
Replacement, one of the 3Rs helps to ensure ethical animal research by replacing in vivo 
animal models with in vitro or in silico equivalents thereby reducing animal suffering. This 
chapter explores Lutz, Muccioli and Na bone marrow derived DC models as appropriate and 
feasible replacement systems for pre-screening of novel adjuvants. Surface expression and 
morphology were examined as indicators of DC-like differentiation. The optimised model 
system was selected based on CD86, CD11c and MHCII expression and was then exploited 
to determine how redox state influences DC surface activation markers, cellular viability, 
oxidation and pH. These readouts, as well as antigen uptake, were examined in the presence 
of adjuvant DDA:TDB liposomes with and without NAC encapsulation.  
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3.1 Introduction 
In order to develop a framework for more humane animal research, the three principles of 
replacement, reduction and refinement (3Rs) were established and incorporated into 
international legislation for animal research. In this chapter, bone marrow used for DC 
production was sourced according to the principles of the 3Rs. Excess C57BLK6 mice from 
breeding colonies were culled and the hind legs used for marrow extraction. The use of 
marrow from this source reduced the number of mice sacrificed specifically for this project and 
at the same time allowed for the development of an in vitro model replacing the need for as 
many in vivo studies to test adjuvant formulations.  
Cellular oxidation of proteins may be the result of an enzymatic reaction or from ROS released 
by cells directly such as nitric oxide (NO) and hydrogen peroxide (H2O2) (174). ROS produced 
by immune cells includes superoxide anions (O2•-), hydrogen peroxide (H2O2), singlet oxygen 
(1O2), and hydroxyl radical (•OH) as by-products of mitochondrial, peroxisomal or NOX 
complex activities (16). ROS are able to act as signalling molecules influencing a variety of 
biological activities (54,175). Low concentrations of ROS (0.02–0.13μM H2O2) have been 
shown to beneficial effects on cell cycle regulation, resolving inflammation and necessary for 
intracellular signalling pathways (11,12,14,176,177). Excessive ROS induced oxidative stress 
has been demonstrated to cause damage to DNA, proteins and lipids. This leads to specific 
interactions and the formation of aggregates (178). Oxidative stress has been linked to 
numerous diseases states such as degenerative disease, atherosclerosis and arthritis 
(42,179). In order to counter excess ROS, an antioxidant such as NAC is often used. NAC is 
a Food and Drug Administration approved small molecule and GSH precursor, it is able to 
some extent protect against oxidative modification or damage (74,75).  
NADPH oxidase NOX2 is recruited to phagosomes during antigen processing where it 
produces ROS creating an alkaline environment within the lumen which in turn down-regulates 
lysosomal protease activity (38). ROS can introduce new functional groups to proteins like 
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hydroxyls and carbonyls that can alter function, change turnover as well as causing 
fragmentation, unfolding and crosslinking. These can in turn significantly affect the rates of 
proteolytic and proteasome-mediated degradation (42,43). The ability of NAC to modulate 
redox state and decrease ROS within the lysosome could cause reduced antigen protein 
crosslinking and simultaneously increase access to protease activity. This may be beneficial 
for the degradation and presentation of difficult to process antigens.  
Due to the strong cationic charge of DDA, DDA/TDB liposomes have a strong electrostatic 
attraction to proteins which allows for the formation of depots and is thought to draw in APCs 
to further enhance immune response, making them a popular adjuvant liposome formulation 
(111,129,133,134). As DDA/TBD liposomes contain no double bonds and so cannot be 
oxidised or reduced an alternative method for changing the oxidative state is necessary. 
Encapsulation of the redox modulator such as NAC within DDA:TDB liposome can be used 
as a method of effectively changing the oxidation state of delivered cargo. This method could 
prove useful for tailoring the oxidation state of specific antigens in a relatively fast and 
inexpensive manner. 
It is hypothesised that due the diversity in APC including DC, in part due to their interactions 
with cytokines over different periods, that not all DC models are equitable. It is also predicted 
that influencing ROS content of APCs (with or without liposomes) will result in distinct 
differences in the levels of activation. This chapter aims to explore different DC bone marrow 
derived models as appropriate systems to test novel adjuvant formulations. Subsequently, the 
optimised model was used to determine the effects of redox modulation, using 2.2-17.6 µM 
H2O2 or 50-500 µM NAC. This is done in the presence of the TLR-4 ligand LPS or OVA as 
commonly used model antigens (165,180). The effects of using NAC-encapsulated within 
DDA:TDB liposomes on redox state are also examined and the effects on DC surface markers, 
cellular viability, DCF oxidation, pH and antigen uptake are investigated throughout. 
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Chapter objectives 
 
• To generate and characterise the use of bone marrow DCs models 
• To characterise H2O2 and NAC treatments on DC antigen association 
• To characterise DDA:TDB liposomes with and without NAC encapsulation 
• To determine the effects of delivery of OVA in liposomes on DC phenotype  
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3.2 Methods 
3.2.1 Granulocyte-macrophage colony-stimulating factor 
induced differentiation of mouse bone marrow progenitor cells 
to generate immature dendritic cells 
Three methods were compared for their potential application in screening novel adjuvants 
from Lutz (1999), Muccioli (2011) and Na (2016).  
3.2.1.1 The Lutz (1999) model 
Mouse bone marrow cells were seeded in 10 mL RPMI 1640 media supplemented with 
GMCSF (0.4 ng/mL final concentration after correction for units of activity and cell 
concentration) was added to bone marrow cells at a density of 2x105 cells/mL (10 mL) in a 
100 x 21mm petri dish. Cells were incubated for three days at 37°C in a humidified atmosphere 
with 5% CO2 in air. An additional 10 mL RPMI 1640 media supplemented with 0.4 ng/mL 
GMCSF was added to each dish and incubation was continued as before for a further three 
days. On day six, 10 mL of supplemented media was removed from each petri dish and the 
cells pelleted at 200 x g for 5mins at room temperature. The pellet was then resuspended in 
fresh 10 mL RPMI 1640 media supplemented with 0.4 ng/mL GMCSF and returned to the 
same dish. Following a further two days of incubation as before the day, six protocol was 
repeated and incubation continued for a further two days. On day 10 immature DCs were 
harvested by removing cells in suspension without disturbing adherent cells (181).  
3.2.1.2 The Muccioli (2011) model 
Mouse bone marrow cells were seeded in 10 mL RPMI 1640 media supplemented with 20 
ng/mL GMCSF at a concentration of 2x105 cells/mL in a 100 x 21mm petri dish. Cells were 
incubated for three days at 37°C in a humidified atmosphere with 5% CO2 in air. An additional 
10 mL RPMI 1640 media supplemented with 20 ng/mL GMCSF was added to each dish and 
Page 80 of 212 
 
incubation was continued as before for a further three days. On day six 10 mL was removed 
from each petri dish and the cells pelleted at 200 xg for 5mins at room temperature. The pellet 
was then resuspended in fresh 10 mL RPMI 1640 media supplemented with 20 ng/mL GMCSF 
and returned to the same dish. On day eight, immature DCs were harvested by removing cells 
in suspension without disturbing adherent cells (182). 
3.2.1.3 The Na (2016) model 
Mouse bone marrow cells were seeded in 10 mL RPMI 1640 media supplemented with 25 
ng/mL GMCSF at a concentration of 1x106 cells/mL in a 100 x 21mm petri dish. Cells were 
incubated for three days at 37°C in a humidified atmosphere with 5% CO2 in air. Non-adherent 
cells were then discarded, and media replaced with 10 mL RPMI 1640 media supplemented 
with 25 ng/mL GMCSF. On day seven, immature DCs were harvested by removing cells in 
suspension and washing off adherent cells with PBS twice (183). 
 
Table 3.1: Comparison of the bone marrow to dendritic cell differentiation methods between 
the Lutz (1999), Muccioli (2011) and Na (2016) models. 
 
 
  
Model
GMCSF  
(ng/mL)
Days to 
Differentiate Adherent 
Non-
adherent
Lutz 0.4 10 X ✓
Muccioli 20 8 ✓ ✓
Na 25 7 ✓ ✓
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3.3 Results 
3.3.1 Generation and characterisation of bone marrow 
dendritic cells models 
3.3.1.1 Light microscopy images overtime during differentiation  
DCs are morphologically different from bone marrow cells. To better characterise some of the 
differences between the Lutz, Muccioli and Na DC differentiation models (181–183) the size 
and shape of bone marrow as it differentiated into DCs was compared at 10x magnification 
(Figure 3.1).  
Bone marrow cells become adherent within hours of treatment with GMCSF and go through 
morphological changes within three days taking on a “fried egg appearance”. The Na model 
had a higher initial plating density (1x106 cells/mL) compared to Lutz and Muccioli 2x105 
cells/mL thus appears more populated (Figure 3.1).  
Confluency appears to increase for all models during the differentiation period indicating that 
some amount of proliferation continues. By the final day of differentiation for each model DCs 
appear similar being mostly adherent and taking on a fried egg morphology (Figure 3.1).  
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Figure 3.1: Microscope images (x10) of the differentiation of bone marrow into iDCs using 
GMCSF. Microscope image comparison Lutz, Muccioli and Na models respectively (181–183).  
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3.3.1.2 Surface expression of different models following complete 
differentiation 
To better characterise the differences between the Lutz, Muccioli and Na models (181–183), 
they were compared for the change in surface expression of the DC markers MHCII, CD11c 
and CD86. The analysis was always reported from the viable DC gate as described in the 
methods above. 
The Lutz model shows significantly better MHCII, no change in CD11c expression and CD86 
was significantly increased compared to the other two models (Figure 3.2).
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Figure 3.2: Lutz, Muccioli and Na models surface expression of DC markers at the final day of 
differentiation from bone marrow. Cells (2x105 in 200 µl) were incubated on ice for 20mins in RPMI, 
10% FCS and 0.1% BSA. Cells were then stained with A) anti-CD86 FITC, B) anti-CD11c Alexa Fluor 
647 and C) anti-MHC-II PE antibody and 10,000 cells analysed by a BD FACSCelesta and BD 
FACSDiva analysis software. Mean values are shown with SEM. These values result from three 
independent experiments. Data were analysed by ANOVA with Tukey’s post-test p<0.0001. 
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3.3.1.3 Flow cytometry images over time (to day 10) of side scatter 
and forward scatter  
To examine changes in cellular granularity and size indicating differentiation, the side scatter 
and forward scatter properties of DCs generated by the Lutz model were examined using BD 
FACSCelesta and BD FACSDiva analysis software. Over the differentiation period using the 
Lutz model, a marked separation between non-DC material represented by black dots outside 
the DC gate and DCs (red) can be seen in figure 3.3. On day 0 there is no clear separation of 
these two populations but by day 6 a shift in forward scatter is seen distinguishing them. By 
day 10 complete separation is visible indicating that the bone marrow cells increase in size in 
response to GMCSF treatment. Throughout differentiation (day 0-10) no clear change is seen 
in granularity (SS) (Figure 3.3). 
 
Figure 3.3: Forward and side scatter comparison of DC during differentiation from bone marrow 
using the Lutz model over the 10 day period. Cells (2x105 in 200 µl) were analysed by a BD 
FACSCelesta and BD FACSDiva analysis software. These results are representative of three 
independent experiments carried out on separate cultures at different times.  
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3.3.1.4 Cell surface antigen expression and intracellular reactive 
oxygen species over time (to day 10) 
To better characterise the differences in the surface expression and redox state due to 
differentiation MHCII, CD11c and CD86 as well as intracellular oxidation of DCF was 
examined. This work was done over the 10-day differentiation period using the Lutz model 
and analysis was always reported from the DC gate. The surface markers examined are not 
DC specific but are associated with their differentiation and maturation. The analysis was 
always reported from the DC gate.  
DCs show significantly increased CD11c expression by day 3 which subsequently decreases 
significantly between day 3 and 6. MHCII and CD86 expression do not change throughout 
differentiation (Figure 3.4A). DCs show significantly increased intracellular DCF oxidation by 
day 3 but this subsequently decreases significantly from day 3 to day 6 and again from day 6 
to day 10 (Figure 3.4B). 
  
Figure 3.4: Surface expression and intracellular ROS of DC during differentiation from bone 
marrow using the Lutz model over the 10 day period. A) Cells (2x105 in 200 µl) were incubated on 
ice for 20mins in RPMI, 10% FCS and 0.1% BSA. Cells were then stained with anti-CD11c Alexa Fluor 
647, anti-CD86 FITC and anti-MHC-II PE antibody. B) Cells (2x105 in 200 µl) were treated with 50 µM 
DCFDA. 10,000 cells analysed per sample by a BD FACSCelesta and BD FACSDiva analysis software. 
Mean values are shown with SEM. These values result from three independent experiments. Data were 
analysed by ANOVA with Tukey’s post-test ****p <0.0001. 
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3.3.1.5 Maturation of immature dendritic cells by lipopolysaccharide 
effects on size, shape and viability 
To better characterise some of the differences following maturation of DCs using the Lutz, 
model, the size and shape of DCs as well as viability (propidium iodide) were examined 
following treatment with 100 ng/mL LPS for 24 hours was examined. 
LPS treatment caused DCs to take on an even more pronounced fried egg appearance with 
more pronounced pseudopodia at 10x magnification. Cell number appears to increase 
indicating proliferation during the maturation period (Figure 3.5A & B). To examine changes 
in cellular granularity and size during maturation side scatter and forward scatter were 
examined using BD FACSCelesta and BD FACSDiva analysis software. No clear change is 
seen in granularity (side scatter) or size (forward scatter) in response to LPS treatment (Figure 
3.5D & F). No change was seen in viability was observed in response to LPS treatment (Figure 
3.5C, E & G). 
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Figure 3.5: Maturation of immature dendritic cells by lipopolysaccharide effects on size, shape 
and viability. A) Microscope images (x10) comparing DCs treated with or without 100 ng/mL LPS for 
24hours. These images are representative of at least three independent experiments. B) Effect of 100 
ng/mL LPS treatments on DC viability (propidium iodide staining). Cells (2x105 in 200 µl) were treated 
with 0.2 µg/mL propidium iodide at room temperature and 10,000 cells were analysed immediately by 
a BD FACSCelesta and BD FACSDiva analysis software. Mean values are shown with SEM. These 
values result from three independent experiments. Data were analysed by ANOVA with Tukey’s post-
test. Example histograms and accompanying dot plots of propidium iodide staining following 100 ng/mL 
LPS treatments. D) Dot plot showing untreated DCs highlighted by the white gate and propidium iodide 
stain (pink associated with cell death). E) Histogram showing +ve gating of DCs of untreated DCs. F) 
Dot plot showing side scatter and propidium iodide stain (pink associated with cell death) following 24hr 
treatment with 100 ng/mL LPS. G) Histogram showing +ve gating of DCs following 24hr treatment with 
100 ng/mL LPS. This data is representative of at least three independent experiments. 
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3.3.1.6 Maturation of immature dendritic cells – effect of 
lipopolysaccharide on cell surface antigen 
To better characterise the differences in the surface expression of the DC activation markers 
on maturation, MHCII, CD11c and CD86 were examined in response to 100 ng/mL LPS or 0.8 
mg/mL OVA treatment for 24hours given at day 10. The analysis was always reported from 
the DC gate.  
DCs show significantly increased CD86 and MHCII expression in response to LPS and OVA 
however OVA treatments increased CD86 expression significantly more than LPS. CD11c 
expression does not change significantly with any treatment (Figure 3.6). 
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Figure 3.6: Surface expression of DC following treatment with LPS or OVA. Cells 2x105 were 
treated with 100 ng/mL LPS or 0.8 mg/mL OVA for 24hours at 37°C at 5% CO2. Cells were then stained 
with A) anti-CD86 FITC, B) anti-CD11c Alexa Fluor 647 and C) anti-MHC-II PE antibody and 10,000 
cells analysed by a BD FACSCelesta and BD FACSDiva analysis software. Mean values are shown 
with SEM. These values result from three independent experiments. Data were analysed by ANOVA 
with Tukey’s post-test ****p <0.0001.  
Page 89 of 212 
 
3.3.1.7 Maturation of immature dendritic cells – effect of 
lipopolysaccharide on redox state (dichlorofluorescin oxidation/ 
glutathione) 
To better characterise the differences in the redox state of DCs during maturation with 100 
ng/mL LPS or 0.8 mg/mL OVA, cellular GSH and intracellular oxidation of DCF was measured 
following 4hours of treatment. DCF oxidation analysis was always reported from the DC gate.  
DCs show significantly increased intracellular DCF oxidation and decreased GSH in response 
to OVA but not LPS (Figure 3.7A & B).  
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Figure 3.7: Effect of LPS or OVA treatments on intracellular oxidation measurements (DCF) and 
GSH levels (GSH-Glo). A) Cells (2x105 in 200 µl) were treated with 100 ng/mL LPS or 0.8 mg/mL OVA 
for 30mins at 37°C at 5% CO2. DCFDA (50 µM) was then added at room temperature and 10,000 cells 
were analysed immediately by a BD FACSCelesta and BD FACSDiva analysis software. B) Cells (1x105 
in 2 ml) were treated with 100 ng/mL LPS or 0.8 mg/mL OVA for 24hours at 37°C at 5% CO2. 10,000 
cells were analysed using GSH-Glo™ kits from Promega UK as per manufacturer’s instructions. Mean 
values are shown with SEM. These values are from three independent experiments. Data were 
analysed by ANOVA with Tukey’s post-test ***p <0.001, ****p <0.0001. 
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3.3.1.8 Effect of H2O2/ n-acetyl cysteine with lipopolysaccharide on 
redox state  
To characterise the differences induced by redox-active compounds, intracellular oxidation of 
DCF was measured following 4hours of treatment 2.2-17.6 µM H2O2 or 50-500 µM NAC in the 
presence of 100 ng/mL LPS. Cellular DCF analysis was always reported from the DC gate.  
DCs show significantly increased intracellular oxidation in response to 17.6 µM H2O2 but no 
other treatment at any other concentrations shows any significant change (Figure 3.8A). 
Differences in the GSH levels of DCs following treatment with 2.2-17.6 µM H2O2 or 50-500 µM 
NAC in the presence of 100 ng/mL LPS cellular GSH was measured using the GSH-Glo assay 
following 24hours of treatment. 
DCs show no significant difference in GSH levels in response to H2O2 treatments under the 
conditions used here. All NAC treatments significantly increased GSH when compared to the 
LPS antigen only control (Figure 3.8B). 
As this experiment was designed to represent how DCs in vivo would respond to the inclusion 
of the ROS modulators H2O2 and NAC in an adjuvant LPS were included in these treatments 
as a model antigen. 
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Figure 3.8: Effect of NAC or H2O2 treatments in the presence of LPS on intracellular oxidation 
measurements (DCF) and cellular GSH levels (GSH-Glo). A) Cells (2x105 in 200 µl) were treated 
with 2.2-17.6 µM H2O2 or 50-500 µM NAC in the presence of 100 ng/mL LPS or for 30mins at 37°C at 
5% CO2. DCFDA (50 µM) was then added at room temperature and 10,000 cells were analysed 
immediately by a BD FACSCelesta and BD FACSDiva analysis software. B) Cells (2x105 cells in 2 ml) 
were treated with 2.2-17.6 µM H2O2 or 50-500 µM NAC in the presence of 100 ng/mL LPS or for 24hours 
at 37°C at 5% CO2. 10,000 cells were analysed using GSH-Glo™ kits from Promega UK as per 
manufacturer’s instructions. Mean values are shown with SEM. These values result from three 
independent experiments. Data were analysed by ANOVA with Tukey’s post-test *p <0.01, ****p 
<0.0001. Mean values are shown with SEM. These values result from three independent experiments. 
Data were analysed by ANOVA with Tukey’s post-test ****p <0.0001. 
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3.3.1.9 Effect of H2O2/ n-acetyl cysteine on cell surface antigen 
expression after lipopolysaccharide 
To better characterise the effect of redox state, differences in the surface expression of the 
DC activation markers MHCII, CD11c and CD86 in response to treatment with 2.2-17.6 µM 
H2O2 or 50-500 µM NAC in the presence of 100 ng/mL LPS were examined. The analysis was 
always reported from the DC gate. The effects of H2O2 and NAC were not examined in 
absence of LPS in these experiment as the primary objective was to model how these 
treatments altered maturation. 
CD86 expression increases significantly in response to LPS. NAC treatments further 
increased expression relative to the LPS only treatment. MHCII expression decreased 
significantly only in the presence of 17.6 µM H2O2. CD11c expression did not change in 
response to any treatments (Figure 3.9).  
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Figure 3.9: Surface expression of DC following treatment with NAC or H2O2 in the presence of 
LPS. Cells (2x105 cells in 2 mL) were treated with 2.2-17.6 µM H2O2 or 50-500 µM NAC in the presence 
of 100 ng/mL LPS or for 24hours at 37°C at 5% CO2. Cells were then stained with anti-CD11c Alexa 
Fluor 647, anti-CD86 FITC and anti-MHC-II PE antibody and 10,000 cells analysed by a BD 
FACSCelesta and BD FACSDiva analysis software. Mean values are shown with SEM. These values 
result from three independent experiments. Data were analysed by ANOVA with Tukey’s post-test p< 
0.0001. 
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3.3.2 Characterisation of liposomes 
3.3.2.1 Size and charge analysis of liposomes 
In order to determine hydrodynamic diameter (nm), polydispersity index and zeta potential of 
DDA:TDB liposomes coated with 20 µg OVA, a ZetaSizer from Malvern Instruments was used 
to carry out PCS and dynamic light scattering analysis. Liposomes were prepared two days 
prior to analysis and stored at 4oC. 
Although DDA:TDB-NAC appear to be smaller than DDA:TDB alone zeta potential and poly 
dispersion index were unchanged (table 3.2).  This indicates that they may perform similarly 
to DDA:TDB regarding antigen association and depot formation. 
 
SIZE (nm) PDI ZP (mv) 
Formulation Mean SD Mean SD Mean SD 
DDA:TDB + 20 µg 
OVA/dose 1748 837 0.68 0.16 55.7 3.6 
DDA:TDB-NAC + 20 µg 
OVA/dose 1342 362 0.53 0.25 53.0 4.9 
 
Table 3.2: Hydrodynamic diameter; Polydispersity index; Zeta potential of DDA:TDB and 
DDA:TDB-NAC liposomes coated with 20 µg OVA using a ZetaSizer from Malvern Instruments. 
Results denote the mean ± SD of at least 3 experiments. 
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3.3.2.2 Effect on dendritic cell viability of liposomes with and 
without N-acetyl cysteine 
To examine liposomal dose-dependent changes in DC viability, cells were treated with 
DDA:TDB or DDA:TDB-NAC liposomes (0.5-64 µg/mL) for 24hours and the levels of 
propidium iodide staining were examined. The analysis was always reported from the DC gate.  
At >12 µg/mL, DDA:TDB is significantly more toxic than DDA:TDB-NAC as shown in Figure 
3.10 A and highlighted in Figure 3.10 B. 
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Figure 3.10: Effect of DDA:TDB and DDA:TDB-NAC treatments on DC viability (propidium iodide 
staining). Cells (2x105 cells in 2 mL) were treated with DDA:TDB or DDA:TDB-NAC liposomes for 
24hours at 37°C at 5% CO2. Following treatment cells (2x105 in 200 µl) were then treated with 0.2 µg/mL 
propidium iodide at room temperature and 10,000 cells were analysed immediately by a BD 
FACSCelesta and BD FACSDiva analysis software. A: Dose dependent response of cells treated with 
DDA:TDB or DDA:TDB-NAC liposomes (0.5-64 µg/mL) for 24hours. B: Highlighting DDA:TDB or 
DDA:TDB-NAC (12 µg/mL) liposome treatments selected for in vitro experiments. Mean values are 
shown with SEM. These values result from three independent experiments. Data were analysed by 
ANOVA with Tukey’s post-test **p <0.0016. 
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3.3.2.3 Ovalbumin effect on dendritic cell viability over time in the 
presence and absence of liposomes 
propidium iodide was used to examine DC viability during 24hr maturation with 0.8 µg/mL OVA 
alone or coated to 12 µg/mL of DDA:TDB or DDA:TDB-NAC. The analysis was always 
reported from the DC gate.  
Both OVA-coated DDA:TDB and DDA:TDB-NAC show significantly more toxicity than OVA 
alone by 12hours and DDA:TDB also shows significantly more toxicity than DDA:TDB-NAC at 
this time point. This difference in toxicity is even more prominent for DDA:TDB by 24hours 
(Figure 3.11). 
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Figure 3.11: Effect of OVA treatment in the presence and absence of liposomes on DC viability 
(propidium iodide staining) during maturation with OVA. Cells (2x105 cells in 2 mL) were treated 
with 0.8 µg/mL OVA for 24hours at 37°C at 5% CO2. During maturation, cells were sampled at 0, 1, 12 
and 24hours and treated with 0.2 µg/mL propidium iodide at room temperature and 10,000 cells were 
analysed immediately by a BD FACSCelesta and BD FACSDiva analysis software. Mean values are 
shown with SEM. These values result from three independent experiments. Data were analysed by 
ANOVA with Tukey’s post-test. 
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3.3.3 Effect of delivery of antigen in liposomes on dendritic cell 
phenotype 
3.3.3.1 Bovine serum albumin -FITC uptake fluorescence 
microscopy images in the presence and absence of liposomes 
BSA-FITC conjugate was used to assess antigen uptake by DCs in response to 12 µg/mL of 
DDA:TDB or DDA:TDB-NAC. DCs were treated with 0.8 µg/mL of BSA-FITC conjugate alone 
or coated to liposomes for 4hours at 37°C, 5% CO2 and examined by fluorescence 
microscopy.  
DCs show bright fluorescence when treated with BSA-FITC conjugate alone and less 
fluorescence when treated in combination with DDA:TDB or DDA:TDB-NAC (Figure 3.12). 
This is presumably due to electrostatic interactions from the liposome preventing antigen 
uptake and the artificial depot formed by the well that would not be present in vivo. In this 
experiment FITC-BSA alone serves as a positive control and is not reflective of an actual 
immunisation. 
 
Figure 3.12: BSA-FITC conjugate uptake of DC treated with or without DDA:TDB and DDA:TDB-
NAC liposomes. Cells (1x106 cell/mL in 200 µl) were treated with 1 µg/mL of BSA-FITC alone or 
bound to the surface of DDA:TDB or DDA:TDB-NAC (12 µg/mL) liposomes for 4hours at 37°C, 5% 
CO2. Cells were resuspended in PBS to 1x106 cell/mL and (20 µl) were mounted onto glass slides. 
Confocal microscopy images using Nikon Ti-Eclipse with A1M Confocal and NIS-Elements Acquisition 
software were then captured.   
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3.3.3.2 Bovine serum albumin -FITC uptake by flow cytometry 
(effect of temperature) in the presence and absence of liposomes  
BSA-FITC conjugate was used to assess antigen uptake by DCs in response to 12 µg/mL of 
DDA:TDB or DDA:TDB-NAC. DCs were treated with 0.8 µg/mL of BSA-FITC conjugate alone 
or bound to 12 µg/mL liposomes for 4hours at 37°C to examine active uptake or at 4°C to 
examine passive antigen association. 
Antigen uptake at 37°C is significantly decreased in DCs treated with either liposome 
formulation compared to antigen-only treatments. However, on ice when there is no active 
uptake and endocytosis has stopped, antigen-only uptake shows no significant difference from 
no-treatment controls. Both liposome formulations show significantly more antigen association 
with the DC relative to the antigen-only treatment. This is probably due to electrostatic 
interactions between the liposomes and the DCs (Figure 3.13). 
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Figure 3.13: Effect of DDA:TDB and DDA:TDB-NAC treatments on antigen uptake (BSA-FITC 
conjugate). Cells (2x105 cells in 2 mL) were treated with 12 µg/mL DDA:TDB or DDA:TDB-NAC 
liposomes coated with 0.8 µg of BSA-FITC for 1hr at 37°C at 5% CO2 or at ~5°C as a negative 
control.10,000 cells were analysed immediately by a BD FACSCelesta and BD FACSDiva analysis 
software. A: BSA-FITC (0.8 µg) coated DDA:TDB or DDA:TDB-NAC (12 µg/mL) liposome treatments 
at 37°C for 1hr. B: BSA-FITC (0.8 µg/mL) coated DDA:TDB or DDA:TDB-NAC (12 µg/mL) liposome 
treatments on ice for 1hr as a negative control. Mean values are shown with SEM. These values result 
from three independent experiments. Data were analysed by ANOVA with Tukey’s post-test ****p 
<0.0001.   
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3.3.3.3 Effect of ovalbumin on cell surface antigen in the presence 
and absence of liposomes 
To better characterise the effect of OVA delivery formulation on DC maturation, differences in 
the surface expression of the DC activation markers MHCII, CD11c and CD86 in response to 
treatment DDA:TDB or DDA:TDB-NAC (12 µg/mL), different liposomes coated with OVA (0.8 
µg) were examined. The analysis was always reported from the DC gate after 24 hours.  
CD11c, CD86 and MHCII expression all increased significantly due to DDA:TDB-NAC 
treatments relative to DDA:TDB treatments alone (Figure 3.14). 
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Figure 3.14: Surface expression of DC following treatment with DDA:TDB and DDA:TDB-NAC 
liposomes coated with OVA. Cells (2x105 cells in 2 mL) were treated with DDA:TDB or DDA:TDB-
NAC (12 µg/mL) liposomes coated with OVA (0.8 mg/mL) for 24hours at 37°C at 5% CO2. Cells (2x105) 
were then stained with anti-CD11c Alexa Fluor 647, anti-CD86 FITC and anti-MHC-II PE antibody and 
10,000 cells analysed by a BD FACSCelesta and BD FACSDiva analysis software. Mean values are 
shown with SEM. These values result from three independent experiments. Data were analysed by 
ANOVA with Tukey’s post-test ****p <0.0001. 
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3.3.3.4 Total pH after ovalbumin in presence and absence of 
liposomes 
pHrodo™ Red AM staining solution was used to assess DC cytoplasmic pH in response to 12 
µg/mL of DDA:TDB or DDA:TDB-NAC. DCs were treated with 0.8 µg/mL of OVA alone or 
coated to liposomes for 24hours at 37°C at 4°C. The analysis was always reported from the 
DC gate and normalised by positive gating for 2% fluorescence of the negative no stain 
control. 
Cellular pH is significantly decreased in DCs treated with DDA:TDB-NAC relative to OVA only 
treatments. DDA:TDB shows no significant change (Figure 3.15). This could result in more 
antigen availability to MHCII depending due to differences in degradation. 
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Figure 3.15: Intracellular pH measurements of DC following treatment with DDA:TDB and 
DDA:TDB-NAC liposomes coated with OVA (pHrodo™ Dye). Cells (2x105 cells in 2 mL) were 
washed and resuspended in 2 mL pHrodo™ Red AM staining solution for 30mins at 37°C, 5% CO2 as 
per manufacturer’s instructions. The cells were then treated with DDA:TDB or DDA:TDB-NAC (12 
µg/mL) liposomes coated with OVA (0.8 mg/mL) for a further 30mins at 37°C at 5% CO2. 10,000 cells 
were analysed by a BD FACSCelesta and BD FACSDiva analysis software. pHrodo™ Red AM 
expression levels were reported as MdX after positive gating for 2% fluorescence of the negative no 
stain control. Mean values are shown with SEM. These values result from three independent 
experiments. Data were analysed by ANOVA with Tukey’s post-test *p < 0.0254.  
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3.3.3.5 Phagosomal pH in the presence and absence of liposomes 
pHrodo™ Red E. coli BioParticles™ were used to determine phagosomal pH in response to 
12 µg/mL DDA:TDB and DDA:TDB-NAC liposomes. DCs were seeded at 1x106 cell/mL in 200 
µl resuspended homogenised bioparticles and treated with DDA:TDB or DDA:TDB-NAC for 
1.5 hours at 37°C. 10,000 cells were then examined using BD FACSCelesta and BD 
FACSDiva analysis software at excitation 596 nm, emission 615 nm. pHrodo™ Red 
expression levels were reported as MdX after positive gating for 2% fluorescence of the 
negative no stain control. Alternatively, 50 µl of 1x106 cell/mL were mounted onto glass slides 
and imaged by confocal microscopy using Nikon Ti-Eclipse with A1M Confocal and NIS-
Elements Acquisition software. Cells were resuspended in PBS to 1x106 cell/mL and (20 µl) 
were mounted onto glass slides. 
Confocal images show bright fluorescence in cells treated with pHrodo Red E. coli Bio 
Particles only but reduced fluorescence when treated in combination with DDA:TDB or 
DDA:TDB-NAC (Figure 3.16 A). Flow cytometry analysis showed no significant change in 
fluorescence indicative of phagosomal pH in cells treated with pHrodo Red E. coli Bio Particles 
alone or in combination with DDA:TDB or DDA:TDB-NAC (Figure 3.16 B). These contrasting 
results from the confocal microscope and flow cytometer may be due to the differences in the 
quantitative and qualitative nature of each method respectively. Confocal microscopy is also 
fixed on a single plane for imaging whereas the flow cytometer does not have this limitation. 
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Figure 3.16: Phagosomal pH of DC following treatment with DDA:TDB and DDA:TDB-NAC 
liposomes (pHrodo™ Red E. coli BioParticles™). Cells (1x106 cell/mL in 200 µl) were washed and 
resuspended in 200 µl homogenised bioparticles with DDA:TDB or DDA:TDB-NAC (12 µg/mL) 
liposomes for 1.5hours at 37°C, 5% CO2 as per manufacturer’s instructions. A) Confocal microscopy 
images using Nikon Ti-Eclipse with A1M Confocal and NIS-Elements Acquisition software. Cells were 
resuspended in PBS to 1x106 cell/mL and (20 µl) were mounted onto glass slides. B) 10,000 cells were 
analysed by a BD FACSCelesta and BD FACSDiva analysis software. pHrodo™ Red E. coli 
BioParticles™ emission levels were reported as MdX after positive gating for 2% fluorescence of the 
negative no stain control. Mean values are shown with SEM. These values result from three 
independent experiments. Data were analysed by ANOVA with Tukey’s post-test.  
Page 103 of 212 
 
3.3.3.6 Dendritic cell reactive oxygen species / Glutathione after 
ovalbumin in presence and absence of liposomes 
To better characterise the differences in the redox state of DCs in response to 12 µg/mL of 
DDA:TDB or DDA:TDB-NAC, cellular GSH and intracellular oxidation of DCF were measured. 
DCs were treated with 0.8 µg/mL of OVA alone or coated to liposomes for 24hours. DCF 
analysis was always reported from the DC gate.  
DCs show significantly increased intracellular oxidation in response to OVA, however, 
DDA:TDB-NAC decreases intracellular ROS compared to DDA:TDB and OVA alone. GSH-
Glo results show reduced GSH in response to OVA and DDA:TDB treatments. DDA:TDB-NAC 
treatments GSH levels are comparable to no treatment control and significantly higher than 
DDA:TDB alone. (Figure 3.17).  
ROS is known to influence the pH within the lumen which in turn regulates lysosomal protease 
activity and antigen processing. Manipulation of this system could lead to better immunity in 
cases where over processing of antigen and thus poor MHCII loading is an issue.  
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Figure 3.17: Effect DDA:TDB and DDA:TDB-NAC liposomes coated with OVA treatments on A) 
Intracellular oxidation measurements (DCF). Cells (2x105 in 200 µl) were treated with DDA:TDB or 
DDA:TDB-NAC (12 µg/mL) liposomes coated with OVA (0.8 µg/mL) for 24hours at 37°C at 5% CO2. A) 
DCF (50 µM) was then added at room temperature and 10,000 cells were analysed immediately by a 
BD FACSCelesta and BD FACSDiva analysis software. B) Cellular GSH levels (GSH-Glo), cells (2x105 
cells in 2 mL) were treated with DDA:TDB or DDA:TDB-NAC (12 µg/mL) liposomes coated with OVA 
(0.8 mg/mL) for 24hours at 37°C at 5% CO2. 10,000 cells were analysed using GSH-Glo™ kits from 
Promega UK as per manufacturer’s instructions. Mean values are shown with SEM. These values result 
from three independent experiments. Data were analysed by ANOVA with Tukey’s post-test ****p 
<0.0001. 
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3.4 Discussion 
Originally proposed by Russell and Burch in 1959 in The Principles of Humane Experimental 
Technique, the 3Rs give a framework to approach animal experiments in the UK that has been 
incorporated into the Animal (Scientific) Procedures Act. It has been argued that due to more 
detailed planning being required, the 3Rs may increase the quality of the science produced 
by better standardising the experiment. This, along with animals being in a state of reduced 
stress, produces more reliable and reproducible data (184,185).  
The 3Rs have also been criticised principally in the use of replacement models as these can 
be difficult to validate. This can be particularly challenging for toxicological studies and drug 
development with different regulatory authorities holding different views. The reduction has 
led to cases of too few animals being used for study power in instances where expert statistical 
support is not available. This inadvertently runs counter to the 3Rs as it causes suffering 
without producing meaningful results. The standardisation of treatments under refinement has 
also been questioned. Although this may help to ensure reproducibility and is done in what is 
thought to be the best interests of animals as a whole it may not necessarily be what is best 
for a specific animal or for a specific procedure. Standard procedures may mean that these 
treatments are given nevertheless again going against the principles of the 3Rs (185). 
To minimise the number of animals needed for this project the possibility of using a bone 
marrow derived DC model was tested with marrow from mice from a breeder colony that were 
due to be culled. Donated from the Sir William Dunn School (Oxford), mice were sacrificed in 
accordance with schedule 1 and used in this study to maximise the usefulness of these 
animals. Three methods of DC differentiation used by Lutz (181), Muccioli (182) and Na (183) 
were evaluated and the morphological differences as well as the expression of the DC surface 
markers MHCII, CD11c and CD86 were evaluated. All three models use only GMCSF to 
differentiate with no addition of IL-4 which is commonly added in many models to stimulate 
bone marrow differentiation (186–188). IL-4 has been demonstrated to not be required when 
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high levels of GMCSF are used. Each model uses different doses of GMCSF, cell 
concentrations and times, however (181–183,189).  
GMCSF helps to form haematopoietic progenitor colonies which can differentiate into 
granulocytes, macrophages and macrophages as well as stimulate proliferation and survival 
in haematopoietic cells (190,191). It is not constantly present in vivo but is produced in 
response to inflammatory signals. In GMCSF deficient mice, inflammatory DCs are 
diminished, highlighting its importance for differentiation and its necessity for a proper 
inflammatory response (183).  
Morphologically the Lutz, Muccioli and Na DC differentiation models appear similar by their 
respective endpoints, all going from non-adherent spherical cells to becoming mixtures of 
adherent, fried egg-shaped or some cells remaining non-adherent. Confluency also appears 
to increase for all models indicating some amount of proliferation continues during the 
differentiation period, similar to what is reported in other studies (192). These changes are 
apparent despite the differentiation periods being so different which may be due to differences 
in GMCSF concentration with the Lutz model using 0.4 ng/mL GMCSF over an eleven-day 
period whereas the Muccioli and Na use 20 ng/mL and 25 ng/mL over eight and seven days 
respectively (181–183). 
In order to validate these models the common DC surface markers MHCII, CD11c and CD86 
were assessed by flow cytometry following 24hr stimulation with 100 ng/mL LPS (193). All 
three models showed similar expression levels of CD11c however the Lutz model consistently 
gave the best expression the CD86 band MHCII markers following activation. This may be 
because the GMCSF concentration used is more physiologically representative (194). The 
Lutz model was further examined for changes in size & granularity during differentiation as 
well as intracellular oxidation and surface expression of the DC markers discussed above.  
Over the 1-day differentiation period, a clear distinction between non-DC and DCs is shown 
by an increase in forward scatter of the DC population. On day 0, there is a single population 
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but by day 6, two populations are distinguishable then by day 10, complete separation is visible 
indicating that the bone marrow cells increase in size in response to GMCSF treatment. This 
confirms the morphological observation of the cells. Throughout differentiation (day 0-10) no 
clear change is seen in granularity (SS). 
CD86 expression necessary for costimulatory signalling of T cells does not change throughout 
the 10 day differentiation period (96). This may be reflective of the lack of need for this marker 
in the absence of processing as no antigen for presentation is present. CD11c expression 
remains relatively stable although peaks on day 3, this might be because the sudden 
introduction of GMCSF causes an upregulation of this marker over the first three day which is 
subsequently downregulated due to its habitual presence. It may also relate to the higher 
GMCSF concentration 0.4 ng/mL relative to cell number which increases throughout. When 
CD11c expression is compared to cellular morphology, no clear change is visible other than 
the emergence of adherent cells. And when side scatter and forward scatter are considered 
there is little distinction between cells and non-DC cells. MHCII is a key antigen-presenting 
molecule necessary for the development and activation of CD4+ T cells (195). Its expression 
does not change during differentiation, this is likely because no antigen is present to stimulate 
surface expression. 
Redox state as measured by a combination of ROS (DCF oxidation) and GSH. DCF becomes 
fluorescent in response to oxidation. However, this probe is extremely unstable and must be 
kept in darkness throughout its use as it auto-oxidizes upon exposure to light. This combined 
with increasing signal over time makes the timings and conditions under which this probe may 
be added challenge when trying to produce reproducible results (196). Due to these issues, 
the probe was added to each tube exactly 30mins before the signal was quantified by the BD 
FACS Celesta. All tubes were kept in the dark throughout this period and during acquisition. 
The DCF signal appears to peak on day three and then steadily reduces in the days that follow. 
This could be because initially the DCs are adapting to their new culture conditions where the 
oxygen tension is significantly lower and GMCSF is present, which is known to increase ROS 
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(197–200). As this data is gathered from the DC gate which is more populated (relative to total 
event numbers) by day 3 then it may be that DCs are in a particularly high proliferative stage 
in which it has been established that they produce ROS (201). 
To further characterise the DC model 100 ng/mL LPS from Escherichia coli O26:B6 was used 
to stimulate DC. The effects on morphology, viability granularity and size, DC activation 
markers, oxidation and phagosomal pH were all assessed.  
Confluency appears to increase as a result of LPS treatment as does the appearance of more 
pronounced pseudopodia making the cells more fried egg-shaped in appearance. This agrees 
with already published data showing increased proliferation and development of 
pseudopodium in the presence of LPS. This is likely due to the DCs stimulation by this TLR-4 
inflammatory signal causing them to mature and priming them for further activation by T cells 
(192,202).  
Despite changes in pseudopodia, the granularity, size and viability of DCs following LPS 
activation remains unchanged. LPS 100 ng/mL and OVA 0.8 mg/mL both significantly increase 
the surface expression of MHCII and CD86, however, LPS stimulation is significantly better at 
increasing CD86 surface expression possibly due to its strong immunogenic nature. 
Downregulation of CD11c upon activation has not been reported; it has been shown to be the 
case after maturation through TLR activation, however, no significant change was seen due 
to LPS (203). Variances with the data observed here could be down to differences in LPS 
treatment concentration, the LPS source or the methods of generating the DCs themselves 
(204).  
Intracellular oxidation as measured by DCF is significantly higher following OVA treatment, 
but not LPS in line with GSH which decreases in response to OVA only. Although both OVA 
and LPS are antigens, LPS may be considered a weaker antigen in some regards, however, 
due to its glycoprotein structure, it is a direct TLR agonist (165). Because of differences in their 
structure, such as containing many repeating units, APCs process glycoproteins differently. 
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APCs interact with exogenous glycoproteins through CD1, use different signalling pathways 
compared to other antigens like OVA and release different cytokines as a result (205–211). 
These differences may explain the distinctive change in intracellular oxidation which has also 
been demonstrated previously (211). Low levels of GSH were observed here. This may relate 
to the very low values of GSH present in mouse APCs and lack of sensitivity of the assay 
(212). Low molecular weight thiols which are major targets for reversible redox modifications 
in immune cells and Trx1, an NADPH dependent redox modulator used to protect against 
oxidative stress, could be used as alternative indicators of redox change in these cells 
(31,213,214).  
To assess the importance of a reducing environment on DC antigen interaction, the GSH 
precursor and antioxidant NAC (50-500 µM) was added to DC in the presence of 100 ng/mL 
LPS. H2O2 (2.2-17.6 µM) was similarly added as a positive oxidation control and to assess its 
effects at non-toxic concentrations. NAC is membrane-permeable. Inside the cell, NAC is 
hydrolysed releasing cysteine the precursor which is usually a limiting substrate precursor of 
GSH synthesis (215,216).  
CD86 expression increases significantly in response to LPS and NAC treatments further 
increased CD86 expression in a dose-independent manner. This runs counter to previous 
studies but may be explained by the 10x lower dose of LPS and the up to 500x greater dose 
of NAC used in that previous study (211). Although LPS and NAC have opposite effects on 
redox state, the increase in CD86 expression with increasing quantities of NAC indicate that 
reduced ROS is preferable for this marker and that the ROS produced by LPS treatment may 
hinder its expression. MHCII expression decreased significantly only in the presence of 17.6 
µM H2O2 and could be explained by excess ROS down-regulating lysosomal protease activity 
(38). CD11c expression did not change in response to NAC nor H2O2 treatments. GSH content 
increased in response to NAC treatments when compared to the LPS antigen only treatment 
control. This has been demonstrated previously and may be a result of NAC being a bottleneck 
procurer molecule necessary for the production of GSH (75). Intracellular oxidation of DCF 
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was demonstrated by 17.6 µM H2O2. This is likely due to oxidation of the probe by ROS 
introduced from the highest dose of H2O2 (196). 
DDA:TDB liposomes have been shown to drain to lymph nodes and to have a strong 
electrostatic attraction to proteins which allows for the formation of depots and is thought to 
draw in APCs to lymph nodes to further enhance the immune response (142). This charge 
may also be used to electrostatically bind negatively charged antigens such as OVA to the 
surface (111,129,133,134). ROS were shown above to reduce MHCII presentation suggesting 
reduced antigen presentation by DCs in the presence of peroxide. As DDA/TBD liposome 
lipids contain no carbon double bonds and so cannot be oxidised or reduced without changing 
formulation, NAC was instead encapsulated to introduce a reducing entity as a potential 
method of enhancing antigen presentation. Loading efficiency of OVA was assessed and 
found to be ≥70% based on initial load for both DDA:TDB and DDA:TDB encapsulating NAC. 
DDA:TDB-NAC appear to be smaller than DDA:TDB alone 1342 ± 362 nm as opposed to 1747 
± 836 nm but zeta potential and poly dispersion index are unchanged. Differences in DDA:TDB 
liposome size may affect the quantity of liposome reaching the lymph nodes with larger 
liposomes being more effective. Larger liposomes also show better cell proliferation and IL-10 
production than smaller IFN-ɣ stimulating liposomes. No differences in antigen uptake or 
antibody production associated with size are known, however (154). 
The development of adjuvant for human use is notoriously difficult due to strict regulations 
regarding vaccine toxicity and the fact that the immune-stimulating components are often toxic 
to some degree. Few adjuvants under development will ever reach human trials and fewer still 
will be approved for use in humans as alum and MF59 have (146,217,218). The inclusion of 
NAC in the DDA/TBD liposome formulation resulted in significantly increased DC viability in a 
dose-dependent manner as well as overtime. OVA alone seems to have no effect on viability 
over 24 hours. However DDA:TDB and DDA:TDB-NAC both show some toxicity as early as 
12hours after treatment but DDA:TDB also shows significantly more toxicity than DDA:TDB-
NAC at this time point. By 24hours, this difference in viability between formulations is even 
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more pronounced. This may or may not be related to their size as it goes against the common 
dogma that increased size of liposomes is associated with less cell death. It may instead be 
explained by the NAC itself somehow reducing the toxicity of the DDA:TDB liposome through 
one of its many modes of action (219). With greatly reduced toxicity comes the opportunity for 
increasing the amount of adjuvant used and potentially antigen load. This comes with the 
caveat that the new formulation DDA:TDB-NAC is able to work as effectively as an adjuvant 
as DDA:TDB currently does. 
Antigen uptake is markedly increased in the presence of FITC-BSA alone over either FITC-
BSA DDA:TDB or DDA:TDB-NAC. This is presumably in part due to toxicity and electrostatic 
interactions preventing antigen uptake as easily and the artificial depot formed by the well. In 
vivo, the antigen would not be constantly present as it is in a well in vitro thus adjuvants 
capable of prolonging presentation to the immune system whilst preventing degradation are 
necessary (220–222). In this experiment FITC-BSA alone serves as a positive control and is 
not reflective of an actual immunisation. Comparing antigen uptake between formulations at 
37°C DDA:TDB no significant difference in the formulation is observed with regards to antigen 
association. From this it may be assumed that any differences observed in DC activation or 
oxidation state are therefore antigen dose-independent indicating that the change is down to 
the presence of NAC, or the differences in toxicity. At 4°C where there is no active uptake no 
significant uptake of free FITC-BSA is observed indicating that endocytosis has stopped. 
Significant uptake of DDA:TDB and DDA:TDB-NAC can still be seen relative to this control, 
however, this is probably due to electrostatic interactions between the liposomes and the DCs 
that is temperature independent and down to the cationic DDA content of the formulation 
(220).  
Surface expression of the DC activation markers MHCII, CD11c and CD86 all showed a 
significant increase in response to DDA:TDB-NAC relative to DDA:TDB alone using OVA as 
an antigen. This may be because of the increased reducing conditions introduced by the NAC 
during antigen processing as DDA:TDB-NAC has significantly less oxidation than DDA:TDB 
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alone again using OVA as a model antigen. The pH and lysosomal proteases of phagosomes 
are tightly controlled in order to regulate cleavage of foreign antigens for future presentation 
to T cells. NADPH oxidase NOX2 is recruited to phagosomes during antigen processing where 
it produces ROS creating an alkaline environment within the lumen which in turn regulates 
lysosomal protease activity (38). Phagosome pH is not significantly affected by the addition of 
the DDA:TDB or DDA:TDB-NAC formulation indicating protease specifically cathepsins 
activity would not be altered due to pH (90,223). However cell-wide pH is significantly reduced 
in DDA:TDB-NAC treated DCs compared to OVA over a 24 hr period. This may be due to the 
reduced levels of ROS resulting in lower consumption of protons and could lead to more 
antigen availability to MHCII depending on its size (38,224). This combined with the 
differences in ROS production which can regulate cysteine cathepsins activity could lead to 
better presentation by DCs with this liposome formulation in an antigen-specific manner (41) 
Compared to no treatment controls OVA antigen produces increased oxidation but reduced 
GSH likely due to antigen processing. DDA:TDB-NAC liposomes treatments result in 
decreased ROS and increased GSH levels compared to DDA:TDB alone. NAC is an 
antioxidant and so could reduce ROS produced by antigen processing but may also be from 
increases levels of GSH, produced from NAC (75). This may lead to differences in antigen 
processing with the addition of NAC in the liposomal formulation that may be beneficial or 
detrimental depending on the antigen and desired immunological outcome. 
In summary, this chapter has demonstrated an effective DC model based on methods by Lutz 
which is used throughout the rest of this thesis. This model was developed to better align the 
project with the principles of the 3Rs. NAC (50-500 µM) treatments increased CD86 
expression in a dose-independent manner over the concentrations examined. MHCII 
expression was decreased on DCs in the presence of 17.6 µM H2O2. The DDA:TDB-NAC 
liposome formulation has been demonstrated to decrease cellular pH has whilst increasing 
DC activation surface markers including MHCII relative to DDA:TDB in a manner that is 
independent of antigen dose. DDA:TDB-NAC treatments also show far less cellular toxicity. 
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This combination makes it an ideal candidate adjuvant as it has the potential to allow DCs to 
better present antigen without the difficulties typical adjuvant associated toxicity issues, 
indicating the potential for use of higher adjuvant concentrations and subsequently stronger 
immune responses. This could allow for better antibody production without conflicting with the 
3Rs or other adjuvant toxicity regulations. 
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Chapter 4: Effect of redox state on 
the immune response to ovalbumin 
Preface 
C57BLK6 Ncf1-/- mice lack a functional NADPH oxidase NOX2 complex as Ncf1 (p47phox) is 
unable to locate to the membrane when activated (31,35). This results in lower ROS 
production. In this section, we explore the effects this mutation has in response to the antigen 
OVA alone or coated to DDA:TDB liposomes with and without NAC.  
An immunisation study using OVA as a model antigen was carried out to assess the 
effectiveness of DDA:TDB-NAC compared to DDA:TDB alone in C57BLK6 wild type mice. 
DDA:TDB liposomes drive a Th1 mediated immune response often demonstrated by strong 
IgG2 titre and high IFN-ɣ, IL-2 and TNFα secretion after immunisation (225). Here we examine 
antibody titre of total IgG and IgG1. Cytokine production from splenocyte and lymph node cell 
following re-stimulation with OVA were also examined with regards to the Th1 cytokines IFN-
ɣ, TNF-α & IL-2 and the Th2 cytokine IL-5. Con A stimulation of immune cells from pre-
immunised wild type mice was also examined.  
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4.1 Introduction 
The cellular redox state is in part determined by the activity of NADPH oxidase complex. 
NADPH oxidase exists as a variety of complexes with a range of functions. The NADPH 
oxidase complex is made up of several NOX subunits located both intracellularly and in the 
membrane. The catalytic part NOX2/gp91phox is located in the membrane and dimerises with 
p22phox to form the flavocytochrome b558 complex. In the resting state, subunits found in the 
cytosol include the neutrophil cytosolic factors Ncf1 (p47phox), Ncf2 (p67phox) and Ncf4 (p40phox) 
(33,34). 
When a phagocyte is activated, Ncf1 is phosphorylated causing a conformational change and 
enabling it to translocate to the membrane where it can interact with p22phox. Ncf1 is essential 
for other subunits to bind to and to elicit the respiratory burst. It is, therefore, an essential 
organising protein for the generation of ROS during immune activation. The NOX2 complex is 
primarily expressed in phagocytes upon activation and is responsible for generating ROS (15). 
Due to the inability of Ncf1 (p47phox) to relocate to the membrane when immune cells are 
activated from C57BLK6 Ncf1-/- mice which lack a functional NOX2 complex reduced ROS 
production is observed. This is due to the insertion of a neomycin resistance cassette into 
exon 7 interrupting normal Ncf1 gene function (31,35). 
NADPH oxidase NOX2 is recruited to phagosomes during antigen processing. There it 
produces ROS and protons in the reaction NADPH + 2O2 ↔ NADP+ + 2O2− + H+. Each electron 
translocated produces a proton with 108 protons produced every second in the cytosol. The 
early endosomal lumen then becomes alkalised through the V-H+-ATPase proton pump 
decreasing phagosomal lysosomal protease activity. In DCs lacking NOX2, it is likely that this 
cannot take place. Increased phagosomal acidification may affect proteolytic enzyme activity 
and antigen degradation resulting in impaired cross-presentation (38–40). ROS are highly 
reactive within the cellular environment only having a half-life of milliseconds and so are only 
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able to react with molecules in the immediate surroundings of where it is produced (41). The 
localisation of NOX2 to the phagosome ensures a high ROS environment that may regulate 
the functions of proteins by oxidising functional groups on proteins like hydroxyls and 
carbonyls by adding oxygen. In addition, ROS may change protein turnover, cause 
fragmentation, unfolding and crosslinking. These changes may also then influence the cross-
presentation of antigen and the immune response (41–44). 
NAC, a cysteine donor and GSH precursor, is able to some extent, protect against oxidative 
modification or damage (74). DDA:TDB-NAC which may have the capacity to scavenge ROS 
within the lysosome could influence antigen processing in APCs as it may lessen antigen 
protein crosslinking and simultaneously prevent loss of cysteine protease activity. This could 
be beneficial for the degrading and presenting of antigens that are difficult to process (42,43). 
Acquired immunity can be described as a specific response to a particular pathogen and 
broadly broken down into two types, Th1 and Th2. This is based on the cytokine secretion 
profile of the immune cells involved (161,226,227). The balance between Th1 and Th2 
response can be hugely influential for disease outcome (228). A high IFN-ɣ, TNF-α and/or IL-
2 secretion profile from T cells is associated with a strong Th1 response and a high IL-4 and/or 
IL-5 production is associated with a Th2 response. Cytokines produced by each Th subset 
encourage the production of that Th subset and often run counter to the other Th subset 
leading to a strong preference for one response over the other (161,225,229). Mouse strain is 
a major determining factor in the Th1/Th2 response; T cells from C57BL/6 mice showing a 
strong Th1 cytokine dominance in response to a range of stimuli producing high IFN-ɣ and low 
IL-4 secretions relative to other strains such as BALB/c (161,229–231). DDA:TDB liposomes 
have also been demonstrated to skew the immune response towards Th1 as demonstrated by 
the strong IFN-ɣ secretions usually observed following immunisations (225). In order to 
determine the efficacy of adjuvants in developing immune responses, antigen-specific 
antibody titres are often evaluated. DDA:TDB liposomes are known to produce IgG2 and IgG1 
in response to a variety of antigens including H56, OVA and MVA (154,220,232). These are 
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often themselves used as further markers of Th1 and Th2 responses respectively and have 
been used to evaluate the effectiveness of variations of DDA:TDB liposome formulation at 
producing a strong immune response (220,232,233).  
It is hypothesised that Ncf1-/- derived DCs and wild types will have a more similar response to 
DC activation and processing when NAC is included in the liposomal formulation due to its 
antioxidant capabilities. It is also hypothesised that wild type mice will produce an exaggerated 
immune response similar to those seen in Ncf1-/- models. Possibly due to delayed clearance 
of dead and dying cells that is associated with the low ROS environments of NOX2 knockouts. 
This has been shown to be corrected for with the introduction of H2O2 (234). This chapter aims 
to determine whether NAC-encapsulated within DDA:TDB liposomes affects DC maturation 
using OVA as a model antigen in DCs derived from C57BLK6 Ncf1-/- mice bone marrow 
compared to wild type. OVA antigen was used as it is well characterised and has been used 
in other studies with DDA:TDB liposomes making for easier comparison (134,155,235,236). 
GSH, DC surface markers, cellular viability, DCF oxidation, pH and antigen uptake using are 
all explored. Additionally the effectiveness of the DDA:TDB-NAC formulation is compared to 
DDA:TDB alone in an immunisation study using C57BLK6 wild type mice using Th1/Th2 
cytokine secretory profile from re-stimulated splenocytes and lymph node cells with OVA or 
Con A and antibody titres as endpoints. 
Chapter objectives 
 
• To characterise the effects of delivery of NAC on OVA coated DDA:TTB liposomes on 
the maturation of DC phenotype in C57BLK6 Ncf1-/- compared to C57BLK6. 
• To determine the effect of immunisation with OVA coated liposomes in the presence 
and absence of NAC on antibody titres. 
• To determine the effect of immunisation with OVA coated liposomes in the presence 
and absence of NAC on splenocyte and lymph node cell cytokine secretion.   
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4.2 Methods 
4.2.1 C57BLK6 Ncf1-/- bone marrow progenitor cells 
C57BLK6 Ncf1-/- developed by in house breeding at Redoxis (Lund, Sweden) and wild type 
C57BLK6 donated from the Sir William Dunn School (Oxford) were sacrificed in accordance 
with schedule 1. Tissue was cleared from the femur of hind legs and the bone was removed, 
then the femurs were sterilised with 70% ethanol solution. The proximal and distal ends of the 
femur were then removed, and the marrow was flushed out using sterile PBS. The marrow 
was then centrifuged at 200 xg for 5mins and the supernatant removed. The marrow was then 
re-suspended in FBS with 10% DMSO and stored at -70°C until needed. Marrow was 
defrosted and centrifuged at 200 xg for 5mins, the pellet was then treated with 2 mL Gibco™ 
ACK Lysing Buffer (Ammonium-Chloride-Potassium lysis buffer) from ThermoFisher 
(Loughborough, UK) containing ammonium chloride, potassium bicarbonate and EDTA for 
10mins at 37°C (3). 
4.2.2 Ovalbumin immunisation 
C57BLK6 wild type mice 8-12 weeks old were immunised as described in section 2.2.12 by 
the intramuscular route with 50 µg OVA coated to liposomes consisting of 250 µg DDA and 
50 µg TDB with or without 10mM NAC in a volume of 100 µl. Mice were immunised on days 
0, 14 and 28 and the study ended on day 49. This was done to allow for sufficient time for 
differences in immunological readouts in response to adjuvant formulation to become more 
apparent. This was carried out at Strathclyde University (PPL: 30/3289). 
4.2.3 Ex vivo re-stimulation of splenocytes and lymph node 
cells 
Spleens and lymph nodes were homogenised separately to single-cell suspensions and 
Pharmlyse diluted 1:10 in HBSS was used to lyse red blood cells. Cells were resuspended at 
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2x106 cells/mL in complete RPMI (10% FBS and 1% penicillin-streptavidin) and 100μl cells 
were stimulated with 0.5μg OVA antigen or 0.5μg Con A and incubated for 24h at 37°C, 5% 
CO2. Cells were washed, and the supernatant was stored for Th1/Th2 cytokine analysis using 
the cytometric bead array method as described in section 2.2.15. 
4.2.4 Antibody titre determination by ELISA 
An ELISA using HRP-conjugated goat polyclonal IgG anti-mouse, IgG, IgG1 and IgG2a were 
developed to determine antibody titre following DDA:TDB and DDA:TDB-NAC OVA 
immunisation in C57BLK6 wild type as described in section 2.2.16. 
Serum was obtained from tail bleeds withdrawn on days 7, 21 and 49 and added at a 1:400 
to a 1:25600 dilution to OVA coated Nunc MAXISORB 96 well plates in serial dilution. Plates 
were incubated for 2 hours at 37°C and washed. Goat polyclonal HRP-conjugated anti-mouse 
total IgG or anti-mouse IgG1 or anti-mouse IgG2a antisera were then added to all wells at a 
1:4000 dilution using blocking buffer as a diluent (Tween-20 1% v/v in PBS, 50 µl/well). The 
plates were then incubated for 1hr at 37°C and washed again. Substrate solution ((10 mL 
citrate-phosphate buffer (0.15M, pH 5), 8 µl hydrogen peroxide, and 1 o-phenylenediamine 
tablet) was added and the plates were then incubated for 30mins to allow colour development 
before sulphuric acid was used to quench the reaction. The absorbance at 490 nm was 
measured using a SpectraMax iD3 spectrometer and the titre was calculated using the 
midpoint log method. 
Total IgG anti-OVA titres were determined using goat polyclonal anti-mouse IgG conjugated 
to HRP in a serum serial dilution ELISA with OVA coated plates.  
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4.3 Results 
4.3.1 Importance of nicotinamide adenine dinucleotide 
phosphate oxidase 2 in immune response in vivo 
4.3.1.1 Ovalbumin effect on dendritic cell viability in the presence 
and absence of liposomes in bone marrow derived dendritic cell 
from C57BLK6 Ncf1-/- compared to wild type 
Propidium iodide was used to examine DC viability as described in section 2.2.3.1 during 24 
hour maturation with 0.8 µg/mL OVA alone or OVA coated to 12 µg/mL of DDA:TDB or 
DDA:TDB-NAC in C57BLK6 Ncf1-/- derived DCs compared to wild type DCs. Viability analysis 
was always reported from the DC gate.  
At 12 µg/mL, DDA:TDB is significantly more toxic than DDA:TDB-NAC in both wild type and 
Ncf1-/-. No significant difference is toxicity is observed between wild type and Ncf1-/- DC models 
with OVA treatments alone or in conjunction with DAA:TDB or DDA:TDB NAC treatments as 
shown in Figure 4.1. 
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Figure 4.1: Effect of OVA treatment in the presence and absence of liposomes on DC viability 
(propidium iodide staining) during maturation with OVA in C57BLK6 Ncf1-/- compared to wild 
type. Cells (2x105 cells in 2 mL) were treated with 0.8 µg/mL OVA for 24hours at 37°C at 5% CO2. Cells 
were treated with 0.2 µg/mL propidium iodide at room temperature and 10,000 cells were analysed 
immediately by a BD FACSCelesta and BD FACSDiva analysis software. Mean values are shown with 
SEM. These values result from three independent experiments. Data were analysed by ANOVA with 
Tukey’s post-test. 
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4.3.1.2 Bovine serum albumin-FITC uptake in presence of 
liposomes by C57BLK6 Ncf1-/--derived bone marrow dendritic cells 
compared to wild type dendritic cells 
BSA-FITC conjugate was used to assess antigen uptake as described in section 2.2.7 by 
C57BLK6 Ncf1-/- and wild type derived DCs in response to 12 µg/mL of DDA:TDB or 
DDA:TDB-NAC. DCs, were treated with 0.8 µg/mL of BSA-FITC conjugate alone or bound to 
12 µg/mL of DDA:TDB or DDA:TDB-NAC liposomes for 4hours at 37°C to examine active 
uptake or at 4°C to examine passive antigen association.  
Using confocal microscopy DCs derived from C57BLK6 Ncf1-/- and wild type shows bright 
fluorescence when treated with BSA-FITC conjugate alone and reduced fluorescence when 
treated in combination with DDA:TDB or DDA:TDB-NAC (Figure 4.2 A). This is likely in part 
due to electrostatic interactions from the liposome preventing antigen uptake as easily as free 
antigen. The results from the liposome treatments are further diminished in comparison to free 
antigen due to the artificial depot formed by the well that would not be possible in vivo. In this 
experiment FITC-BSA alone serves as a positive control and is not reflective of an actual 
immunisation. 
Flow cytometry shows antigen uptake at 37°C is significantly decreased in Ncf1-/- DCs with 
antigen only treatments compared to wild type. BSA is taken up by pinocytosis into endosomes 
and this appears to be impeded by lack of NOX2 and has been reported previously possibly 
because they do not generate the O2- necessary for upregulating an unknown redox-sensitive 
pathway for micropinocytosis which is a primary method of uptake (237). DDA:TDB-NAC 
liposomes show significantly more uptake compared to DDA:TDB alone in Ncf1-/- DCs and 
more relative to the wild type DCs treated with DDA:TDB-NAC (Fig 4.2 C). When bound to 
liposomes BSA uptake is possibly achieved via a receptor mediate endocytosis process 
through TLRs and the binding affinity of this receptor for liposomes may be inhibited by ROS. 
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There was also significant uptake of both liposome formulations on ice (Fig 4.2 B). In contrast, 
antigen-only was not taken up significantly on ice and there was no difference between wild 
type and Ncf1-/- DC models (Figure 4.2 B and C). Differences in results from the confocal 
microscope and flow cytometer may be due to the quantitative and qualitative nature of each 
method. Confocal microscopy is qualitative and examines only a single plane whereas the 
flow cytometer is quantitative and does not have this limitation.  
Page 124 of 212 
 
 
 
N
o 
Tr
ea
tm
en
t
A
lb
um
in
 F
IT
C
 
D
D
A
:T
D
B
 A
lb
um
in
 F
IT
C
D
D
A
:T
D
B
 N
A
C
 A
lb
um
in
 F
IT
C
0
1
2
3
4
5
F
IT
C
 A
lb
 U
p
ta
k
e
 M
d
X
Wild Type
Ncf1
-/-
***
**
****
****
4C
N
o 
Tr
ea
tm
en
t
A
lb
um
in
 F
IT
C
 
D
D
A
:T
D
B
 A
lb
um
in
 F
IT
C
D
D
A
:T
D
B
 N
A
C
 A
lb
um
in
 F
IT
C
0
1
2
3
4
5
F
IT
C
 A
lb
 U
p
ta
k
e
 M
d
X
***
****
****
*
*
****
37CB C
 
Figure 4.2: Effect of DDA:TDB and DDA:TDB-NAC treatments on antigen uptake (BSA-FITC 
conjugate) in 57BL/6 Ncf1-/- and wild type derived DCs. Cells (2x105 cells in 2 mL) were treated with 
12 µg/mL DDA:TDB or DDA:TDB-NAC liposomes coated with 0.8 µg of BSA-FITC for 1hr at 37°C at 
5% CO2 or at ~5°C as a negative control. A) Confocal microscopy images comparing C57BL/6 Ncf1-/- 
and wild type derived DCs treated with BSA-FITC alone or coated to liposomes at 37°C. Flow cytometry 
analysis of 10,000 cells analysed by a BD FACSCelesta and BD FACSDiva analysis software. BSA-
FITC (0.8 µg) coated DDA:TDB or DDA:TDB-NAC (12 µg/mL) liposome treatments at 0°C (B) or at 
37°C  (C) for 4 hours. Mean values are shown with SEM. These values result from three independent 
experiments. Data were analysed by ANOVA with Tukey’s post-test ****p <0.0001.  
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4.3.1.3 Effect of ovalbumin in the presence of liposomes on cell 
surface antigen derived bone marrow dendritic cells derived from 
C57BLK6 Ncf1-/- compared to wild type 
To better characterise the effect of OVA delivery formulation on C57BLK6 Ncf1-/- and wild type 
derived DC maturation, differences in the surface expression of the DC activation markers 
MHCII, CD11c and CD86 in response to treatment DDA:TDB or DDA:TDB-NAC (12 µg/mL) 
liposomes coated with OVA (0.8 µg) were examined as described in section 2.2.32. Surface 
marker analysis was always reported from the DC gate after 24 hours.  
MHCII expression is significantly decreased in wild type animals treated with DDA:TDB OVA 
compared to free antigen (Figure 4.3 A). This is presumably due to electrostatic interactions 
from the liposome preventing as easy antigen uptake. 
Ncf1-/- DCs did not show any significant increase in expression of the surface markers MHCII 
and CD86 relative to the wild type in response to free antigen or treatment with either liposome 
formulation (Figure 4.3 A and B). However, the CD11c increase in expression between free 
OVA and OVA bound to DDA:TDB-NAC in Ncf1-/- is comparable with wild type (Figure 4.3 C). 
CD86 and MHCII expression do not change in response to any treatments compared to the 
no treatment control in the Ncf1-/- and appear similar to the wild type control (Figure 4.3 A and 
B). This is consistent with previous studies and is likely due to a number of factors including 
reduced uptake, reduced regulation of phagosomal pH and enzymatic proteolytic digestion 
(237–239). CD11c showed an increase in expression on Ncf1-/- DCs when treated with 
DDA:TDB-NAC relative to the OVA only control (Figure 4.3 C).  As previously, wild type DCs 
showed an increase in surface antigen expression following liposome-OVA with NAC 
compared to without (Figure 4.3). 
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Figure 4.3: Surface expression of C57BLK6 Ncf1-/- and wild type derived DCs following treatment 
with DDA:TDB and DDA:TDB-NAC liposomes coated with OVA. Cells (2x105 cells in 2 mL) were 
treated with DDA:TDB or DDA:TDB-NAC (12 µg/mL) liposomes coated with OVA (0.8 mg/mL) for 24hrs 
at 37°C at 5% CO2. Cells (2x105) were then stained with A) anti-CD86 FITC, B) anti-MHC-II PE and 
C) anti-CD11c Alexa Fluor 647 antibody and 10,000 cells analysed by a BD FACSCelesta and BD 
FACSDiva analysis software. Mean values are shown with SEM. These values result from three 
independent experiments. Data were analysed by ANOVA with Tukey’s post-test ****p <0.0001 
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4.3.1.4 Effect of ovalbumin on pH (pHrodo) in the presence of 
liposomes in derived bone marrow dendritic cells derived from 
C57BLK6 Ncf1-/- compared to wild type 
pHrodo™ Red AM staining solution was used to assess cytoplasmic pH in C57BLK6 Ncf1-/- 
and wild type derived DCs in response to 12 µg/mL of DDA:TDB or DDA:TDB-NAC. DCs were 
treated with 0.8 µg/mL of OVA alone or coated to liposomes for 24hours at 37°C at 4°C as 
described in section 2.2.7. The analysis has been reported from the DC gate. 
Significantly increased phagosomal pH was observed in Ncf1-/- derived DCs treated with 
DDA:TDB but not with DDA:TDB-NAC compared to pHrodo Red E. coli Bio Particles only 
treatments. Ncf1-/- DCs showed significantly decreased phagosomal pH compared to wild 
types when treated with DDA:TDB-NAC or Bio Particles only (Figure 4.4). This indicates a 
ROS independent method for pH regulation in this case where ROS is already diminished. 
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Figure 4.4: Intracellular pH measurements of C57BLK6 Ncf1-/- and wild type derived DCs 
following treatment with DDA:TDB and DDA:TDB-NAC liposomes coated with OVA (pHrodo™ 
Dye). Cells (2x105 cells in 2 mL) were washed and resuspended in 2 mL pHrodo™ Red AM staining 
solution for 30mins at 37°C, 5% CO2 as per manufacturer’s instructions. The cells were then treated 
with DDA:TDB or DDA:TDB-NAC (12 µg/mL) liposomes coated with OVA (0.8 mg/mL) for a further 
30mins at 37°C at 5% CO2. 10,000 cells were analysed by a BD FACSCelesta and BD FACSDiva 
analysis software. pHrodo™ Red AM expression levels were reported as MdX after positive gating for 
2% fluorescence of the negative no stain control. Mean values are shown with SEM. These values 
result from three independent experiments. Data were analysed by ANOVA with Tukey’s post-test *p < 
0.0254.  
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4.3.1.5 Dendritic cell reactive oxygen species and glutathione in 
derived bone marrow dendritic cells derived from C57BLK6 Ncf1-/- 
after treatment with ovalbumin in liposomes compared to wild type 
dendritic cells 
To better characterise the differences in the redox state of C57BLK6 Ncf1-/- and wild type 
derived DCs in response to 12 µg/mL of DDA:TDB or DDA:TDB-NAC cellular GSH and 
intracellular oxidation (as DCF fluorescence) were measured. DCs were treated with 0.8 
µg/mL of OVA alone or coated to liposomes for 24hours as described in section 2.2.7. DCF 
analysis was always reported from the DC gate.  
DCs show significantly lower intracellular DCF oxidation in Ncf1-/- DCs compared to wild type 
in response to OVA, DDA:TDB, DDA:TDB-NAC and with no treatment. No significant change 
in intercellular oxidation is seen in Ncf1-/- with any treatment (Figure 4.5 A). GSH-Glo results 
show lower GSH levels in Ncf1-/- DCs compared to wild type with all treatments and in no 
treatment control (Figure 4.5 B). No significant change in GSH levels is seen in Ncf1-/- with 
any treatment but was increased with the addition of DDA:TDB-NAC compared to DDA:TDB 
alone in Wts (Figure 4.5). 
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Figure 4.5: Effect DDA:TDB and DDA:TDB-NAC liposomes coat ed with OVA  treatments on A) Intracellular  oxidation measurement s (DCF) and B) GSH  in C 57BLK6 Ncf 1-/- and wild  type derived DC s.  
Figure 4.5: Effect DDA:TDB and DDA:TDB-NAC liposomes coated with OVA treatments on A) 
Intracellular oxidation measurements (DCF) and B) GSH in C57BLK6 Ncf1-/- and wild type derived 
DCs. Cells (2x105 in 200 µl) were treated with DDA:TDB or DDA:TDB-NAC (12 µg/mL) liposomes 
coated with OVA (0.8 µg/mL) for 24hours at 37°C at 5% CO2. A) DCF (50 µM) was then added at room 
temperature and 10,000 cells were analysed immediately by a BD FACSCelesta and BD FACSDiva 
analysis software. B) Cellular GSH levels (GSH-Glo), cells (2x105 cells in 2 mL) were treated with 
DDA:TDB or DDA:TDB-NAC (12 µg/mL) liposomes coated with OVA (0.8 mg/mL) for 24hours at 37°C 
at 5% CO2. 10,000 cells were analysed using GSH-Glo™ kits from Promega UK as per manufacturer’s 
instructions. Mean values are shown with SEM. These values result from three independent 
experiments. Data were analysed by ANOVA with Tukey’s post-test ****p <0.0001. 
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4.3.2 Effect of immunisation with ovalbumin using liposomes in 
the presence and absence of n-acetyl cysteine on antibody 
titres and cytokine secretion 
4.3.2.1 Titre of serum IgG1 anti- ovalbumin overtime after 
immunisation with liposomes (+/- n-acetyl cysteine) 
Total IgG anti-OVA serum titres were used to determine the effectiveness of the DDA:TDB-
NAC liposome formulation relative to DDA:TDB using OVA as a model antigen as described 
in section 2.2.16. Mice were immunised on days 0, 14 and 28 and the study ended on day 49. 
No significant difference was seen between antibody titres raised in response to OVA in the 
DDA:TDB-NAC and DDA:TDB liposomes on day 21 and day 49 (endpoint), both of which were 
significantly higher than after 7 days. Both liposomes have similar efficacy at producing IgG1 
antibodies against OVA (Figure 4.6). 
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Figure 4.6: IgG1 anti-OVA titres levels measured in C57BLK6 mice following treatment with OVA 
DDA:TDB or DDA:TDB-NAC liposomes on days 7, 21 and 49 (endpoint). Mice in two groups of five 
animals were immunised with 50 µg OVA using 250 µg DDA and 50 µg TDB with or without 10mM NAC 
as adjuvants. A serial dilution ELISA using goat polyclonal anti-mouse IgG1 conjugated to HRP was 
used to determine final titres. The absorbance at 490 nm was measured using a SpectraMax iD3 
spectrometer and the maximum dilution that signal could still be detected was assessed after the 
removal of background absorbance. For comparisons of sera, values were converted to midpoint titres 
(the midpoint of the fitted sigmoid curve obtained from the titration). Data were analysed by unpaired 
two-tailed t-test. 
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4.3.2.2 Titre of serum total IgG anti- ovalbumin after immunisation 
with liposomes (+/- n-acetyl cysteine) 
Total IgG anti-OVA serum titres were used to determine the effectiveness of the DDA:TDB-
NAC liposome formulation relative to DDA:TDB using OVA as a model antigen. C57BLK6 
mice were immunised as above.  
No significant difference was seen between the antibody titres raised in response to OVA in 
DDA:TDB-NAC and DDA:TDB liposomes at day 49 (endpoint). No detectable signal was found 
on days 7 and 21. Both liposomes have similar efficacy at producing IgG antibodies against 
OVA (Figure 4.7). 
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Figure 4.7: Total IgG anti-OVA titres levels measured in C57BLK6 mice following treatment with 
OVA DDA:TDB or DDA:TDB-NAC liposomes at the study endpoint (Day 49). Mice in two groups of 
five animals were immunised with 50 µg OVA using 250 µg DDA and 50 µg TDB with or without 10mM 
NAC as adjuvants. A serial dilution ELISA using goat polyclonal anti-mouse IgG conjugated to HRP 
was used to determine final titres. The absorbance at 490 nm was measured using a SpectraMax iD3 
spectrometer and the maximum dilution that signal could still be detected was assessed after the 
removal of background absorbance. For comparisons of sera, values were converted to midpoint titres 
(the midpoint of the fitted sigmoid curve obtained from the titration). Data were analysed by unpaired 
two-tailed t-test. 
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4.3.2.3 Cytokine release after re-stimulation of splenocytes derived 
from C57BLK6 mice immunised with ovalbumin coated liposomes 
(+/- n-acetyl cysteine) 
The BD cytometric bead array Mouse Th1/Th2 Cytokine Kit was used to determine the serum 
concentrations of IL-2, IL-4, IL-5, IFN- γ & TNF-α in response to OVA coated DDA:TDB-NAC 
or DDA:TDB. C57BLK6 mice were immunised as above and the splenocytes removed and 
stimulated with 5 µg/mL OVA or 5 µg/mL Con A or left untreated for 24hours. Cytometric bead 
array analysis of the supernatants was then carried out using BD FACSCelesta and BD_FCAP 
Array™ Software Version 3.0 analysis software. 
There was a significant effect of re-stimulation on cytokine secretion after ConA for both 
formulations with the exception of IL-2 where no increase in DDA-TDB v control. No significant 
difference in cytokine secretion was detected from splenocytes of mice immunised with either 
OVA coated DDA:TDB-NAC or DDA:TDB following either OVA re-challenge or Con A 
stimulation. Con A treatment resulted in greater secretion in IFN- γ and TNF-α compared to 
OVA re-stimulation (Figure 4.8). IL-4 was not detectable with any stimulation however it was 
detectable in standards indicating levels were below 20 pg/mL (the lowest standard) in 
samples tested. 
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Figure 4.8: Secretion of IL-2, IL-5, IFN- γ & TNF-α by stimulated splenocytes from C57BLK6 
mice immunised with OVA coated DDA:TDB or DDA:TDB-NAC. Splenocyte (2x105 in 200 µl) were 
treated with 5 µg/mL OVA or 5 µg/mL Con A for 24hours at 37°C at 5% CO2. Media was then 
analysed by cytometric bead array analysis using BD FACSCelesta and BD_FCAP Array™ Software 
Version 3.0 analysis software A) IL-5 secretion. B) IL-2 secretion. C) IFN- γ secretion. D) TNF-α 
secretion. Mean values are shown with SEM. These values result from three independent 
experiments. Data were analysed by ANOVA with Tukey’s post-test ****p <0.0001. 
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4.3.2.4 Cytokine release after re-stimulation of lymph node cells 
derived from C57BLK6 mice immunised with ovalbumin coated 
liposomes (+/- n-acetyl cysteine)  
The mouse Th1/Th2 cytometric bead array Kit was used to determine cytokine secretion from 
isolated lymph node cells that were stimulated Ex vivo with 5 µg/mL OVA or 5 µg/mL Con A 
or left untreated for 24hours. Cytometric bead array analysis was then carried out using BD 
FACSCelesta and BD_FCAP Array™ Software Version 3.0 analysis software. 
OVA-DDA:TDB-NAC immunised mice lymph node cells showed significantly increased IL-5, 
IFN-γ and TNF-α secretion after Con A stimulation relative to lymph node cells from mice 
immunised with OVA-DDA:TDB. IL-2 secretion by lymph node cells from OVA-DDA:TDB 
immunised mice lymph node cells stimulated with Con A was significantly greater than those 
immunised with DDA:TDB-NAC where levels were almost undetectable. No significant 
difference in cytokine secretion was detected between immunised mice lymph node cells by 
OVA coated DDA:TDB-NAC or DDA:TDB with OVA re-stimulation. Con A treatment resulted 
in greater cytokine secretion in IL-5, IL-2, IFN-γ and TNF-α compared to OVA with the 
exception of IL-2 where secretion was higher after OVA re-challenge (Figure 4.9). Relative to 
splenocytes stimulated with ConA lymph nodes showed higher IL-2 secretion but lower IL-2 
and IFN- γ secretion. IL-4 was not detectable with any stimulation however it was detectable 
in standards indicating levels were below 20 pg/mL (the lowest standard) in samples tested. 
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Figure 4.9: Secretion of IL-2, IL-5, IFN- γ & TNF-α by stimulated lymph node cells from C57BLK6 
mice immunised with OVA coated DDA:TDB or DDA:TDB-NAC. Lymph node cells (2x105 in 200 µl) 
were treated with 5 µg/mL OVA or 5 µg/mL Con A for 24hours at 37°C at 5% CO2. Media was then 
analysed by cytometric bead array analysis using BD FACSCelesta and BD_FCAP Array™ Software 
Version 3.0 analysis software A) IL-5 secretion. B) IL-2 secretion. C) IFN- γ secretion. D) TNF-α 
secretion. Mean values are shown with SEM. These values result from three independent experiments. 
Data were analysed by ANOVA with Tukey’s post-test ****p <0.0001. 
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4.4 Discussion 
C57BLK6 Ncf1-/- mice lack a functional NOX2 complex due to the insertion of a neomycin 
resistance cassette into exon 7. This stops Ncf1 (p47phox) from translocating upon activation 
which is essential for oxidative function and other subunits binding (15,31,35). NOX2 is found 
in activated phagocytes where it is recruited to phagosomes during antigen processing (3). 
This makes DC generated from the marrow of C57BLK6 Ncf1-/- mice ideal for investigating the 
influence of ROS on antigen uptake and DC maturation and to investigate the influence of the 
antioxidant and GSH precursor NAC. The DDA:TDB-NAC formulation carrying OVA was 
compared to DDA:TDB alone in DCs generated from this KO model as well as in DCs from 
wild type animals.  
No difference in loss of viability is seen between wild type and Ncf1-/- DCs between liposome 
formulations, however, NAC was protective in both indicating that the reduced toxicity may be 
either due to scavenging of ROS generated by mitochondria or also relate to NAC’s other 
modes of action (74,219). Using DCF to examine whether there was an increase in 
intracellular oxidation in the presence of OVA bound to liposomes confirmed a lack of ROS 
production in Ncf1-/- DCs suggesting that the effect of NAC was ROS-independent.  
Two protein antigens were used for these studies. BSA like OVA is monomeric, they have 
similar isoelectric points (4.5 and 4.6) but different mass and sizes (45 and 68 kDa). The 
charge at neutral pH allows them to bind to the cationic surface of DDA:TDB liposomes and 
as such have been used in other studies (155–157). FITC labelled BSA and OVA show similar 
uptake by DCs in vitro (240,241).  
As before, antigen uptake is markedly increased in the presence of FITC-BSA alone over 
either FITC-BSA DDA:TDB or DDA:TDB-NAC in wild type DCs and between FITC-BSA and 
FITC-BSA DDA:TDB in Ncf1-/- DCs. This could be related to a number of factors such as 
toxicity, electrostatic interactions preventing antigen uptake and cell culture artificial well 
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depot. In vivo, free antigen would not be constantly present as it is in a well and so an adjuvant 
is necessary to prolong presentation and prevent degradation (220–222).  
Free antigen uptake was lower in Ncf1-/- DCs treated with FITC-BSA alone compared to wild 
type DCs. However, the DDA:TDB-NAC formulation carrying BSA was more efficiently taken 
up by Ncf1-/- DCs. Given that Ncf1-/- DCs already have lower ROS and the additional NAC 
does not impact on DC ROS, the increased uptake following the DDA:TDB-NAC formulation 
appears to be independent of NAC’s antioxidant properties. The difference in active uptake of 
BSA between DCs with and without NOX in a manner dependant on whether BSA was in 
liposomes or as free antigen suggests that the mechanisms of uptake are differentially affected 
by the loss of NOX2 activity. It is likely that free BSA is taken up by pinocytosis into endosomes 
and this appears to be impeded by lack of NOX2. Others have reported that DC uptake of 
OVA antigen is reduced in NOX2 KOs relative to wild types. This was proposed to be due to 
failure to generate O2- which was necessary for upregulating an unknown redox-sensitive 
pathway for micropinocytosis which is a primary method of uptake (237). However in this 
study, when BSA was presented on liposomes, uptake was significantly increased. In this case 
a receptor mediate endocytosis process through TLRs is the likely mechanism. Whether the 
binding affinity of this receptor for liposomes is inhibited by ROS is unknown. 
NOX2 has been demonstrated to contribute to the alkalinisation of the endosomal pH in 
macrophages and DCs as a result of recruitment of the vacuolar-type H+ ATPase (242,243). 
This may help to explain the decreased FITC albumin uptake shown in in Ncf1-/- DCs in this 
study as FITC fluorescence is pH-dependent with lower pHs significantly reducing 
fluorescence (244). The lack of NOX2 activity in Ncf1-/- DCs could, therefore, contribute to a 
more acidic environment and affect fluorescence.  
DCs show significantly lower intracellular GSH in Ncf1-/- DCs compared to wild type under all 
conditions tested. No significant change with any treatment tested was observed in Ncf1-/- DCs 
however GSH levels do decrease in wild type treated with OVA and increase with the inclusion 
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of NAC in the DDA:TDB formulation. Ncf1 (p47phox) are unable to translocate upon activation 
in C57BLK6 Ncf1-/- mice resulting in lower base levels of intercellular oxidation. This is 
consistent with previous studies that report lower ROS production in NOX2 deficient DC 
models (237). The antioxidant GSH may be so low in the Ncf1-/- DCs due to lack of necessity, 
intracellular oxidation is lower and therefore less GSH is required to prevent excess ROS. This 
is achieved at a molecular level through the redox-active transcription factor Nrf2. Nrf2 
dissociates from KEAP1 in the presence of ROS then migrates to the nucleus to upregulate 
antioxidant response genes such as glutathione synthetase. In NOX2 deficient cells, we have 
shown lower intracellular ROS and then would likely result in less Nrf2 activation and lower 
gene expression of GSH biosynthetic genes. 
Here, surface expression of the DC activation markers CD86 and MHCII showed no significant 
increase in response to any treatment including antigen only in NOX2 deficient DCs. In 
previous studies using OVA in NOX2 deficient mice, CD86 and MHCII have similarly been 
shown to not change in response to stimulation likely due to the lack of maturation caused by 
reduced uptake (237,238). It may also relate to an inability to control low phagosomal pH 
leading to increased antigen degradation and a possible inability to present on MHCII. 
Previous studies have shown a decrease in MHCI in Ncf1-/-. MHCI bind smaller peptides (8-
10 residues) than MHCII 13-25 residues it is possible that the peptide degradation is 
responsible for reduced surface expression of MHCII in an antigen-specific pattern (166,245). 
It has been demonstrated that NOX2 deficient mice have altered patterns of proteolytic 
digestion via ROS regulation of cysteine cathepsins which can change CD4+ T cell activation 
in an antigen-specific manner (239). These differences may in part explain the increase in 
CD11c expression in Ncf1-/- DCs treated with DDA:TDB-NAC relative to the no treatment 
control. 
To determine the effectiveness of adjuvants in eliciting a strong immune response to the target 
antigen, antigen-specific antibody titres are assessed. In the case of liposomal formulation 
DDA:TDB, total IgG and IgG1 titres are often evaluated (220,225,232,233). Titres of total IgG 
Page 141 of 212 
 
and IgG1 produced by immunisation in this study are not easily compared to other studies, 
however, it was surprising at first that total IgG titre appears lower than IgG1 (225,233). IgG1 
is a subclass of IgG so the differences in titres may be explained by differences in affinities 
between the anti-IgG1 and anti-IgG antibodies used (246). 
No significant difference in antibody titre was observed between mice immunised with 
DDA:TDB or DDA:TDB-NAC for either total IgG or IgG1. This data combined with previous 
toxicity data indicates that the presence of NAC enables DDA:TDB liposomes to produce as 
strong an immune response as the existing formulation but at reduced cost to health. Such a 
finding is important in the context of refining animal testing as defined in the 3R principles.  
The mouse Th1/Th2 cytometric bead array kit developed by BD Bioscience uses a cytometric 
bead array to evaluate the levels of the Th1 associated cytokines IFN-ɣ, TNF-α & IL-2 and the 
Th2 cytokines IL-4 & IL-5 within the range of 5000-20 pg/mL (161,225,229). Splenocytes and 
lymph node cells were taken from the C57BLK6 mice used in the immunisation study and 
stimulated with 5 μg/mL OVA antigen or Con A over 24hours. Concanavalin A (Con A) 
originally isolated from Jack beans (Canavalia ensiformis), it is a lectin that specifically binds 
glucose and mannose. It is frequently used as a T cell mitogen which can stimulate cytokine 
secretion and recruit lymph node cells. Con A activates a nuclear factor of activated T cells 
(NFAT) transcription factors that are responsible for the immune response and mimics TCR 
engagement. Con A binding is able to activate cells by causing cross-linking of the TCR 
complex (247–250). Data from other studies examining splenocyte and in particular lymph 
node cell secretion is, for the most part, limited and where it is available different antigens, 
mouse strains and immunisation schedules have been used making it difficult to compare 
(154,155). For example, IL-5 secretion has been reported to be as high as 500 pg/mL and as 
low as 0 pg/mL using the Ag85B-ESAT-6 antigen. The same study demonstrated IFN-ɣ of up 
to 20,000 pg/mL from stimulated splenocytes (225). Another study using the same antigen 
reported IL-5 of <250 pg/mL and IFN-ɣ as high as 20,ss000 pg/mL using the same route of 
administration (154). Lower values of IL-5 and IL-2 secretion relative to IFN-ɣ in splenocyte 
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supernatant are common shown (154,225). Here splenocytes secreted were not different upon 
stimulation between either Con A or OVA in either formulation. However, in lymph node cells, 
there were discrete profiles of cytokine secretion response of those cells re-stimulated with 
Con A between mice that were previously immunised with OVA-DDA:TDB-NAC and those 
immunised with DDA:TDB alone.  
Splenocytes are mainly made up of B cells (45-50%), however, the lymphocyte population is 
primarily T cells (60-70%). CD4+ T cells have the potential to differentiate into several subsets 
including Th1, Th2, Th17 and regulatory T cells in response to activation by the binding of 
peptide antigen to MHC II via APCs. This is dependent on cytokine signalling, antigen 
concentrations, TCR antigen peptide–MHC complex affinity, APC type and co-stimulatory 
signals. The Th1 response is used to defend against intracellular micro-organisms and Th2 to 
protect against helminths and other extracellular pathogens (52,251). High IL-12 secreted by 
APCs causes NK cells to secrete IFNɣ which in turn suppresses Th2 differentiation. These 
cytokines activate signal transducer and activator of transcriptions (STAT) STAT1, STAT4 and 
T-bet transcription factors. Th1 cells which are associated with the cell-mediated immune 
response; require IL-4 and IL-2 for differentiation and secrete IL-2, LT-α, and IFN-γ. IL-4 is the 
primary cytokine secreted by Th2 cells and suppresses Th1 related transcription factors as well 
as upregulating B cell growth. Th2 is associated with humoral immunity and is controlled 
through the transcription factor STAT 6 which upregulates GATA3, c-MAF and NFATp. IL-6 
has also been demonstrated to cause naïve CD4+ T cells to produce IL-4 through NFAT 
upregulation which inhibits Th1 differentiation (50–53,252).  
The data obtained in this chapter, taken together, indicates cytokine secretion may shift in 
Th1/Th2 polarisation due to the change in liposome formulation. The high IL-5 low IL-2 secreted 
from lymph node cells as a result of DDA:TDB-NAC immunisation is indicative of a stronger 
Th2 response however high IFN-ɣ and TNF-α would indicate a Th1 response signifying that 
both arms of the T helper immune response may be activated. This suggests that T cell 
polarisation may be influenced by the inclusion of reducing agents through changing the 
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cytokine secretion profile within the immune cells from the spleen. For all samples, IL-4 was 
not detectable with any stimulation however it was detectable in standards indicating that 
levels in the supernatants were likely to be below 20 pg/mL (the lowest standard) in samples 
tested. This may relate to the strain of mice used in these experiments. C57BL/6 mice show 
typically a strong Th1 cytokine dominance with high IFN-ɣ and low IL-4 secretion due to low 
IL-2 being observed relative to other strains such as BALB/c (161,229–231). IL-2 controls the 
secretion of IL-4 which in turn is responsible for CD4+ T cell differentiation. STAT5 is not as 
sensitive to IL-2 and IL-4 activation in C57BL/6 mice. When STAT5A and STAT5B are induced 
it causes the differentiation of naive Th2 CD4+ T cells (251). 
In summary, this chapter has demonstrated that DCs-derived from C57BLK6 Ncf1-/- mice show 
significantly reduced free antigen uptake, poor/no upregulation of the DC activation markers 
and failure to mature relative to DCs derived from the wild types. This contrasted with the 
liposomal delivery which enabled effective delivery, but with only CD11c upregulation. This 
may be the result of changes phagosomal lumen pH resulting in increased antigen 
degradation and failure to associate with the MHC complex (38–40,237). As expected, Ncf1-/- 
DCs show lower GSH and intracellular oxidation (DCF) (253).  
The immunisation study in C57BLK6 wild type mice using OVA coated DDA:TDB or DDA:TDB-
NAC has shown equal success in the production of IgG and IgG1 titre between liposome 
formulation. Splenocyte and lymph node cell cytokine secretions in responses to immunising 
antigen stimulation were similar with regards to the Th1 cytokines IFN-ɣ, TNF-α & IL-2 and the 
Th1 cytokines IL-5. However, Con A stimulation of lymph node cells from OVA-DDA:TDB-NAC 
immunised mice significantly increased IL-5, IFN- γ & TNF-α secretion but decreased IL-2 
secretion relative to OVA-DDA:TDB indicating a shift in Th1/Th2 polarisation. The Th1 or cell 
mediated immunity promotes phagocytosis and microbial opsonization through the production 
of IgG 2a. IFN-ɣ produced by the Th1 response increases phagocytosis through the 
upregulation of the expression of FC receptor FcγR. IFN-ɣ is also responsible for the 
production of the superoxide anon radials, NO and H2O2 (246,254). The Th2 Immune response 
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is associated with high levels of IL-4 secretion and leads to the production of IgE and IgG 
neutralising antibodies and the upregulation of MHCII. The IgE receptor involved in parasitic 
antigen detection is used to defend against intra-cellular micro-organisms and Th2 to protect 
against helminths and other extracellular pathogens (255,256). The ability to potentially 
influence the immune response towards Th2 with the encapsulation of NAC could be 
advantageous depending on the purpose of the immunisation. Eliciting a strong immune Th2 
response towards antigen, using DDA:TDB-NAC adjuvant could make for more effective 
antibodies for diagnostic or therapeutic purposes. Whereas an adjuvant that would traditionally 
raise a Th1 response such as DDA:TDB and CFA may be more beneficial in some types of 
vaccination depending on their purpose. For examples for vaccines developed against TB a 
strong Th1 response is desirable (225,257).   
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Chapter 5: Improving the efficacy of 
immune response to complex 
antigens 
Preface 
The symptoms of rheumatoid arthritis induced chronic inflammation, accumulation of 
inflammatory cells in the synovial membrane, oxidative stress, pain and bone erosion of the 
joints. Establishing models to study this disease is necessary in order to develop treatments 
in future. The collagen induced arthritis model is one of many but is the most common used. 
Type II collagen which makes up the majority of collagen in cartilage is used in combination 
with Freund's adjuvant to stimulate immunogenicity in this model resulting in clinical symptoms 
within 2-3 weeks. NOX2 KO rodents are particularly susceptible to this disease. 
Although Freund’s adjuvant is associated with strong immune in part due to the mycobacterial 
component, it is known to have many negative side effects. When considered in line with the 
3Rs, the use of non-toxic alternatives to Freund’s adjuvant in the collagen-induced arthritis 
model could refine the model and minimise suffering.  
An immunisation study using rat collagen type II was carried out comparing DDA:TDB with 
and without NAC against complete Freund’s adjuvant (CFA) in the hopes of developing a more 
humane method of developing a rheumatoid arthritis model for future studies. Both DDA:TDB 
formulations were demonstrated to be less harmful alternatives to CFA. Better weight gain 
was seen in Ncf1-/- mice, the most diseased state animals along with reduced erythema at the 
site of injection was observed. Rat collagen type II vaccination produced the highest total IgG 
antibody titre when used in combination with DDA:TDB without NAC in wild types. IgG1 titres 
remained unchanged across all groups. Interestingly the NCf1-/- mice did not show as high 
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midpoint titres expected, this may indicate that arthritic severity is independent of antibody 
titre. Cytokine secretion from lymph node cells were mostly higher in Ncf1-/- mice. The 
DDA:TDB-NAC formulation significantly increased the secretion of IFN γ and TNF-α, 
suggesting further polarising to Th1.   
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5.1 Introduction 
During the development of an autoimmune response, the immune system must in part fail to 
discriminate self from non-self. This can come about when self-tolerance is lost and T cells 
that recognise self-antigens are not eliminated during selection (55).  
RA is associated with chronic inflammation, accumulation of inflammatory cells in the synovial 
membrane, oxidative stress, swelling, pain, lack of function and bone erosion in the joints (56). 
It is associated with activation of DCs, macrophages, monocytes, T cells and synovial-like 
fibroblasts, the secretion of IL-6, IL-1β and TNF-α and other pro-inflammatory cytokines and 
the production of ROS and RNS (54). 
As a model for rheumatoid arthritis, collagen-induced arthritis is the most common model in 
rodents. This method uses type II collagen which makes up the majority of collagen in 
cartilage, it is used in combination with an adjuvant, usually Freund's, to stimulate 
immunogenicity with clinical symptoms appearing in 2-3 weeks (57–59). Collagen-induced 
arthritis is primarily a T cell-driven, receptor-independent disease. Activation of T cells requires 
glycosylated type II collagen to be presented by APC, most likely macrophages, as DCs are 
not able to present type II collagen as effectively (60). Collagen-induced arthritis results in the 
production of Abs against type II collagen, anti-citrullinated protein antibodies and anti-IgG 
antibodies (5,61). Anti-rat collagen type II antibodies are detectable a few weeks after 
immunisation and can be used to induce arthritis in non-immunised mice (61,62).  
The NADPH oxidase enzyme which generates ROS in immune cells is made up of several 
subunits. NOX2 (gp91phox) dimerises with p22phox to form the catalytic component 
flavocytochrome b558 complex in the membrane. Key regulatory components of NOX2 
including Ncf1 (p47phox), Ncf2 (p67phox) and Ncf4 (p40phox) are found in the cytosol in the resting 
state. Upon phosphorylation, Ncf1 is activated causing a conformational change and 
translocation to the membrane and is thus a critical organising protein during immune 
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activation (15). NOX2 is primarily found in phagocytes and is crucial for creating ROS during 
inflammation but is also found in other cell types such as T cells where it is the primary 
continuous source of ROS (258). 
Although it has been established that ROS are a key factor in inflammation during autoimmune 
disease development it was found that rodents with non-functional NADPH oxidase are more 
susceptible to rheumatoid arthritis and have increased the severity of the condition (259). For 
example, the Ncf1 mutation in mice leads to increased serum levels of anti-CII antibodies 
which suggests the presence of activated autoreactive T cells when ROS production is 
inhibited (258). NOX derived ROS protects against arthritis by reducing T cell activation. 
Activated cells from the joints of wild type animals show reduced response to TCR stimulation 
in comparison to NOX2 knockouts indicating a protective role for ROS (260). NOX2 deficient 
mice have altered differentiation of Th and Treg into Th1, Th2 and a strong Th17 through the 
production of increased CD11b+Gr-1+ myeloid cells. These have been identified as myeloid-
derived suppressor cells which cause T-cell dysfunction and antigen-specific T-cell tolerance 
(261,262).  
CII is found only in cartilage and forms the basis of the fibrillar structure of the extracellular 
matrix through covalent bonds cross-linking through pyridinoline (263,264). type II collagen is 
primarily targeted for enzyme degradation in arthritis by metalloproteinases and cysteine 
proteases which cleave specific sites in the collagen structure and in some cases only the 
denatured form (265). Several cysteine proteases including cathepsins B, L, K, and S are also 
involved in rat collagen type II degradation at targeted regions (266). Cathepsins B and L 
cleave non-helical telopeptide of collagens and cathepsin K cleaves numerous sites within the 
triple helix (267,268). Cathepsin S is unique in that it is functional at neutral and alkaline pH 
but is less active on type II collagen than other cathepsins that function at higher pHs 
(263,269).  
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The pH and lysosomal proteases of phagosomes are usually tightly regulated in order to 
regulate cleavage of foreign antigens for future presentation to T cells. NOX2 has been 
demonstrated to contribute to the alkalinisation of the endosomal pH in macrophages and DCs 
as a result of recruitment of the vacuolar-type H+ ATP-ase (242,243). This, in turn, down-
regulates some lysosomal protease activity modifying antigen cleavage for presentation (38).  
Considering the framework for humane animal research the use of non-toxic alternatives to 
Freund’s adjuvant for use as an adjuvant in the collagen-induced arthritis model could be used 
to refine the process and minimise suffering. Freund’s adjuvant is associated with a strong 
immune response to protein antigens due to the mycobacterial component of the cell wall 
activating APCs, however, it is known to have several negative consequences when used. It 
can cause pain at the site of injection, abscesses, chronic granulomas ulceration, tissue 
necrosis, the formation of fistulous tracts and spread to other muscles and organs in the 
animal. Because of this monitoring at the site of injection is essential when this adjuvant is 
necessary and replacement of this adjuvant where possible is desirable (257). The 
development of vaccine adjuvants with reduced toxicity that is still able to produce a strong 
immune response is highly desirable. This may be accomplished by taking advantage of the 
unique antigen properties of type II collagen and the way it is processed. 
This chapter addresses the hypothesis that the presence of NAC in liposome formulations will 
improve MHCII expression as a proxy for antigen presentation, and also the immune 
response, by favouring peptide processing in the multichain, disulphide crosslinked type II 
collagen protein. This chapter explores the differences in the immunisation response to the rat 
collagen type II antigen using DDA:TDB liposomes with or without NAC in C57BLK6 Ncf1-/- 
mice bone marrow compared to wild type. The formulation effectiveness with regards to 
Th1/Th2 cytokine secretory profile from re-stimulated splenocytes and lymph node cells with 
rat collagen type II or Con A and antibody titres are determined.  
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Chapter objectives 
• Induce collagen-induced arthritis used rat collagen type II mixed in combination with 
DDA:TDB or DDA:TDB-NAC 
• Determine the effectiveness liposomal formulations at inducing collagen-induced 
arthritis in wild type and Ncf1-/- models.  
• Examine arthritic severity, weight changes and erythema at the site of injection (SOI) 
in immunised mice as well as antibody tires and cytokine release from re-stimulated 
lymph node cells. 
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5.2 Methods 
5.2.1 Induction of arthritis  
For eliciting collagen-induced arthritis, 37 C57BL/6 (20 females, 6-12 weeks old and 17 males, 
6-12 weeks old) and 21 C57B6N.Q.Ncf1-/- (6 females, 10 weeks old and 15 males, 6-10 weeks 
old) developed by in-house breeding at Redoxis (Lund, Sweden) were used. rat collagen type 
II (Chondrex, Inc, Redmond, USA) was dissolved in 0.1M acetic acid to a final concentration 
of 5 mg/mL. 
Mice were immunised (100 µl) with liposomes consisting of 250 µg DDA and 50 µg TDB with 
100 µg of rat collagen type II and with or without 10mM NAC, added during hydration. For 
comparison CFA with equivalent amounts of rat collagen type II was used. Boosters composed 
were administered on day 29 composed of the same liposomal formulation as before or with 
IFA in place of CFA. The experiment ended on day 40 to be consistent with other studies that 
reported significant arthritic severity and antibody production at this time (270). 
The aims of the collagen-induced arthritis model study were 1) To establish whether NOX2 
was necessary for any benefit of NAC to be seen. 2) To determine if a more reducing 
environment during antigen presentation by co-delivery of NAC with antigen enhances the 
immune response. Mice were injected (100 µl s.c) at the base of the tail with 100 µg of rat 
collagen type II in groups of six using DDA:TDB, DDA:TDB-NAC or IFA as an adjuvant as 
described in 2.2.13.  
5.2.2 Arthritis severity  
All four limbs were monitored for swelling and redness as an indicator of arthritis development. 
Red or swollen regions were assessed and attributed points based on location to a maximum 
potential value of 60 points. Each inflamed knuckle, toe or midfoot digit was assigned a value 
of 1 and each ankle had a value of 5. 
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5.2.3 Ex vivo re-stimulation of lymph node cells 
Lymph nodes were homogenised separately to single-cell suspensions as described in 2.2.14. 
Cells were re-suspended at 2x106 cells/mL in complete RPMI (10% FBS and 1% penicillin-
streptavidin) and 100μl cells were stimulated with ConA (5 μg/mL) or rat collagen type II (100 
µg/mL) was added to wells and incubated for 24h at 37°C, 5% CO2. Cells were washed, and 
the supernatant was stored for Th1/Th2 cytokine analysis using the cytometric bead array. 
5.2.4 Mouse Th1/Th2 cytokine kit multiplex 
BD cytometric bead array Mouse Th1/Th2 Cytokine Kit (New Jersey, US) was used to 
determine the serum concentrations of IL-2, IL-4, IL-5, IFN- γ & TNF-α as per manufacturer’s 
instructions. Standards consisting of each cytokine were made up in assay diluent to the 
concentration of 5000 pg/mL. The top standard (5000 pg/mL) was then serially diluted in assay 
diluent to 20 pg/mL as described in 2.2.15. 
Capture bead suspension for each cytokine was mixed in equal volumes to make a single 
mixed bead solution. Mouse serum samples were diluted at a 1:5 ratio in assay diluent and 
25 µl of each sample and standard was added individually to each tube in duplicate. 25 µl of 
the mixed bead solution and 25 µl PE Detection Reagent was then added to each tube and 
incubated for 2hours at room temperature in darkness. Samples were washed and the beads 
were re-suspended in 200μl of Wash Buffer.  
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5.3 Results 
5.3.1 The effect of rat collagen type II -coated liposomes (+/- n-
acetyl cysteine) liposomes on weight in C57BLK6 Ncf1-/- and 
wild type compared to Freund’s adjuvant 
Weights of Ncf1-/- and wild type mice immunised with 100 µg of rat collagen type II in 
combination with DDA:TDB or DDA:TDB-NAC or Freund’s adjuvant were assessed at 10 day 
intervals until day 40 as an indicator of adjuvant toxicity. 
No significant difference was seen between wild type animals with any of the adjuvant 
formulations tested. However, the rate of weight gain was lower in CFA-adjuvanted Ncf1-/- 
mice compared to animals that were immunised using DDA:TDB formulations (Figure 5.1).  
 
Figure 5.1: Weights of C57BLK6 Ncf1-/- and wild type mice following immunisation with rat 
collagen type II Freund’s adjuvant, rat collagen type II DDA:TDB or DDA:TDB-NAC liposomes at 
10-day intervals. Mice were immunised with 100 µg rat collagen type II using Freund’s adjuvant or 250 
µg DDA and 50 µg TDB with or without 10mM NAC as adjuvants. Weights were assessed at 10-day 
intervals until day 40 as an indicator of adjuvant toxicity. A) Percentage weight change from day 0 of 
mice immunised Ncf1-/- mice in grams over the 40-day period. B) Percentage weight change from day 
0 of mice immunised wild type mice in grams over the 40-day period. Mean values are shown with SEM. 
Data were analysed by ANOVA with Tukey’s post-test. C) The gradient of slope of weight gain by Ncf1-
/- mice using linear regression analysis. Mean values are shown with SD. 
Page 154 of 212 
 
5.3.2 Arthritis severity in C57BLK6 Ncf1-/- and wild type 
immunised with rat collagen type II coated liposomes (+/- n-
acetyl cysteine) or Freund’s adjuvant  
Arthritis severity in Ncf1-/- and wild type mice immunised with 100 µg of rat collagen type II in 
combination with DDA:TDB or DDA:TDB-NAC or Freund’s adjuvant was assessed on days 
19, 22, 26, 28, 33, 36 and 41 (endpoint) as an indicator of disease development. All four limbs 
were monitored for swelling and redness and scored out of a possible 60 points. 
By day 41 arthritis severity was significantly greater in the Ncf1-/- model (P<0.001) after treated 
with Freund’s adjuvant relative to other formulations tested and compared to wild type animals 
(Figure 5.2). 
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Figure 5.2: Arthritis severity of C57BLK6 Ncf1-/- and wild type mice following immunisation with 
rat collagen type II Freund’s adjuvant, rat collagen type II DDA:TDB or DDA:TDB-NAC liposomes. 
Mice were immunised with 100 µg rat collagen type II using Freund’s adjuvant or 250 µg DDA and 50 
µg TDB with or without 10mM NAC as adjuvants. Arthritis severity was assessed on days 19, 22, 26, 
28, 33, 36 and 41 (endpoint) and scored out of a possible 60 points as an indicator of disease 
development. Mean values are shown with SEM. Data were analysed by ANOVA with Tukey’s post-
test. 
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5.3.3 Lymphocyte cytokine release after stimulation from rat 
collagen type II coated liposomes (+/- n-acetyl cysteine) and 
Freund’s adjuvant immunised C57BLK6 Ncf1-/- and wild type 
mice 
The BD cytometric bead array Mouse Th1/Th2 Cytokine Kit was used to determine the serum 
concentrations of IL-2, IL-4, IL-5, IFN- γ & TNF-α in response to rat collagen type II coated 
DDA:TDB-NAC, DDA:TDB or Freund’s adjuvant. C57BLK6 Ncf1-/- and wild type mice were 
immunised as above, then the lymph nodes were removed and stimulated on day 41 (end 
point) with 5 µg/mL rat collagen type II or 5 µg/mL Con A or left untreated for 24hours. 
Cytometric bead array analysis of the supernatants was then carried out using BD 
FACSCelesta and BD_FCAP Array™ Software Version 3.0 analysis software. 
Ncf1-/- mice lymph node-derived cells showed significantly increased TNF-α secretion in 
response to Con A stimulation relative to cells from wild type immunised with the same 
formulation (P<0.001) (Figure 5.3 E). DDA:TDB-NAC immunised mice showed greater 
secretion of TNF-α in response to Con A stimulation in Ncf1-/- mice relative to Ncf1-/- mice 
immunised with CFA (P<0.05) (Figure 5.3 E). IFN-γ secretion was higher in DDA:TDB-NAC 
immunised Ncf1-/- mouse lymph node cells stimulated with Con A relative to wild types 
immunised with the same formulation or Ncf1-/- immunised with DDA:TDB or CFA (P<0.001) 
(Figure 5.3 F). Rat collagen type II re-challenge caused significantly greater secretion of TNF-
α from Ncf1-/- immunised with DDA-TDB-NAC compared to CFA (Figure 5.3 I). Many lymph 
node cell samples did not produce detectable IL-5 when stimulated with Con A or rat collagen 
type II; IL-5 values from Con A stimulated wild type immunised using CFA, and rat collagen 
type II stimulated Ncf1-/- immunised using DDA/TDB NAC are from only one mouse with the 
rest in the group failing to produce any detectable IL-5 (Figure 5.3 G and K). Con A stimulated 
Ncf1-/- lymphocyte immunised using DDA/TDB NAC produced detectable IL-5 in the majority 
of mice immunised (Figure 5.3 G). With the exception of Con A stimulated cells from wild type 
previously immunised with DDA:TDB-NAC and Ncf1-/- pre-immunised with DDA:TDB, only 
stimulated lymph node cells from one mouse produced detectable IL-2 (Figure 5.3 H and L). 
Similarly, IL-4 was not detectable with any stimulation for cells isolated from any model. No 
signal from a cytometric bead array kit analysis indicates that the value fell below the lowest 
standard 20 pg/mL. 
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Figure 5.3: Secretion of IL-2, IL-5, IFN- γ & TNF-α by stimulated lymph node cells from C57BLK6 
Ncf1-/- and wild type mice immunised with rat collagen type II coated DDA:TDB or DDA:TDB-NAC 
or Freund’s adjuvant. Lymph node cells (2x105 in 200 µl) were treated with 100 µg/mL rat collagen 
type II or 5 µg/mL Con A for 24hours at 37°C at 5% CO2. Media was then analysed by cytometric bead 
array analysis using BD FACSCelesta and BD_FCAP Array™ Software Version 3.0 analysis software. 
A) Bar graph of TNF-α secretion in response to RPMI. B) Bar graph of IFN-γ secretion in response to 
RPMI. C) Bar graph of IL-5 secretion in response to RPMI. D) Bar graph of IL-2 secretion in response 
to RPMI. E) Bar graph of TNF-α secretion in response to ConA (5 µg/mL). F) Bar graph of IFN-γ 
secretion in response to ConA (5 µg/mL). G) Bar graph of IL-5 secretion in response to ConA (5 µg/mL). 
H) Bar graph of IL-2 secretion in response to ConA (5 µg/mL). I) Bar graph of TNF-α secretion in 
response to rat collagen type II (100 µg/mL). J) Bar graph of IFN-γ secretion in response to rat collagen 
type II (100 µg/mL). K) Bar graph of IL-5 secretion in response to rat collagen type II (100 µg/mL). L) 
Bar graph of IL-2 secretion in response to rat collagen type II (100 µg/mL). Mean values are shown with 
SEM. These values result from five mice per group. Data were analysed by ANOVA with Tukey’s post-
test. 
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5.3.4 Titres of serum IgG1 anti- rat collagen type II overtime 
after immunisation of C57BLK6 Ncf1-/- and wild types mice with 
liposomes (+/- n-acetyl cysteine) or Freund’s adjuvant 
Total IgG1 anti-rat collagen type II serum titres from seven mice from each immunisation group 
were used to determine the effectiveness of the DDA:TDB and DDA:TDB-NAC liposome 
formulation relative to Freund’s adjuvant using rat collagen type II antigen as described in 
section 2.2.16.  
No significant difference was seen between IgG1 antibody titres raised in response to rat 
collagen type II in the FCA, DDA:TDB-NAC and DDA:TDB liposomes on day 41 (endpoint) in 
wild type or Ncf1-/- mice. All formulations have similar efficacy at producing IgG1 antibodies 
against rat collagen type II (Figure 5.4). 
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Figure 5.4: IgG1 anti-rat collagen type II titres levels measured in C57BLK6 Ncf1-/- and wild type 
mice following treatment with rat collagen type II DDA:TDB , DDA:TDB-NAC or Freund’s adjuvant 
on day 41 (endpoint). Ncf1-/- and wild type mice were immunised with 100 µg rat collagen type II using 
250 µg DDA and 50 µg TDB with or without 10mM NAC or with Freund’s adjuvant. A serial dilution 
ELISA using goat polyclonal anti-mouse IgG1 conjugated to HRP was used to determine final titres. 
The absorbance at 490 nm was measured using a SpectraMax iD3 spectrometer and the maximum 
dilution that signal could still be detected was assessed after the removal of background absorbance. 
For comparisons of sera values were converted to midpoint titres (the midpoint of the fitted sigmoid 
curve obtained from the titration). Data were analysed by one-way ANOVA. 
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5.3.5 Titre of serum total IgG anti- rat collagen type II after 
immunisation with liposomes (+/- n-acetyl cysteine) or with 
Freund’s adjuvant 
Total IgG anti-rat collagen type II serum titres from seven mice from each immunisation group 
were used to determine the effectiveness of DD:TDB or DDA:TDB-NAC liposome formulation 
relative to Freund’s adjuvant using rat collagen type II as a model antigen. C57BLK6 Ncf1-/- 
and wild type mice were immunised as above. 
There was a significant increase in total IgG titre to rat collagen type II in wild type and Ncf1-/- 
mice immunised using the DDA:TDB formulation compared to CFA on day 41 (endpoint). The 
DDA:TDB-NAC formulation was able to produce a significantly higher total IgG response to 
rat collagen type II in wild type but not Ncf1-/- mice (Figure 5.5). 
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Figure 5.5: Total IgG anti-rat collagen type II titres levels measured in C57BLK6 Ncf1-/- and wild 
type mice following treatment with rat collagen type II DDA:TDB , DDA:TDB-NAC or Freund’s 
adjuvant at the study endpoint (Day 41). Ncf1-/- and wild type mice were immunised with 100 µg rat 
collagen type II using 250 µg DDA and 50 µg TDB with or without 10mM NAC or with Freund’s adjuvant. 
A serial dilution ELISA using goat polyclonal anti-mouse IgG conjugated to HRP was used to determine 
final titres. The absorbance at 490 nm was measured using a SpectraMax iD3 spectrometer and the 
maximum dilution that signal could still be detected was assessed after the removal of background 
absorbance. For comparisons of sera values were converted to midpoint titres (the midpoint of the fitted 
sigmoid curve obtained from the titration). Data were analysed one way ANOVA. 
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5.4 Discussion 
Several models of rheumatoid arthritis exist, rheumatoid arthritis collagen-induced arthritis 
being the most common with symptoms appearing within 2-3 weeks (57–59). Although it has 
clear efficacy at stimulating APCs, the prevalent use of CFA in these methods adds further 
burdens to the animals such as pain at the site of injection, abscesses, chronic granulomas 
ulceration, tissue necrosis, the formation of fistulous tracts and spread to other muscles and 
organs in the animal (257). Considering the framework for humane animal research the use 
of less toxic alternatives to Freund’s adjuvant for use as an adjuvant in the collagen-induced 
arthritis model could be used to refine the process and minimise suffering. 
Bodyweight is often used to gauge animal welfare during studies in which tumour growth is 
unlikely (271). In the Ncf1-/- but not wild type mice, the use of CFA slowed the rate of weight 
gain over time. These animals are more susceptible to disease induction and showed higher 
indices of joint swelling. Therefore it is not possible to discriminate between the effect on 
weight gain due to disease induction in these animals compared to the effect of using CFA as 
an adjuvant. Due to the primarily localised nature of CFAs detrimental effects erythema was 
non quantitively assessed at the site of injection and found to be visibly reduced in mice 
injected with DDA:TDB or DDA:TDB-NAC.  
As with previous studies, the Ncf1-/- model showed significantly increased arthritis severity 
compared to wild type when using CFA. It has previously been reported that rodents with non-
functional NADPH oxidase are more susceptible to rheumatoid arthritis and have increased 
the severity of the condition (13). This contrasted with prevailing dogma at the time and is 
thought to be through a breaking of T-cell tolerance to type II collagen. Higher T cell activation 
in the presence of macrophages with decreased ROS has been described (35,259,270). This 
was only observed in T cell-dependent models of rheumatoid arthritis. Unpublished data 
(Remtulla PhD 2019, Aston University) has identified the CD4 T cell NMDA3 receptor as a 
target for ROS. In the presence of ROS, rapid calcium entry into activated T cells is inhibited 
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and IL-2 production after 24 hours was significantly reduced. This may explain at least in part 
why a lack of ROS enhances rheumatoid arthritis symptoms because there is a lack of 
inhibition of the activating calcium entry signal in the absence of ROS. Although joint swelling 
was reported in some Ncf1-/- mice immunised with DDA:TDB and DDA:TDB-NAC it was not 
significantly different from wild type controls possibly due to the differences in the nature of 
the adjuvants used. Failure to induce the physical symptoms of rheumatoid arthritis by the 
liposomal adjuvants may be used to argue the ineffectiveness of their use in this model.  
Both DDA:TDB and CFA are associated with a strong adjuvant depot that enables prolonged 
antigen presentation along with other synergistic adjuvant effects priming the immune 
response towards Th1. However, due to its bacterial component, the mode of action of CFA is 
somewhat more complex and results in a combination of effector and regulatory cell 
production weeks after injection as well as the many early stimulatory effects. Early on after 
injection CFA causes rapid adjuvant component uptake by DCs, improved phagocytosis 
boosts cytokine secretion and activation and proliferation of CD4+ lymph node cells. The 
strong Th1 polarisation observed when CFA is administered is a result of the mycobacterial 
components stimulating T lymph node cells through IFN-ɣ and is thought to be responsible for 
the hypersensitivity against autoantigens taken advantage of by the collagen-induced arthritis 
model. This is in part due to haemopoietic system remodelling over a period of weeks post-
injection resulting in expansion of Mac-1+ immature myeloid cells which along with its 
sensitivity to MTB phagocytosis is also associated with prolonged cell survival and increased 
rat collagen type II severity (117).  
The use of IFA which lacks the mycobacterial component of CFA results in T-lymphocyte 
differentiation towards Th2 usually resulting in strong antibody titres. In all collagen-induced 
arthritis models using Freund’s adjuvant, an initial injection consisting of rat collagen type II 
and CFA is used followed by a booster several weeks later using IFA as the adjuvant. This is 
done in order to give a more balanced immune response with high antibody titre and include 
the long term benefits of CFA (15,60,117).  
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The current literature explores the efficacy of DDA:TDB liposomes when compared to 
Freund’s adjuvant focusing only on IFA (155,220,272). These studies often emphasise that 
greater antibody titres are observed with various forms of DDA:TDB relative to IFA without 
lending consideration to the synergistic effects of CFA and IFA when used in combination. 
This may explain why comparing IgG1 titres did not show significant changes in midpoint 
values when immunising type II collagen in DDA:TDB compared to CFA/IFA combination 
boosting. Future experiments could compare rat collagen type II immunisations using 
DDA:TDB liposomes and IFA only as an adjuvant, as rat collagen type II IFA has been 
demonstrated to produce arthritis in certain strains. This would allow for a comparison of the 
effects of DDA:TDB and DDA:TDB-NAC without the complexity added by the mycobacterial 
component (60). It is challenging to compare antibody affinity between studies due to 
differences in the methods by which they are calculated with some studies only reporting initial 
absorbance without dilution, some using units of activity compared to a pool and others 
reporting mid-point titre (273). It is possible to have many low specificity antibodies being 
present. Dilution methods and midpoint titres should be carried out. In this study Ncf1-/- IgG 
and IgG1 absorbance at 490 nm using HRP-conjugated anti-mouse total IgG and IgG1 were 
higher than for wild type, suggesting a higher concentration of lower affinity antibodies in Ncf1-
/-. However, following dilutions the absorbance dropped more significantly for Ncf1-/- animals 
than wild type indicating the antibodies are lower affinity.  
Ncf1-/- mice have produced similar IgG & IgG1 titres to wild type immunised with rat collagen 
type II-CFA. Higher titres in Ncf1-/- were expected. This could be a result of differences in the 
times between the injection of the boost or when and how antibody titres are evaluated or may 
correspond to the low levels of DC activation observed in the previous chapter. The significant 
increase in total IgG titre to rat collagen type II when using DDA:TDB in wild types compared 
to CFA indicates that IgG2 or IgG3 may be raised in response to DDA:TDB treatment. IgG2 
responses are associated with carbohydrate antigens and IgG3 with intercellular bacteria, 
parasites and viruses, both have been reported in collagen-induced arthritis studies (273). 
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This could indicate that the immune system is being primed differently with these two different 
Th1 adjuvants possibly due to the large IFN-ɣ response causing IgG2a class switching in B 
cells through the STAT1 T-box transcription factor T-bet (198). However, a stronger IFN-ɣ 
response is observed when using the DDA:TDB-NAC formulation than the DDA:TDB alone. 
The higher titre observed does not translate to higher arthritic severity scoring, however. 
Overall lymphocyte cytokine release after stimulation with Con A was higher in Ncf1-/- models 
similar to other studies and makes sense in the context of greater autoreactive T cell activation 
due to reduced oxidative burst from macrophages (270,274). The further increase in secretion 
from Ncf1-/- mice immunised with DDA/TDB-NAC could be explained by a further decrease in 
regulatory ROS due to scavenging by NAC.  
In summary the DDA:TDB liposome formulation when used as an adjuvant for rat collagen 
type II collagen-induced arthritis appears to be a less harmful alternative to CFA. Better weight 
gain in Ncf1-/- mice, the most diseased state animals was observed along with reduced 
erythema (not recorded) at the site of injection. In line with the overall aim of this project to 
produce a strong antibody response, rat collagen type II produced the highest total IgG 
antibody titre when used in combination with DDA:TDB in wild types. IgG1 titres remained 
unchanged across all groups indicating IgG2a class switching. Interestingly the Ncf1-/- mice 
did not show as high midpoint titres expected, this may indicate that arthritic severity is 
independent of antibody titre and is consistent with rheumatoid arthritis being a T cell-driven 
disease. Cytokine secretion from lymph node cells was generally higher in Ncf1-/- mice 
however the inclusion of NAC in the DDA:TDB formulation significantly increased the secretion 
of TNF-α indicating the significance of the inclusion of NAC and a further polarising towards 
Th1. This greatly increased secretion of cytokines could theoretically have led to a cytokine 
storm however no evidence of this was observed in the mice models. DDA:TDB yields a 
different immune response to CFA and under the right circumstances may be a more 
appropriate adjuvant for use in future studies that aim to produce a greater quantity of high-
affinity antibody’s. However, for studies that aim to induce a rheumatoid arthritis disease state 
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symptoms such as joint swelling CFA would be the choice adjuvant due to the enhanced 
rheumatoid arthritis symptoms demonstrated in this study.   
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Chapter 6: The use of adjuvants to 
improve glycolipid antigen 
immunogenicity  
Preface 
This section outlines future potential opportunities for using the DDA:TDB or DDA:TDB-NAC 
liposome formulations to present glycolipid antigens. The incidence of TB is difficult to monitor 
and improved point of care tests are needed. A specific glycolipid antigen, Lipoarabinomannan 
(LAM) is of particular interest for the World Health Organization in developing a urine-based 
point of care testing due to easy and safe sample collection and the relative cheapness of this 
type of assay. For effective point of care testing, high-affinity antibodies are required but 
existing anti-LAM antibodies lack high avidity. Currently, urine-based LAM testing kits do exist 
but lack the sensitivity required for effective diagnosis. 
LAM has a lipid anchor, which ordinarily connects it to the TB cell wall. This anchor can be 
exploited to integrate it into liposomal membranes during the lipid hydration process. 
Preliminary feasibility investigations for LAM-glycolipid loading into liposomes are presented 
confirming successful LAM availability on the surface of DDA:TDB liposomes in a 
conformation detectable by patient-derived anti-LAM antibodies. Further DDA:TDB-LAM 
liposome uptake was studied to investigate the likely efficacy of DC maturation by LAM-
containing liposomes.  
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6.1 Introduction 
Mycobacterium tuberculosis (Mtb) is the causative agent of TB which is estimated to have 
been responsible for 1.6 million deaths in 2017. TB is one of the top ten causes of death 
worldwide. The number of cases of TB is still growing with 10 million new cases being reported 
that year. It is also the leading cause of death for those infected with HIV who are 26 times 
more likely to develop TB (275,276). In many cases, the bacteria Mtb may persist whilst 
remaining asymptomatic (277). Differences in outcome can range from Mtb, active TB, latent 
TB or no disease and are dependent on the strain and in particular the host immune systems 
particularly in the early stages (278,279). It is estimated that nearly a quarter of the world’s 
population, 1.7 billion people, have a latent TB infection and could consequently develop TB 
later in life. The number of cases of multidrug-resistant TB is rising compared to previous 
years, increasing the necessity for vaccination and other methods of disease prevention. It is 
estimated that 54 million lives were saved through diagnosis and treatment of TB since 2000, 
although more work remains to be done. The development of an effective urine-based point 
of care testing for the detection of TB is considered of high importance by the WHO. This is 
due to it being easier, safer and cheaper to collect samples for testing than it currently is from 
sputum (1,2). Diagnosis in situ, particularly in rural communities, is thought to reduce the risk 
of patient loss to follow up treatment and enables early treatment to reduce the risk of infection 
spread.  
The cell wall of Mtb contains several glycolipids and polysaccharides that act as PAMPs and 
trigger the innate immune response through their recognition by macrophages and DCs. TLRs, 
CLRs including the C-type lectin receptor Dendritic Cell-Specific Intercellular adhesion 
molecule-3-Grabbing Non-integrin (DC-SIGN), have been demonstrated to recognise Mtb 
PAMPs (280,281). Once triggered by Mtb antigens, these mature APCs can then migrate to 
lymph tissue and enable the adaptive immune response to develop (282).  
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LAM or mannosylated lipoarabinomannan (ManLAM) is a glycoprotein derived from the cell 
wall of Mtb. The H37Rv strain is most commonly used an is most easily available. LAM is 
made up of α1,5-linked D-arabinofuranose units which branch into linear tetra- arabinoside or 
hexa- arabinoside with a phosphatidylinositol lipid anchor (mannosyl-phosphatidyl-myo-
Inositol) (283–285). The number of mannosyl residues on the terminal end varies between 
strains and is key to the DC response and governs the release of cytokines and the 
upregulation of PRRs in response to LAM. The non-reducing arabinan termini of H37Rv LAM 
are extensively capped with mannose relative to other strains (286).  
Depending on the strain and the extent of the mannose cap, LAM stimulates the release of 
cytokines and the upregulation of PRRs. LAM induces the release of TNFα and other cytokines 
like IL-6 and IL-12 which triggers the secretion of IFN -γ from T cells. IL-6 guides a Th17 
response to naïve T cells which is necessary for extracellular immunity to bacterial infections 
(287,288). Similarly, IL-12p40 and IL-12p70 cause Th1 differentiation in naïve T cells which is 
necessary for immunity to mycobacterial infection (289). TNFα suppression has been shown 
to be important for the early inflammatory response with studies showing knockouts having an 
increased chance of primary TB disease after mycobacterial infection (290–292). DCs also 
show upregulation of PRRs in response to LAM such as DC-SIGN which detects a broad 
range of mannose- residues and Dectin-2 which is more specific. This response is dependent 
on the mannosylation level of the LAM (286,293). 
LAM is considered a key candidate molecule for urine-based point of care testing and TB 
detection because few infection control measures are necessary for the health care worker. 
The presence of LAM in urine is indirectly related to human immune response and it may be 
detected in rural communities by cheaper point of care platforms. However current assays to 
detect LAM are not considered sensitive enough for testing purposes (275). 
It is hypothesised that as LAM has a lipid anchor, which connects it to the bacterial cell 
membrane, it may also allow for its integration into liposomal membranes during the lipid 
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hydration process (285,294). Combining LAM may produce DDA:TDB liposomal adjuvant 
which would allow for the formation of depots whilst protecting the LAM from degradation and 
providing stability. This could be used to enhance vaccine effectiveness and provide 
antibodies specific for mannosylated LAM necessary for point of care testing 
(111,129,133,134). 
For the development of antibody-based detection assays, the production of high-affinity 
antibodies against LAM is required. Antibodies developed against LAM such as mAb IgG CS-
35 have shown some affinity for the hexasaccharide branched terminal structure but low 
avidity when the non-reducing terminal arabinosyl end is mannosylated (295,296). The 
development of novel antibodies with the potential for higher affinity for the commonly 
occurring form of mannosylated LAM is necessary. 
Chapter objectives 
• To determine the size and distribution of the Bodipy-labelled DDA:TDB-LAM by Coulter 
EPICS Elite ESP. 
• To establish the presence and immunoreactive availability of DDA:TDB surface-
exposed LAM. 
• To explore the uptake of DDA:TDB-LAM liposomes compared to those coated with 
OVA in the DC model. 
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6.2 Methods 
6.2.1 Lipid hydration of Dimethyldioctadecylammonium D-(+)-
trehalose 6,6'-dibehenate - lipoarabinomannan liposomes 
stained with Bodipy 
DDA:TDB liposomes stained with Bodipy ((diaza-s-indacene-3-propionyl)-1,2-
dihexadecanoyl-sn-glycero-3-phosphoethanolamine, triethylammonium salt) from 
ThermoFisher (Loughborough, UK) were made up in the ratio 5:1:0.01 respectively. Lipid film 
hydration was then carried out using 10mM Tris-buffer at pH 7 with 50 µg/mL LAM from Mtb 
strain H37Rv from BEI Resources (Washington, USA). 
6.2.2 Dimethyldioctadecylammonium D-(+)-trehalose 6,6'-
dibehenate - lipoarabinomannan flow cytometry analysis 
A modified Coulter EPICS Elite ESP was used to determine liposome homogeneity and to 
establish the availability of surface LAM. The size of Bodipy stained DDA:TDB-LAM liposomes 
was compared to green fluorescent bead stock of 390 nm diameter using side scatter. To 
determine the presence of surface LAM, APC-labelled monoclonal anti-LAM antibodies 
derived from humans infected with TB were used.  
6.2.3 Dimethyldioctadecylammonium D-(+)-trehalose 6,6'-
dibehenate - lipoarabinomannan uptake 
wild type derived DCs (2x105) were treated with DDA/TDB-LAM or DDA-TDB coated in OVA 
(12 µg liposomes /mL) stained with Bodipy in the presence and absence of NAC for 24hours 
at 37°C, 5% CO2. They were then imaged by confocal microscopy using Nikon Ti-Eclipse with 
A1M Confocal and NIS-Elements Acquisition software. Cells were resuspended in PBS to 
1x106 cell/mL and (20 µl) were mounted onto glass slides. To this 2 µl of Vectashield Antifade 
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Mounting Medium from Vector laboratories (Peterborough, UK) was added and coverslipped. 
Bodipy was detected using excitation 503 nm, emission 512 nm. 
Alternatively, treated cells were studied by flow cytometry, 10,000 cells were examined using 
BD FACSCelesta and BD FACSDiva analysis software at excitation 503 nm, emission 512 
nm. DDA:TDB-LAM uptake levels were reported as MdX or %+Ve of the fluorescence intensity 
of Bodipy after positive gating for 2% fluorescence of the equivalent no negative no stain 
control. 
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6.3 Results 
6.3.1 Size and homogeneity of Bodipy stained 
Dimethyldioctadecylammonium D-(+)-trehalose 6,6'-dibehenate 
- lipoarabinomannan liposomes 
DDA:TDB-LAM liposome population was labelled with BODIPY (which emits at 511 nm) as 
described above and analysed by Coulter EPICS Elite ESP using built-in software. They were 
compared with green fluorescent bead, at 390 nm diameter (circled in black).  
Liposomes were distributed into two major populations based on size (encircled in red), and 
the degree of Bodipy staining related to size as shown by the population distributions along 
the line of correlation. One population was close to the bead size (390 nm) (Figure 6.1). 
 
Figure 6.1: Initial gating of Bodipy-stained DDA:TDB-LAM liposomes. Bodipy-stained DDA:TDB 
LAM liposomes (highlighted in red) were gated as shown above using the integrated Coulter EPICS 
Elite ESP software and compared to green fluorescent bead with a diameter of 390 nm (circled in black).  
Page 171 of 212 
 
6.3.2 Lipoarabinomannan is exposed on the surface of 
Dimethyldioctadecylammonium D-(+)-trehalose 6,6'-dibehenate 
liposomes 
Bodipy-stained liposomes with and without LAM were used in conjunction with anti-LAM 
monoclonal antibodies conjugated to allophycocyanin and analysed by Coulter EPICS Elite 
ESP using built-in software. These antibodies were derived at Mologic Ltd from a human B-
cell hybridoma from a person infected with TB. Allophycocyanin has an excitation of 633 nm 
and an emission of 660 nm.  
DDA:TDB liposomes without LAM showed minimal non-specific interactions of the anti-LAM 
antibody (Figure 6.2 B). DDA:TDB-LAM liposomes had significantly more association of the 
antibody as well as increased Bodipy staining due to less debris being present perhaps due 
to stability or differences in liposome dilution prior to antibody staining (Figure 6.2 C & D). 
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Figure 6.2: LAM surface staining on Bodipy gated DDA:TDB-LAM liposomes. DDA:TDB and 
DDA:TDB-LAM liposomes were stained with an anti-LAM APC conjugated antibody. Liposomes were 
discriminated from debris using the Bodipy stain and gated as shown above. A) Bodipy staining of 
DDA:TDB liposomes lacking LAM, stained with the anti-LAM antibody. B) Anti-LAM antibody (APC) 
staining of DDA:TDB liposomes lacking LAM. C) Bodipy staining of DDA:TDB liposomes with LAM and 
anti-LAM antibody. D) Anti-LAM antibody (APC) staining of DDA:TDB liposomes with LAM.  
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6.3.3 Dimethyldioctadecylammonium D-(+)-trehalose 6,6'-
dibehenate - lipoarabinomannan uptake is increased with the 
inclusion of n-acetyl cysteine 
Confocal microscopy images or flow cytometry analysis of DCs treated with Bodipy (excitation 
503 nm, emission 512 nm) as described in section 2.2.19.  
LAM liposomes +/- NAC appear to display better association than their counterpart OVA 
liposomes as shown by confocal microscopy. This is partially confirmed by flow cytometry 
analysis which shows more association per cell (as shown by %+Ve) and greater uptake per 
cell (as shown by MdX) with DDA:TDB-LAM NAC compared to DDA:TDB-OVA NAC 
liposomes but is not seen in combinations using DDA:TDB without NAC (Figure 6.3). 
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Figure 6.3: OVA and LAM antigen uptake when associated with Bodipy stained DDA:TDB 
liposomes in the presence and absence of NAC. Bodipy stained DDA:TDB and DDA:TDB-NAC 
associated with OVA or LAM antigen uptake. A) Analysed by confocal microscopy B) Analysed by flow 
cytometry examining the percentage of DCs taking up antigen based on 2% +Ve gating of a no stain 
control. C) Examining antigen uptake based on uptake per cell as shown by MdX based on 2% +Ve 
gating of a no stain control. Mean values are shown with SEM. These values result from three 
independent experiments. Data was analysed by ANOVA with Tukey’s post-test *p <0.01.   
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6.4 Discussion 
LAM’s lipid anchor may allow for its integration into liposomal membranes during lipid 
hydration (11,22). DDA:TDB-LAM liposomes would be able to create adjuvant depots, protect 
LAM from degradation and provide stability. This might result in enhanced immunogenicity 
and after in vivo immunisation, may ultimately provide a new source of antibodies specific for 
mannosylated LAM necessary for point of care testing (23–26). To determine the efficacy of 
this approach, preliminary characterisation experiments were carried out. 
Using the lipid hydration approach, LAM may be randomly incorporated into the charged 
liposomal membrane and it may be that specific orientation is preferred for antigenic 
recognition. However, antigen may not be present on the liposome surface but encapsulated 
or in the form that it is exposed may be altered due to the surface charge of the liposome. To 
understand the surface distribution of LAM, one assay using ELISA with serum anti-LAM 
antibodies and fluorescently tagged liposomes could be used. After capturing any LAM-
liposomes by immobilised antibodies, they can later be lysed to determine LAM binding and 
compared to a standard curve made up of known concentrations of lysed liposomes. 
There may be a problem with sensitivity in such an assay. As these liposomes are small (~300 
nm in diameter) the surface area for antibody binding is limited to approximately 7700 
antibodies. The entire surface of the liposome will not be coated in LAM and so a reduced 
number of binding sites will be available and due to the nature of a plate ELISA, only part of 
the surface of the liposome will be exposed to antibodies further limiting antibody binding. It 
was thus decided that a flow cytometry method would be used to determine the presence of 
LAM on the surface of liposomes. 
Modern flow cytometers such as the BD FACSCelesta are designed to primarily look at cells 
and so focus on high discrimination of objects of around that size. Built in software also 
includes built in size cut offs to remove debris, giving greater clarity when displaying results 
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for cell or bead analysis. However, because of these improvements discrimination of 
liposomes would be impossible. Due to its versatility and lack of software limitations, a Coulter 
EPICS Elite ESP was used to determine liposome antibody interactions as background noise 
could be better managed when examining liposomal nanoparticles. This work was undertaken 
at Mologic Ltd and the flow cytometry analysis was performed by Professor Gerhard Nebe 
Caron.  
Bodipy-stained liposomes with and without LAM were used in conjunction with an anti-LAM 
monoclonal antibody conjugated to allophycocyanin. These antibodies were derived from a 
human B-cell hybridoma from a person infected with TB. 
Initial analysis showed two separately defined liposome populations being present as 
determined by the side scatter and Bodipy staining. When compared to green fluorescent 
beads of 390 nm diameter one population was close to the 390 nm bead size and in contrast 
to the data from the Zeta sizer that calculated an average particle diameter of 350 nm. This is 
likely due to differences in the nature of OVA and LAM and the method of their incorporation 
and liposomal preparation. The smaller sized population may be indicative of instability of the 
liposomes and further work will be needed to establish whether this distribution changes over 
time and instability contributes to the distribution.  
Having established the size and distribution of the Bodipy-labelled LAM-associated liposomes, 
further experiments were undertaken to identify the immunoreactive, surface-exposed LAM. 
Cationic liposomes are known to increase antigen stability and can change antigen 
conformation. Additionally, the charged property may increase non-specific antigen 
association making the analysis of surface-associated LAM challenging. Sufficient blocking by 
casein reduced non-specific anti-LAM antigen association until antibody binding was only 
detectable in liposomes that included LAM. The presence of LAM on the surface of LAM-
liposomes was thus demonstrated to be in a recognisable conformation. 
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Using confocal microscopy LAM liposomes appear to be taken up more by DCs than OVA- 
coated liposomes. This may relate to the difference in how lipid antigens are taken up. Unlike 
OVA lipid antigens like LAM may be recognised by CLR for uptake. After intracellular 
processing, four distinct CD1 proteins, CD1a, CD1b, CD1c and CD1d mediate presentation to 
T cells. These cluster of differentiations have different pathways of presenting antigens to 
TCRs as they pass through separate compartments after binding along with unique antigen-
capture mechanisms (205,206,297). NAC inclusion in the liposomal formulation may have 
resulted in the reduction of disulphide bonds on receptors molecules in the DCs activating 
them and enhancing uptake. These differences may explain the variances in uptake observed. 
Here an isotype control was used to ensure LAM specific anti-LAM antibody association. Non-
specific anti-LAM antibody binding to LAM-free liposomes was prevented by isotype control.  
Liposome aggregation may be an issue possible representing crosslinking between liposomes 
and sonication, or filtration could be used. This could minimise self-assembly but suggests the 
need to include a neutral blocking protein to minimise the risk of charged liposomes interacting 
with LAM on adjacent liposomes. This could be 0.001% tween which is commonly used as an 
ELISA blocking agent. A higher concentration or Triton could be used but this could cause 
degradation of the liposomes. Another alternative would be to use higher concentrations of 
LAM to achieve saturation and reduce the risk of inter-liposomal interactions. 
An in vitro experiment using the DC model developed in this project could be carried out such 
as examining the expression of surface markers and pH. Subsequent experiments may 
involve using DDA:TDB-LAM to immunise animals. Any immune response would be analysed 
for antibodies produced carried out to determine specificity and affinity. Ultimately the 
DDA:TDB adjuvant in combination with the LAM protein may be used in the development of 
antibodies for use in antibody-based point of care detection assays such as the urine LAM 
lateral flow assay requested by the WHO to help identify those requiring treatment (275). 
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In summary, the work presented has shown that DDA:TDB-NAC-LAM liposomes are taken up 
preferentially by DCs over OVA liposomes. This may relate to differences in the stability of 
liposomes and their aggregation, the density of labelling with smaller antigen or greater 
numbers of DC receptors recognising LAM compared to OVA. Following the immune 
recognition of lipid antigens and their processing through CD1 pathways, their suitability for 
raising high-affinity antibodies to LAM in the presence of NAC merits further study. 
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Chapter 7: Overall discussion 
Vaccination is considered the most effective public health invention and has been one of the 
most cost-effective methods of preventing disease, reducing morbidity and mortality for over 
200 years (77,78). Vaccines are broken down into three categories; killed, attenuated and 
subunit vaccines. As they lack any of the usual signals associated with infectious disease; 
vaccines are less immunogenic than pathogens and unable to mature APCs, like DC, failing 
to stimulate the humoral immune response and are rapidly cleared from the host's immune 
system. The need, therefore, arises for vaccine adjuvants that are able to boost the host's 
immune response, and this is done using a variety of adjuvant types (99).  
The adaptive immunity necessary for successful immunisation by vaccination requires 
phagocytes such as DCs to take up antigen. This is aided by adjuvants that provide the 
additional immunostimulatory signals. DCs then mature, increase surface chemokine receptor 
CCR7 expression and migrate to the lymph node following antigen processing and upregulate 
expression of the maturation proteins MHC II. There they come into contact with T cells where 
they provide the antigen through the MHCII complex along with other costimulatory signals 
causing them to differentiate into effector T cells. These can then go on to cause B cell 
maturation and antibody production (8,36).  
ROS is a key component of an effective immune response and exists in many forms for a 
variety of purposes including as part of the respiratory burst, regulation of antigen processing, 
T cell activation and proliferation and B cell maturation through a series of complex signalling 
molecules (2,8,31,67,69). 
This project has investigated the effects of redox modulation on DC maturation and how the 
inclusion of the redox modulator NAC within the well characterised liposomal adjuvant 
dimethyldioactadecylammonium - trehalose 6,6'-dibehenate affects immune activation.  
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Final Data Summary 
This study identified the Lutz bone marrow-derived DC model as the most representative of 
DCs in vivo with regards to surface marker expression and highlights the differences and 
inconsistencies in the models used today. This model was used extensively throughout this 
study to determine the effectiveness of DDA:TDB and DDA:TDB-NAC liposomal adjuvants in 
both wild type C57BLK6 and Ncf1-/- mice DCs. NOX2 deficient DCs were shown to not mature 
as effectively, possibly due to reduced uptake and changes in pH compared to wild type.  
DDA:TDB-NAC was demonstrated to be less toxic and have increased cellular pH and 
activation markers compared to the DDA:TDB formulation. However, no difference in titre of 
IgG antibodies to OVA was observed between the two formulations in vivo. 
DDA:TDB adjuvant formulations were examined using di-sulphide crosslinked collagen II as 
an antigen to improve a rheumatoid arthritis model. They were more effective than Freund’s 
regarding cytokine release and IgG1 production however arthritic severity scoring was 
decreased calling into question the utility of this method for generating an arthritic model.  
Finally the possibility of DDA:TDB-Lipoarabinomannan nanoparticles were evaluated and 
successful binding of LAM to the surface of DDA:TDB and their uptake by the DC model was 
demonstrated.  
The 3Rs for adjuvants 
The 3Rs; reduce, refine and replace are a series of approaches laid out under the Principles 
of Humane Experimental Techniques that describe a framework for animal experiments in the 
UK under the Animal Procedures Act. They acknowledge the necessity of animal testing but 
encourage methods that reduce the suffering of animals both in the quantity used and the 
procedures performed upon them (184,185). 
Little work is published on the use of alternatives to common adjuvants such as Freund’s for 
animal testing. Understandably nearly all papers are geared towards the production of 
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adjuvants to immunise against disease. However, in some models such as collagen-induced 
arthritis little regard is put towards improving the method and bringing them in line with the 
3Rs. The variation between individual mice and between experiments limits conclusions being 
drawn. Reducing the stress and discomfort in these models may bring about more reliable and 
reproducible data and lower the number of animals needed in any experiment. For example, 
high cortisol levels have been shown to decrease inflammation and reduce immune response 
through changes in cytokine release (298). This would likely have implications on the collagen-
induced arthritis models using Freund’s that causes visible tissue damage at the site of 
injection. This will ultimately lead to more reproducible data for comparison between studies. 
Comparing studies 
Throughout this project, the difficulty in comparison between the results obtained here and 
those published previously have been strongly apparent. In recognition of the 3Rs, bone 
marrow derived DC models were compared with mone barrow being supplied after the animals 
were sacrificed for other experiments. Of the three models investigated the Lutz model 
appeared to best representation of DCs in vivo possibly due to the more physiologically 
representative levels of GMCSF (194). This was determined based on the expression of the 
key T cell interaction proteins CD86 and MHCII following activation which was significantly 
better than the other models tested. This highlights the need for better characterisation of the 
DC models used for experimentation as was shown here when the Lutz model was further 
characterised throughout its differentiation period. Greater awareness of the differences in 
bone marrow DC models is required which can vary in time of differentiation, the doses of 
GMCSF and IL-4 added (if any) and even the cells examined. DCs may be grouped into a 
range of subsets depending on localisation, antigen-presenting and cross-presenting abilities 
and transcriptional factors. The exact outcome of these different kinds of DC differentiation is 
left unaddressed in the majority of the literature and so a comparison between studies is 
challenging at best. 
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Another difficulty came in comparing in vivo experiments where differences in the mouse 
strain, injection route, booster days, dose, age and sex were all variable between studies 
examining the exact same adjuvant antigen combination. The method of reporting antibody 
titre also varies greatly between studies, with some, for example, giving absorbance without 
dilution, some using units of activity compared to a pool and others reporting mid-point titre. 
This all results in a vast array of data that cannot be easily or accurately compared. 
Reduced toxicity  
A key finding of this study was the greatly reduced toxicity of DDA:TDB-NAC liposomes 
compared to DDA:TDB alone. Interestingly the Ncf1-/- derived DCs showed reduced toxicity 
too despite having dramatically lower levels of phagosomal ROS compared to wild type. This 
indicates that the effect is independent of NOX2-dependent (phagosomal) ROS scavenging 
by NAC but may be affecting total cellular or extracellular ROS. It is possible that NACs ability 
to reduce disulphide bonds may also be contributing to survival. Disulphide bonds are covalent 
bonds between the sulphur atoms of two cysteines and exist in highly conserved regions of 
proteins. Reduction of disulphide bonds has been previously reported to be important for 
leukocytes. T cells, for example, are activated and proliferate when disulphide bonds on 
surface proteins SLAMF1, CD44, CD132, ICAM-1 and integrin β are reduced (299).  
The reduction of disulphide bonds on the surface of DCs by NAC may serve to activate DCs 
and provide survival signals that are not present when DDA:TDB alone is added. This may 
also explain in part the increase in activation surface markers reported in the wild types. 
This may be viewed as a positive characteristic as it could indicate that more APCs are 
available for antigen uptake and presentation. Several immune cells, for example, T cells 
protect themselves from ROS which would oxidise thiols in order to proliferate and survive 
(30). It may be that the inclusion of NAC helps to maintain thiols in a reduced state. This gives 
the potential for more antigen and adjuvant to be introduced potentially boosting immune 
response whilst maintaining a similar safety profile to DDA:TDB alone. 
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Countering this argument is the importance of DAMPs which include oxidised mitochondrial 
DNA, uric acid and HSPs that are released upon unintentional cell death. Release of DAMPs 
stimulates the inflammatory response and is a key factor in the effectiveness of many adjuvant 
including alum. Interestingly alum adjuvants are known to release alarmins within hours of 
introduction to APCs however with DDA:TDB liposomes no toxicity was observed until 12 
hours after introduction (300). It could be that the differences were seen in the adjuvanticity 
and antigen specificity of DDA:TDB liposomes compared to alum in other studies may in part 
relate to the timing of the release of DAMPs at the site of injection.  
Differences in priming 
In order to determine the effectiveness in both the OVA and rat collagen type II studies, 
cytometric bead array analysis was carried out on re-stimulated lymphocytes or splenocytes. 
In both studies and two main issues arose, the first being the lack of IL-4 response, probably 
due to the preferential polarisation of C57BLK6 discussed in previous chapters and the lack 
of response upon re-stimulation with the antigen. A specific immune response was mounted 
in both studies as demonstrated by the antibody titres however that did not translate into 
increased cytokine release by splenocytes on re-challenge. This indicates that either the B 
cells that make up the splenocytes (45-50%) or the T cells that makeup lymph node cells (60-
70%) are unable to recognise the antigen or that the antigen was there for an insufficient time 
during re-challenge. The cells were able to secrete cytokines in response to Con A so the 
issue was not cell viability. However, Con A is a potent nuclear factor and able to easily 
stimulate cytokine release so is not comparable to the antigen in this manner (43–46). Future 
experiments might consider using antigen fragments to stimulate as the issue may be that the 
whole antigen may be too large to be recognised. Alternatively stimulating with the vaccine 
adjuvant over a 72hr period to increase the chances of cytokine secretion. 
The lymph node cells taken from mice previously immunised using DDA:TDB-NAC as an 
adjuvant showed increased secretion of IFN γ and TNF-α relative to CFA and DDA:TDB alone 
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indicating the significance of the inclusion of NAC and a further polarising towards Th1 
response which is associated with defence against intracellular micro-organisms (52,251). 
The reason for this increase in secretion could be a combination of the reduced size of 
DDA:TDB-NAC and because of its disulphide bond reducing abilities, both of which have been 
shown to influence DC activation. The flexibility of liposomes relative to other vaccine 
adjuvants allows for more freedom in the development of antigen tailored vaccines designed 
to maximise immune response to subunit vaccines that lack their own immunogenicity. 
DDA:TDB liposomes are already characterised as driving a majority Th1 response but the 
inclusion of NAC may help to further polarise this under the correct circumstances, for 
example, to vaccinate against diseases where a strong Th1 response is necessary like MTB 
and cutaneous Leishmania. The effects of NAC when used in conjunction with DDA:TDB were 
different between studies with the first showing higher IL-5 and lower IL-2 indicating a Th2 shift 
if interpreted alone, this points to NAC-dependent antigen-specific polarization of the immune 
response. 
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Future work 
The development of adjuvant for human use is notoriously difficult due to strict regulations 
regarding vaccine toxicity. This is compounded by the fact that immune-stimulating 
components are often toxic themselves. The use of liposomal adjuvants of different kinds has 
been explored in the literature, examining different formulations and their properties such as 
size, charge, surface fluidity, different methods of manufacture and inclusion of various 
PAMPs. The use of cationic liposomes as ROS inducers using Dioleoyl-3-trimethylammonium 
propane (DOTAP) and phosphatidylcholine based liposomes have been previously 
demonstrated. These have been shown to cause the release ROS in an NADPH dependent 
manner in neutrophils and cause the release of macrophage inflammatory and 
chemoattractant substances CCL2, CCL3 and CCL4 as well as upregulation of CD80 and 
CD86 through upregulation of the p38 and ERK pathways (155,301). Although this effect has 
not been shown in DDA:TDB liposomes, if they do induce ROS then the inclusion of the 
antioxidant NAC may limit its effects. However, since the effects of NAC may be directly on 
thiols and independent of ROS this may not be a problem 
Further experiments to characterise DDA:TDB-NAC 
To further characterise the differences between DDA:TDB and DDA:TDB-NAC differences in 
the stability of the two formulations might be evaluated and the importance of sterility for fairer 
comparison might be considered.  
In vivo, it would be interesting to test the hypothesis that DDA:TDB-NAC is altering the activity 
of proteolytic enzymes in the phagosome. As described above antigen processing is ROS-
associated with high ROS increasing the acidity of the vacuole and optimising the activity of 
proteolytic digestion enzymes. ROS regulation of cysteine cathepsins has also been shown to 
change CD4+ T cell activation in an antigen-specific manner (41). Changes in antigen 
digestion may explain some of the differences observed between liposome formulations. rat 
collagen type II is a cross-linked protein whereas OVA is not and so would benefit from 
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different levels of cleavage before presentation to MHC molecules. This might explain why 
differences in cytokine release and relative antibody titres were observed between studies.  
DDA:TDB liposomes have been demonstrated to be larger than those which encapsulate 
NAC. Previous studies have demonstrated size-dependent differences in adjuvant properties 
such as toxicity, lymph node migration and IFN-ɣ release (154). It would be interesting to 
determine how this affects uptake by APC, whether the liposome is engulfed by the cell or 
whether it merges with the membrane releasing its contents into the cytoplasm. 
Future experiments in vivo may consider the timings of boosts and blood sampling in studies 
in order to get a clearer picture of differences in antibody titres. Differences were seen in the 
rheumatoid arthritis study between liposome formulations and CFA however more differences 
in antibody titre might have been elucidated had more time been given for an immune 
response to develop.  
Similar studies to investigate the effects of DDA:TDB with and without NAC in aged mice is 
another potential area of study. Ageing is associated with dysregulation of the immune 
response causing inflammation and ROS production. This is in part due to constant low-level 
activation of the innate immune response driving immune senescence and making vaccination 
more important and challenging to do effectively (298). The addition of reducing compounds 
to vaccine adjuvants could be beneficial in increasing antigen uptake and presentation 
increasing the chances of successful immunisations in these populations.  
As discussed above DAMPs play a vital role in some adjuvant’s efficacy. Further experiments 
could examine the differences in the release of DAMPs between DDA:TDB and the less toxic 
DDA:TDB-NAC and to determine if this has an effect on the differences in immune response 
observed. Distribution studies using labelled antigens could be used to determine any 
differences in depot formation and longevity as well as recruitment to the lymph possibly due 
to differences observed in surface charge. 
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Translational potentials  
 
DDA:TDB-NAC has not been used before now and so the reduced toxicity compared to 
DDA:TDB is a new finding.  Previous phase one clinical studies using DDA:TDB alone in 
humans have discussed the localised adverse side effects such as stiffness, pain, swelling 
and erythema amongst others (302). As previously discussed, these side effects are one of 
the major reasons new vaccine adjuvant for humans are not approved. Other compounding 
factors for getting approval include poor upscaling and lack of scope with regards to 
compatible antigens compared to more traditional alum-based adjuvants (108,109).  
Due to its flexibility through encapsulation and electrostatic binding as well as direct lipid 
interactions, DDA:TDB based liposomal adjuvants allow for a range of different antigens to 
be used (see figure 1.6). This study has demonstrated this versatility but also highlighted 
that the inclusion of NAC in the formulation does not negate this. This study used the lipid 
hydration method for the production of all liposomes due to the small scale nature of the 
studies however upscaling would be possible using microfluidics which could be used to 
tailor the size of the liposomes and reduce variability (303).  
The reduced toxicity of DDA:TDB-NAC combined with its ability to produce a similar immune 
response to DDA:TDB without sacrificing antigen compatibility make it a promising avenue 
for future testing in humans.  This along with existing methods of reproducible mass 
production could potentially make it an ideal alternative to existing well-established adjuvants 
such as alum. They may also potentially provide a more effective alternative to traditional 
adjuvants for example against tuberculosis where a strong cellular immune response is 
required, although further work would need to be carried out to determine the effectiveness 
of the adjuvant antigen combination.  
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Alternative uses of DDA:TDB 
Throughout this project, the efficiency of liposomes has been discussed in relation to the 
humoral response but not cellular and is an area which could be explored. Cross presentation 
adjuvants such as saponin using the CD8+ cytotoxic T cell responses are particularly 
important for cancer vaccines. This requires the endogenous MHCI presentation pathway in 
DCs which haven’t been investigated here. 
A great deal of literature on vaccine adjuvants exists however they may also be used in 
medical research as with the collagen-induced arthritis model or for the development of 
antibody-based diagnostics. A preliminary study examined the use of DDA:TDB liposomes for 
this purpose using LAM a glycoprotein derived from the cell wall of irradiated Mtb. LAM is a 
poor antigen and the present antibodies generated are of low affinity and unsuited to develop 
point of care testing. The next step in that project would be to move in vivo, immunise with 
LAM-liposomes and examine antibody production. Rather than calculating antibody titres 
however it may be more useful to assess the specificity of the antibodies produced rather than 
the overall titres. Antibodies could be affinity purified and then analysed for how specific they 
are to LAM to ensure that if used for point of care testing they would not give false positives 
for other similar molecules.  
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24.  Betten Å, Bylund J, Cristophe T, Boulay F, Romero A, Hellstrand K, et al. A proinflammatory 
peptide from Helicobacter pylori activates monocytes to induce lymphocyte dysfunction and 
apoptosis. J Clin Invest. 2001;108(8):1221–8.  
25.  Vlahos R, Stambas J, Bozinovski S, Broughton BRS, Drummond GR, Selemidis S. Inhibition of 
Nox2 oxidase activity ameliorates influenza a virus-induced lung inflammation. PLoS Pathog. 
2011;7(2).  
26.  Nicholson LB, Raveney BJE, Munder M, Unit A, Sciences C, Bristol S, et al. Monocyte 
Dependent Regulation of Autoimmune Inflammation. 2009;23–9.  
27.  Sahaf B, Heydari K, Herzenberg LA, Herzenberg LA. The extracellular microenvironment plays 
a key role in regulating the redox status of cell surface proteins in HIV-infected subjects. Arch 
Biochem Biophys. 2005;434(1 SPEC. ISS.):26–32.  
Page 191 of 212 
 
28.  Laragione T, Bonetto V, Casoni F, Massignan T, Bianchi G, Gianazza E, et al. Redox 
regulation of surface protein thiols: identification of integrin alpha-4 as a molecular target by 
using redox proteomics. Proc Natl Acad Sci U S A. 2003;100(25):14737–41.  
29.  Angelini G, Gardella S, Ardy M, Ciriolo MR, Filomeni G, Di Trapani G, et al. Antigen-presenting 
dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte 
activation. Proc Natl Acad Sci U S A . 2002;99(3):1491–6.  
30.  Thorén FB, Betten A, Romero AI, Hellstrand K. Cutting edge: Antioxidative properties of 
myeloid dendritic cells: protection of T cells and NK cells from oxygen radical-induced 
inactivation and apoptosis. J Immunol. 2007;179(1):21–5.  
31.  Gelderman K a, Hultqvist M, Holmberg J, Olofsson P, Holmdahl R. T cell surface redox levels 
determine T cell reactivity and arthritis susceptibility. Proc Natl Acad Sci U S A. 
2006;103(34):12831–6.  
32.  Gelderman KA, Hultqvist M, Olsson LM, Bauer K, Pizzolla A, Olofsson P, et al. Rheumatoid 
arthritis: the role of reactive oxygen species in disease development and therapeutic 
strategies. Antioxid Redox Signal. 2007;9(10):1541–68.  
33.  Babior BM. NADPH oxidase. Curr Opin Immunol. 2004;16(1):42–7.  
34.  Babior BM. NADPH oxidase: an update. Blood. 1999;93(5):1464–76.  
35.  Hultqvist M, Holmdahl R. Ncf1 (p47phox) polymorphism determines oxidative burst and the 
severity of arthritis in rats and mice. Cell Immunol. 2005;233(2):97–101.  
36.  Savina A, Amigorena S. Phagocytosis and antigen presentation in dendritic cells. Immunol 
Rev. 2007;219(1):143–56.  
37.  Bedard K, Krause K-H. The NOX family of ROS-generating NADPH oxidases: physiology and 
pathophysiology. Physiol Rev . 2007;87(1):245–313. A 
38.  Savina A, Jancic C, Hugues S, Guermonprez P, Vargas P, Moura IC, et al. NOX2 Controls 
Phagosomal pH to Regulate Antigen Processing during Crosspresentation by Dendritic Cells. 
Cell. 2006;126(1):205–18.  
39.  van Zwieten R, Wever R, Hamers MN, Weening RS, Roos D. Extracellular proton release by 
stimulated neutrophils. J Clin Invest. 1981;68(1):310–3.  
40.  Demaurex N, Petheö GL. Electron and proton transport by NADPH oxidases. Philos Trans R 
Soc B Biol Sci. 2005;360(1464):2315–25.  
41.  Chang CJ, Dickinson BC. Chemistry and biology of reactive oxygen species in signaling or 
Page 192 of 212 
 
stress responses. Nat Chem Biol. 2012;7(8):504–11.  
42.  Ryan BJ, Nissim A, Winyard PG. Oxidative post-translational modifications and their 
involvement in the pathogenesis of autoimmune diseases. Redox Biol . 2014;2(1):715–24.  
43.  Rhee SG, Woo HA. Multiple Functions of Peroxiredoxins: Peroxidases, Sensors and 
Regulators of the Intracellular Messenger H 2 O 2 , and Protein Chaperones. Antioxid Redox 
Signal. 2010;15(3):781–94.  
44.  Ushio-fukai M. Localizing NADPH Oxidase – Derived ROS. Sci STKE. 2006;2006(349):re8.  
45.  Joffre O, Nolte MA, Spörri R, Reis e Sousa C. Inflammatory signals in dendritic cell activation 
and the induction of adaptive immunity. Immunol Rev . 2009 Jan [cited 2019 Sep 
19];227(1):234–47.  
46.  Grakoui A, Bromley SK, Sumen C, Davis MM, Shaw AS, Allen PM, et al. The immunological 
synapse: a molecular machine controlling T cell activation. Science . 1999 Jul 
9;285(5425):221–7.  
47.  Pennock ND, White JT, Cross EW, Cheney EE, Tamburini BA, Kedl RM. T cell responses : 
naïve to memory and everything in between. 2019;273–83.  
48.  Willard-Mack C. Normal Structure , Function , and Histology of Lymph Nodes. 2006;409–24.  
49.  Castellani P, Angelini G, Delfino L, Matucci A, Rubartelli A. The thiol redox state of lymphoid 
organs is modified by immunization: Role of different immune cell populations. Eur J Immunol. 
2008;38(9):2419–25.  
50.  Zhu J, Paul WE. CD4T cells: fates, functions, and faults Jinfang. Blood. 1982;13(3):469.  
51.  Feili-Hariri M, Falkner DH, Morel PA. Polarization of naive T cells into Th1 or Th2 by distinct 
cytokine-driven murine dendritic cell populations: implications for immunotherapy. J Leukoc 
Biol. 2005;78(3):656–64.  
52.  Luckheeram RV, Zhou R, Verma AD, Xia B. CD4 +T cells: Differentiation and functions. Clin 
Dev Immunol. 2012;2012.  
53.  Diehl S, Anguita J, Hoffmeyer A, Zapton T, Ihle JN, Fikrig E, et al. Inhibition of Th1 
differentiation by IL-6 is mediated by SOCS1. Immunity. 2000;13(6):805–15.  
54.  Bennett SJ, Griffiths HR. Studies on Arthritis and Joint Disorders. 2013;3–31.  
55.  Lindstrom TM, Robinson WH. Rheumatoid arthritis: A role for immunosenescence? J Am 
Geriatr Soc. 2010;58(8):1565–75.  
Page 193 of 212 
 
56.  Szabó-Taylor KÉ, Eggleton P, Turner CAL, Lo Faro ML, Tarr JM, Tóth S, et al. Lymphocytes 
from rheumatoid arthritis patients have elevated levels of intracellular peroxiredoxin 2, and a 
greater frequency of cells with exofacial peroxiredoxin 2, compared with healthy human 
lymphocytes. Int J Biochem Cell Biol. 2012;44(8):1223–31.  
57.  Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B. Immunisation against 
heterologous type II collagen induces arthritis in mice. Nature. 1980 Feb;283(5748):666–8.  
58.  Holmdahl R, Goldschmidt TJ, Kleinau S, Kvick C, Jonsson R. Arthritis induced in rats with 
adjuvant oil is a genetically restricted, αβ T-cell dependent autoimmune disease. Immunology. 
1992;76(2):197–202.  
59.  Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen: An experimental model 
of arthritis*. J Exp Med. 1977;146(3):857–68.  
60.  Holmdahl R, Bockermann R, Bäcklund J, Yamada H. The molecular pathogenesis of collagen-
induced arthritis in mice - A model for rheumatoid arthritis. Vol. 1, Ageing Research Reviews. 
2002. p. 135–47.  
61.  Stuart JM, Dixon FJ. Serum transfer of collagen-induced arthritis in mice. J Exp Med. 
1983;158(2):378–92.  
62.  Holmdahl R, Jansson L, Larsson  a, Jonsson R. Arthritis in DBA/1 mice induced with passively 
transferred type II collagen immune serum. Immunohistopathology and serum levels of anti-
type II collagen auto-antibodies. Scand J Immunol. 1990;31(2):147–57.  
63.  Vene R, Delfino L, Castellani P, Balza E, Bertolotti M, Sitia R, et al. Redox remodeling allows 
and controls B-cell activation and differentiation. Antioxid Redox Signal . 2010 Oct;13(8):1145–
55.  
64.  Cenci S, Sitia R. Managing and exploiting stress in the antibody factory. FEBS Lett. 
2007;581(19):3652–7.  
65.  Carta S, Castellani P, Delfino L, Tassi S, Venè R, Rubartelli A. DAMPs and inflammatory 
processes: the role of redox in the different outcomes. J Leukoc Biol . 2009;86(3):549–55.  
66.  Droge W, Droge W. Free radicals in the physiological control of cell function. Physiol Rev. 
2002;82(1):47–95.  
67.  Tassi S, Carta S, Vene R, Delfino L, Ciriolo MR, Rubartelli A. Pathogen-Induced Interleukin-
1  Processing and Secretion Is Regulated by a Biphasic Redox Response. J Immunol . 
2009;183(2):1456–62.  
68.  Rubartelli A, Sitia R. Stress as an intercellular signal: the emergence of stress-associated 
Page 194 of 212 
 
molecular patterns (SAMP). Antioxid Redox Signal . 2009;5(10):1–26.  
69.  Nilsson J, Söderberg O, Nilsson K, Rosén A. Differentiation-associated redox-regulation in 
human B cell lines from stem cell/pro-B to plasma cell. Immunol Lett. 2004;94(1–2):83–9.  
70.  Reth M. Hydrogen peroxide as second messenger in lymphocyte activation. Nat Immunol . 
2002;3(12):1129–34.  
71.  Alberini CM, Bet P, Milstein C, Sitia R. Secretion of immunoglobulin M assembly intermediates 
in the presence of reducing agents. Nature . 1990;347(6292):485–7. 
72.  Valetti C, Sitia R. The differential effects of dithiothreitol and 2-mercaptoethanol on the 
secretion of partially and completely assembled immunoglobulins suggest that thiol-mediated 
retention does not take place in or beyond the Golgi. Mol Biol Cell. 1994;5(12):1311–24.  
73.  DANIELS RS, Xie X. N-acetyl l-cysteine chelates and methods for making and using the same. 
2013.  
74.  Zafarullah M, Li WQ, Sylvester J, Ahmad M. Molecular mechanisms of N-acetylcysteine 
actions. Cell Mol Life Sci. 2003;60(1):6–20.  
75.  van Zandwijk N. N‐Acetylcysteine (NAC) and glutathione (GSH): Antioxidant and 
chemopreventive properties, with special reference to lung cancer. J Cell Biochem. 
1995;59(22 S):24–32.  
76.  Gross CP, Sepkowitz KA. The myth of the medical breakthrough: Smallpox, vaccination, and 
Jenner reconsidered. Int J Infect Dis. 1998;3(1):54–60.  
77.  Wilson‐Welder JH, Torres MP, Kipper MJ, Mallapragada SK, Wannemuehler MJ, Narasimhan 
B. Vaccine adjuvants: current challenges and future approaches. J Pharm Sci. 
2009;98(4):1278–316.  
78.  Guimarães LE, Baker B, Perricone C, Shoenfeld Y. Vaccines, adjuvants and autoimmunity. 
Pharmacol Res . 2015;100:190–209. 
79.  WHO. Global and regional immunization profile. Next WHO UNICEF Estim July 2020. 2019;  
80.  Unicef, WHO. Progress and Challenges with achieving Universal Immunization Coverage: 
2017 WHO/UNICEF Estimates of National immunization Coverage. 2018 WHO/UNICEF Estim 
Natl Immun Cover . 2018;(July). A 
81.  Smith KA. Edward Jenner and the small pox vaccine. Front Immunol. 2011;2(JUN):1–6.  
82.  Siegrist C. General aspects of vaccination. Vaccine Immunol . 2008;22:17–36.  
Page 195 of 212 
 
83.  Cooper NR, Nemerow GR. The role of antibody and complement in the control of viral 
infections. J Invest Dermatol . 1984;83(1 Suppl):121s-127s.  
84.  Ruprecht CR, Lanzavecchia A. Toll-like receptor stimulation as a third signal required for 
activation of human naive B cells. Eur J Immunol. 2006;36(4):810–6.  
85.  Lemoine S, Jaron B, Tabka S, Ettreiki C, Deriaud E, Zhivaki D, et al. Dectin-1 activation 
unlocks IL12A expression and reveals the TH1 potency of neonatal dendritic cells. J Allergy 
Clin Immunol . 2015;  
86.  Sancho D, Reis e Sousa C. Signaling by myeloid C-type lectin receptors in immunity and 
homeostasis. Annu Rev Immunol . 2012;30:491–529.  
87.  Rudolph V, Schopfer FJ, Khoo NKH, Rudolph TK, Cole MP, Woodcock SR, et al. Nitro-fatty 
Acid Metabolome: Saturation, Desaturation, β-Oxidation, and Protein Adduction. J Biol Chem . 
2009 Jan 16;284(3):1461–73.  
88.  Wevers BA, Kaptein TM, Zijlstra-Willems EM, Theelen B, Boekhout T, Geijtenbeek TBH, et al. 
Fungal engagement of the C-type lectin mincle suppresses dectin-1-induced antifungal 
immunity. Cell Host Microbe . 2014;15(4):494–505.  
89.  Cresswell P, Ackerman AL, Giodini A, Peaper DR, Wearsch PA. Mechanisms of MHC class I-
restricted antigen processing and cross-presentation. Immunol Rev. 2005;207(July 2016):145–
57.  
90.  Hsing LC, Rudensky AY. The lysosomal cysteine proteases in MHC class II antigen 
presentation. Immunol Rev. 2005;207:229–41.  
91.  Neefjes J, Jongsma ML, Paul P, Bakke O. Towards a systems understanding of MHC class I 
and MHC class II antigen presentation. Nat Rev Immunol . 2011;11(12):823–36.  
92.  Carbone BFR, Bevan MJ. Class I-restricted processing and presentation of exogenous cell-
associated antigen in vivo. Rockefeller Univ Press. 1990;171(February):377–87.  
93.  Rock KL, Gamble S, Rothstein L. Presentation of exogenous antigen with class I major 
histocompatibility complex molecules. Science (80- ) . 1990;249(4971):918–21.  
94.  Bacchetta R, Gregori S, Roncarolo MG. CD4+ regulatory T cells: Mechanisms of induction and 
effector function. Autoimmun Rev. 2005;4(8):491–6.  
95.  Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat Rev 
Immunol. 2008;8(1):22–33.  
96.  Waisman A, Lukas D, Clausen BE, Yogev N. Dendritic cells as gatekeepers of tolerance. 
Page 196 of 212 
 
Semin Immunopathol . 2016;  
97.  Hussain MJ, Wilkinson A, Bramwell VW, Christensen D, Perrie Y. Th1 immune responses can 
be modulated by varying dimethyldioctadecylammonium and distearoyl-sn-glycero-3-
phosphocholine content in liposomal adjuvants. J Pharm Pharmacol. 2014;66:358–66.  
98.  Lesinski GB, Westerink MAJ. Novel vaccine strategies to T-independent antigens. J Microbiol 
Methods. 2001;47(2):135–49.  
99.  Fine P. Science and society: Vaccines and public health. Public Health . 2014;128(8):686–92.  
100.  Pellegrino P, Clementi E, Radice S. On vaccine’s adjuvants and autoimmunity: Current 
evidence and future perspectives. Autoimmun Rev . 2015;14(10):880–8.  
101.  Perrie Y, Mohammed AR, Kirby DJ, McNeil SE, Bramwell VW. Vaccine adjuvant systems: 
Enhancing the efficacy of sub-unit protein antigens. Int J Pharm. 2008;364(2):272–80.  
102.  Demana PH, Davies NM, Hook S, Rades T. Quil A-lipid powder formulations releasing 
ISCOMs and related colloidal stuctures upon hydration. J Control Release. 2005;103(1):45–
59.  
103.  Vangala A, Kirby D, Rosenkrands I, Agger EM, Andersen P, Perrie Y. A comparative study of 
cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: 
characterisation, environmental scanning electron microscopy and immunisation studies in 
mice. J Pharm Pharmacol. 2006;58:787–99.  
104.  Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med . 
2013;19(12):1597–608.  
105.  Alving C, Peachman K, Rao M, Reed S. Adjuvants for human vaccines. Curr Opin Immunol. 
2013;24(3):310–5.  
106.  Aguilar JC, Rodriguez EG. Vaccine adjuvants revisited. Vaccine. 2007;25(19):3752–62.  
107.  García A, De Sanctis JB. An overview of adjuvant formulations and delivery systems. Apmis . 
2014;122(4):257–67.  
108.  O’Hagan DT, Fox CB. New generation adjuvants - From empiricism to rational design. Vaccine 
. 2015;33(S2):B14–20.  
109.  O’Hagan DT, De Gregorio E. The path to a successful vaccine adjuvant - “The long and 
winding road.” Drug Discov Today. 2009;14(11–12):541–51.  
110.  Smith DM, Simon JK, Baker JR. Applications of nanotechnology for immunology. Nat Rev 
Immunol . 2013;13(8):592–605.  
Page 197 of 212 
 
111.  Schwendener RA. Liposomes as vaccine delivery systems: a review of the recent advances. 
Ther Adv Vaccines . 2014;2(6):159–82. 
112.  Reif K, Ekland EH, Ohl L, Nakano H, Lipp M, Förster R, et al. Balanced responsiveness to 
chemoattractants from adjacent zones determines B-cell position. Nature. 2002;416(6876):94–
9.  
113.  Brewer JM, Conacher M, Satoskar A, Bluethmann H, Alexander J. In interleukin-4-deficient 
mice, alum not only generates T helper 1 responses equivalent to freund’s complete adjuvant, 
but continues to induce T helper 2 cytokine production. Eur J Immunol . 1996;26(9):2062–6.  
114.  Straw BE, MacLachlan NJ, Corbett WT, Carter PB, Schey HM. Comparison of tissue reactions 
produced by Haemophilus pleuropneumoniae vaccines made with six different adjuvants in 
swine. Can J Comp Med . 1985;49(2):149–51.  
115.  Schijns VE. Immunological concepts of vaccine adjuvant activity. Curr Opin Immunol. 
2000;12(4):456–63.  
116.  Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 
2007;81(1):1–5.  
117.  Billiau A, Matthys P. Modes of action of Freund’s adjuvants in experimental models of 
autoimmune diseases. J Leukoc Biol . 2001;70(6):849–60.  
118.  Alving CR, Rao M. Lipid A and liposomes containing lipid A as antigens and adjuvants. 
Vaccine. 2008;26(24):3036–45.  
119.  Gupta RK, Chang AC, Siber GR. Biodegradable polymer microspheres as vaccine adjuvants 
and delivery systems. Dev Biol Stand. 1998;92(April):63–78.  
120.  Moser C, Müller M, Kaeser MD, Weydemann U, Amacker M. Influenza virosomes as vaccine 
adjuvant and carrier system. Expert Rev Vaccines. 2013;12(7):779–91.  
121.  Mowat AM, Maloy KJ, Donachie AM. Immune-stimulating complexes as adjuvants for inducing 
local and systemic immunity after oral immunization with protein antigens. Immunology . 
1993;80(4):527–34.  
122.  Singh P, Prabakaran D, Jain S, Mishra V, Jaganathan KS, Vyas SP. Cholera toxin B subunit 
conjugated bile salt stabilized vesicles (bilosomes) for oral immunization. Int J Pharm. 
2004;278(2):379–90.  
123.  Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of 
swollen phospholipids. J Mol Biol . 1965;13(1):238–52.  
Page 198 of 212 
 
124.  Gregoriadis G, Davis C. Stability of liposomes in vivo and in vitro is promoted by their 
cholesterol content and the presence of blood cells. Biochem Biophys Res Commun. 
1979;89(4):1287–93.  
125.  Gregoriadis G. Engineering liposomes for drug delivery: progress and problems. Trends 
Biotechnol. 1995;13(12):527–37.  
126.  Gregoriadis G, Senior J. The phospholipid component of small unilamellar liposomes controls 
the rate of clearance of entrapped solutes from the circulation. FEBS Lett . 1980 Sep 
22;119(1):43–6.  
127.  Gregoriadis G. Liposomes for drugs and vaccines. Trends Biotechnol. 1985;3(9):235–41.  
128.  Gregoriadis G. Drug entrapment in liposomes. FEBS Lett. 1973;36(3):292–6.  
129.  Watson D, Endsley A, Huang L. Design considerations for liposomal vaccines: Influence of 
formulation parameters on antibody and cell-mediated immune responses to liposome 
associated antigens. Vaccine. 2013;30(13):2256–72.  
130.  Brito LA, Malyala P, O’Hagan DT. Vaccine adjuvant formulations: A pharmaceutical 
perspective. Semin Immunol . 2013;25(2):130–45.  
131.  Gregory AE, Titball R, Williamson D. Vaccine delivery using nanoparticles. Front Cell Infect 
Microbiol  
132.  Zaman M, Good MF, Toth I. Nanovaccines and their mode of action. Methods . 
2013;60(3):226–31.  
133.  Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug 
Discov. 2005;4(2):145–60.  
134.  Christensen D, Henriksen-Lacey M, Kamath AT, Lindenstrøm T, Korsholm KS, Christensen 
JP, et al. A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have 
different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity 
compared to its unsaturated analog. J Control Release 2012;160(3):468–76.  
135.  Ohvo-Rekilä H, Ramstedt B, Leppimäki P, Slotte JP. Cholesterol interactions with 
phospholipids in membranes. Prog Lipid Res . 2002 Jan;41(1):66–97.  
136.  Gall D. The adjuvant activity of aliphatic nitrogenous bases. Immunology . 1966;11(4):369–86.  
137.  Rosenkrands I, Agger EM, Olsen AW, Korsholm KS, Andersen CS, Jensen KT, et al. Cationic 
liposomes containing mycobacterial lipids: A new powerful Th1 adjuvant system. Infect Immun. 
2005;73(9):5817–26.  
Page 199 of 212 
 
138.  Desowitz RS, Barnwell JW. Effect of selenium and dimethyl dioctadecyl ammonium bromide 
on the vaccine-induced immunity of Swiss-Webster mice against malaria (Plasmodium 
berghei). Infect Immun. 1980;27(1):87–9.  
139.  Stanfield JP, Gall D, Bracken PM. Single-Dose Antenatal Tetanus Immunisation. Lancet. 
1973;301(7797):215–9.  
140.  Hilgers LA, Snippe H. DDA as an immunological adjuvant. Res Immunol . 1992 Jun [cited 
2019 Sep 22];143(5):494–503; discussion 574-6.  
141.  Korsholm KS, Marie E, Foged C, Dietrich J. The adjuvant mechanism of cationic 
dimethyldioctadecylammonium liposomes. Immunology. 2007;121(121):216–26.  
142.  Henriksen-Lacey M, Bramwell VW, Christensen D, Agger EM, Andersen P, Perrie Y. 
Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance 
immunogenicity of soluble antigen. J Control Release . 2010;142(2):180–6.  
143.  Ohtake S, Schebor C, Palecek SP, De Pablo JJ. Phase behavior of freeze-dried phospholipid-
cholesterol mixtures stabilized with trehalose. Biochim Biophys Acta - Biomembr. 
2005;1713(1):57–64.  
144.  Semple SC, Chonn A, Cullis PR. Influence of cholesterol on the association of plasma proteins 
with liposomes. Biochemistry. 1996;35(8):2521–5.  
145.  Olsen AW, Van Pinxteren LAH, Okkels LM, Rasmussen PB, Andersen P. Protection of mice 
with a tuberculosis subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. 
Infect Immun. 2001;69(5):2773–8.  
146.  Holten-Andersen L, Doherty TM, Korsholm KS, Andersen P. Combination of the cationic 
surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as 
an efficient adjuvant for tuberculosis subunit vaccines. Infect Immun . 2004;72(3):1608–17.  
147.  Ishikawa E, Ishikawa T, Morita YS, Toyonaga K, Yamada H, Takeuchi O, et al. Direct 
recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle. J Exp 
Med. 2009;206(13):2879–88.  
148.  Bowdish DME, Sakamoto K, Kim MJ, Kroos M, Mukhopadhyay S, Leifer CA, et al. MARCO, 
TLR2, and CD14 are required for macrophage cytokine responses to mycobacterial trehalose 
dimycolate and Mycobacterium tuberculosis. PLoS Pathog. 2009;5(6).  
149.  Hunter RL, Venkataprasad N, Olsen MR. The role of trehalose dimycolate (cord factor) on 
morphology of virulent M. tuberculosis in vitro. Tuberculosis. 2006;86(5):349–56.  
150.  Matsunaga I, Moody DB. Mincle is a long sought receptor for mycobacterial cord factor. J Exp 
Page 200 of 212 
 
Med. 2009;206(13):2865–8.  
151.  Davidsen J, Rosenkrands I, Christensen D, Vangala A, Kirby D, Perrie Y, et al. 
Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic 
cord factor from M. tuberculosis (trehalose 6,6- dibehenate) - A novel adjuvant inducing both 
strong CMI and antibody responses. Biochim Biophys Acta - Biomembr. 2005;1718:22–31.  
152.  Lindenstrøm T, Agger EM, Korsholm KS, Darrah PA, Aagaard C, Seder RA, et al. 
Tuberculosis Subunit Vaccination Provides Long-Term Protective Immunity Characterized by 
Multifunctional CD4 Memory T Cells. J Immunol. 2009;182(12):8047–55.  
153.  Perrie Y, Kastner E, Kaur R, Wilkinson A, Ingham AJ. A case-study investigating the 
physicochemical characteristics that dictate the function of a liposomal adjuvant. Hum 
Vaccines Immunother. 2013;9(6):1374–81.  
154.  Henriksen-Lacey M, Devitt A, Perrie Y. The vesicle size of DDA:TDB liposomal adjuvants 
plays a role in the cell-mediated immune response but has no significant effect on antibody 
production. J Control Release . 2011;154(2):131–7. A 
155.  Henriksen A. Formulation and development of cationic liposomes as adjuvants for subunit 
protein vaccinese. 2011;(September).  
156.  Wang CH, Chen W. Raman characterizing disulfide bonds and secondary structure of bovine 
serum albumin. AIP Conf Proc. 2010;1267(August):346–7.  
157.  Ishimaru T, Ito K, Tanaka M, Tanaka S, Matsudomi N. The role of the disulfide bridge in the 
stability and structural integrity of ovalbumin evaluated by site-directed mutagenesis. Biosci 
Biotechnol Biochem. 2011;75(3):544–9.  
158.  Van Rhijn I, Godfrey DI, Rossjohn J, Moody DB. Lipid and small-molecule display by CD1 and 
MR1. Nat Rev Immunol . 2015;15(10):643–54.  
159.  Yang Lee LY, Izzard L, Hurt AC. A review of DNA vaccines against influenza. Front Immunol. 
2018;9(JUL):1–8.  
160.  Kamphorst AO, Guermonprez P, Dudziak D, Nussenzweig MC. Route of Antigen Uptake 
Differentially Impacts Presentation by Dendritic Cells and Activated Monocytes. J Immunol . 
2010;185(6):3426–35.  
161.  Watanabe H, Numata K, Ito T, Takagi K, Matsukawa A. Innate immune response in Th1- and 
Th2-dominant mouse strains. Shock. 2004;22(5):460–6.  
162.  Lutz MB, Suri RM, Niimi M, Ogilvie  a L, Kukutsch N a, Rossner S, et al. Immature dendritic 
cells generated with low doses of GM-CSF in the absence of IL-4 are maturation-resistant and 
Page 201 of 212 
 
prolong allograft survival in vivo. Eur J Immunol. 2000;30(June):1813–22.  
163.  Buus S, Colon S, Smitht C, Freed JH, Miles C, Grey HM. Interaction between a “processed” 
ovalbumin peptide and Ia molecules. Immunology. 1986;83(June):3968–71.  
164.  FOTHERGILL JE, FOTHERGILL LA, MOIR AJG, NISBET AD, SAUNDRY RH. The Complete 
Amino-Acid Sequence of Hen Ovalbumin. Eur J Biochem. 2005;115(2):335–45.  
165.  Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine. 
2008;42(2):145–51.  
166.  Liu C, Whitener RL, Lin A, Xu Y, Chen J, Savinov A, et al. Neutrophil Cytosolic Factor 1 in 
Dendritic Cells Promotes Autoreactive CD8+ T Cell Activation via Cross-Presentation in Type 
1 Diabetes. Front Immunol. 2019;10(May):952.  
167.  Katayama S, Kukita T, Ishikawa E, Nakashima S, Masuda S, Kanda T, et al. Apple 
polyphenols suppress antigen presentation of ovalbumin by THP-1-derived dendritic cells. 
Food Chem . 2013;138(2–3):757–61.  
168.  Ciancio, A. Pollack, MA. Taupier, Nl. Block NL GI. Measurement of cell-cycle phase-specific 
cell death using Hoechst 33342 and propidium iodide: preservation by ethanol fixation. 
1988;1147–52.  
169.  Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. 
Nat Protoc. 2006;1(3):1458–61.  
170.  Smith PK, Hermanson GT, Gartner FH, Frovenzano MD, Fujimoto EK, Goeke NM, et al. 
Measurement of Protein Using Bicinchoninic Acid. Anal Biochem. 1985;150:76–85.  
171.  Wang W, Ruppert T. Oxidized phagosomal NOX2 is replenished from lysosomes. J Cell Sci. 
2015;31(December).  
172.  Freund J. Some aspects of active immunization. Annu Rev Microbiol. 1946;1(1):291–308.  
173.  Lipton MM, Freund J. Allergic encephalomyelitis in the rat induced by the intracutaneous 
injection of central nervous system tissue and adjuvants. J Immunol. 1953;71(2):98–109.  
174.  Poole L. The basics of thiols and cysteines in redox biology and chemistry. Free Radic Biol 
Med. 2015;80(4):148–57.  
175.  Rhee SG. Redox signaling: hydrogen peroxide as intracellular messenger. Exp Mol Med. 
2013;31(2):53–9.  
176.  Sarsour EH, Kumar MG, Chaudhuri L, Kalen AL, Goswami PC. Redox Control of the Cell 
Cycle in Health and Disease. Antioxid Redox Signal. 2009;11(12):2985–3011.  
Page 202 of 212 
 
177.  Pani G, Colavitti R, Borrello S, Galeotti T. Redox regulation of lymphocyte signaling. IUBMB 
Life . 2000;49(5):381–9.  
178.  Mirzaei H, Regnier F. Protein:protein aggregation induced by protein oxidation. J Chromatogr 
B Anal Technol Biomed Life Sci. 2008;873(1):8–14.  
179.  Gianazza E, Crawford J, Miller I. Detecting oxidative post-translational modifications in 
proteins. Amino Acids. 2007;33(1):51–6.  
180.  Erridge C, Kennedy S, Spickett CM, Webb DJ. Oxidized Phospholipid Inhibition of Toll-like 
Receptor (TLR) Signaling Is Restricted to TLR2 and TLR4: roles FOR CD14, LPS-binding 
protein, and MD2 as targets for specificity of inhibition. J Biol Chem . 2008 Sep 
5;283(36):24748–59. 
181.  Lutz MB, Kukutsch N, Ogilvie ALJ, Roßner S, Koch F, Romani N, et al. An advanced culture 
method for generating large quantities of highly pure dendritic cells from mouse bone marrow. 
Elsevier. 1999;223(1):77–92.  
182.  Muccioli M, Pate M, Omosebi O, Benencia F. Generation and Labeling of Murine Bone 
Marrow-derived Dendritic Cells with Qdot Nanocrystals for Tracking Studies. Jove-Journal Vis 
Exp . 2011;(52):e2785.  
183.  Na YR, Jung D, Gu GJ, Seok SH. GM-CSF Grown Bone Marrow Derived Cells Are Composed 
of Phenotypically Different Dendritic Cells and Macrophages. Mol Cells . 2016;39(10):734–41.  
184.  Russell WMS, Burch RL. The principles of humane experimental technique . London: 
Methuen; 1959.  
185.  Hovell R. Reduction, refinement and replacement. Vet Rec. 2013;172(26):691.1-691.  
186.  Lardon F, Snoeck HW, Berneman ZN, Van Tendeloo VF, Nijs G, Lenjou M, et al. Generation 
of dendritic cells from bone marrow progenitors using GM-CSF, TNF-alpha, and additional 
cytokines: antagonistic effects of IL-4 and IFN-gamma and selective involvement of TNF-alpha 
receptor-1. Immunology. 1997;91(4):553–9.  
187.  Leslie DS, Dascher CC, Cembrola K, Townes MA, Hava DL, Hugendubler LC, et al. Serum 
lipids regulate dendritic cell CD1 expression and function. Immunology. 2008;125(3):289–301.  
188.  Gogolak P, Rethi B, Szatmari I, Lanyi A, Dezso B, Nagy L, et al. Differentiation of CD1a-and 
CD1a+monocyte-derived dendritic cells is biased by lipid environment and PPARγ. Blood. 
2007;109(2):643–52.  
189.  Lutz MB, Schnare M, Menges M, Rossner S, Rollinghoff M, Schuler G, et al. Differential 
Functions of IL-4 Receptor Types I and II for Dendritic Cell Maturation and IL-12 Production 
Page 203 of 212 
 
and Their Dependency on GM-CSF. J Immunol. 2002;169(7):3574–80.  
190.  Hercus TR, Thomas D, Guthridge MA, Ekert PG, King-Scott J, Parker MW, et al. The 
granulocyte-macrophage colony-stimulating factor receptor: Linking its structure to cell 
signaling and its role in disease. Blood. 2009;114(7):1289–98.  
191.  Cebon J, Layton JE, Maher D, Morstyn G. Endogenous haemopoietic growth factors in 
neutropenia and infection. Br J Haematol. 1994;86(2):265–74.  
192.  Cavanagh LL, Saal RJ, Grimmett KL, Thomas R. Proliferation in Monocyte-Derived Dendritic 
Cell Cultures Is Caused by Progenitor Cells Capable of Myeloid Differentiation. Blood. 
1998;92(5):1598–607.  
193.  Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol. 
2002;2(3):151–61.  
194.  Higgins DM, Sanchez-Campillo J, Rosas-Taraco AG, Higgins JR, Lee EJ, Orme IM, et al. 
Relative Levels of M-CSF and GM-CSF Influence the Specific Generation of Macrophage 
Populations during Infection with Mycobacterium tuberculosis. J Immunol . 2008;180(7):4892–
900.  
195.  Kamide Y, Utsugi M, Dobashi K, Ono A, Ishizuka T, Hisada T, et al. Intracellular glutathione 
redox status in human dendritic cells regulates IL-27 production and T-cell polarization. Allergy 
. 2011;66(9):1183–92. 
196.  Reiniers MJ, Van Golen RF, Bonnet S, Broekgaarden M, Van Gulik TM, Egmond MR, et al. 
Preparation and Practical Applications of 2′,7′-Dichlorodihydrofluorescein in Redox Assays. 
Anal Chem. 2017;89(7):3853–7.  
197.  Jagannathan L, Cuddapah S, Costa M. Oxidative Stress Under Ambient and Physiological 
Oxygen Tension in Tissue Culture. Curr Pharmacol Reports. 2016;2(2):64–72.  
198.  Del Prete A, Zaccagnino P, Di Paola M, Saltarella M, Oliveros Celis C, Nico B, et al. Role of 
mitochondria and reactive oxygen species in dendritic cell differentiation and functions. Free 
Radic Biol Med. 2008;44(7):1443–51.  
199.  Sattler M, Winkler T, Verma S, Byrne CH, Shrikhande G, Salgia R, et al. Hematopoietic growth 
factors signal through the formation of reactive oxygen species. Blood . 1999;93(9):2928–35.  
200.  Sinha A, Singh A, Satchidanandam V, Natarajan K. Impaired Generation of Reactive Oxygen 
Species during Differentiation of Dendritic Cells (DCs) by Mycobacterium tuberculosis 
Secretory Antigen (MTSA) and Subsequent Activation of MTSA-DCs by Mycobacteria Results 
in Increased Intracellular Survival. J Immunol. 2014;177(1):468–78.  
Page 204 of 212 
 
201.  Sheng K-C, Pietersz GA, Tang CK, Ramsland PA, Apostolopoulos V. Reactive Oxygen 
Species Level Defines Two Functionally Distinctive Stages of Inflammatory Dendritic Cell 
Development from Mouse Bone Marrow. J Immunol. 2010;184(6):2863–72.  
202.  Abdi K, Singh NJ, Matzinger P. LPS Activated Dendritic cells: “Exhausted” or alert and 
waiting? DCs: “Exhausted”, alerted or waiting? Methods Enzymol. 1995;251(12):5981–9.  
203.  Singh-Jasuja H, Thiolat A, Ribon M, Boissier MC, Bessis N, Rammensee HG, et al. The 
mouse dendritic cell marker CD11c is down-regulated upon cell activation through Toll-like 
receptor triggering. Immunobiology . 2013;218(1):28–39.  
204.  Rescigno M, Martino M, Sutherland CL, Gold MR, Ricciardi-Castagnoli P. Dendritic cell 
survival and maturation are regulated by different signaling pathways. J Exp Med . 
1998;188(11):2175–80.  
205.  Briken V, Jackman RM, Dasgupta S. Intracellular trafficking pathway of newly synthesized 
CD1b molecules. EMBO J. 2002;21(4):825–34.  
206.  Park JJ, Kang SJ, De Silva AD, Stanic AK, Casorati G, Hachey DL, Cresswell P JS. Lipid-
protein interactions: biosynthetic assembly of CD1 with lipids in the endoplasmic reticulum is 
evolutionarily conserved. Proc Natl Acad Sci U S Ad Sci U S A . 2004;101(4):15.  
207.  Briken V, Jackman RM, Watts GF, Rogers R a, Porcelli S a. Human CD1b and CD1c isoforms 
survey different intracellular compartments for the presentation of microbial lipid antigens. J 
Exp Med. 2000;192(2):281–8.  
208.  Jackman RM, Stenger S, Lee A, Moody DB, Rogers RA, Niazi KR, et al. The tyrosine-
containing cytoplasmic tail of CD1b is essential for its efficient presentation of bacterial lipid 
antigens. Immunity. 1998;8(3):341–51.  
209.  Spada BFM, Koezuka Y, Porcelli SA. CD1d-restricted Recognition of Synthetic Glycolipid 
Antigens by Human Natural Killer T Cells. J Exp Med. 1998;188(8):1529–34.  
210.  Dowds CM, Kornell S-C, Blumberg RS, Zeissig S. Lipid antigens in immunity. Biol Chem . 
2014;395(1):61–81.  
211.  Ding F, Liu B, Zou W, Tian D, Li Q, Dai J, et al. LPS Exposure in Early Life Protects Against 
Mucus Hypersecretion in Ovalbumin-Induced Asthma by Down-Regulation of the IL-13 and 
JAK-STAT6 Pathways. Cell Physiol Biochem. 2018;46(3):1263–74.  
212.  Peterson JD, Herzenberg LA, Vasquez K, Waltenbaugh C. Glutathione levels in antigen-
presenting cells modulate Th1 versus Th2 response patterns. Proc Natl Acad Sci. 
2002;95(6):3071–6.  
Page 205 of 212 
 
213.  Forman HJ, Maiorino M, Ursini F. Signaling functions of reactive oxygen species. 
Biochemistry. 2010;49(5):835–42.  
214.  Poole LB, Karplus PA, Claiborne A. Protein Sulfenic Acids in Redox Signaling. Annu Rev 
Pharmacol Toxicol . 2004;44(1):325–47. 
215.  Sen CK. Nutritional biochemistry of cellular glutathione. J Nutr Biochem. 1997;8(12):660–72.  
216.  Alton Meister. Glutathione metabolism. Methods Enzymol. 1995;113(1995):3–7.  
217.  Lindblad EB, Elhay MJ, Silva R, Appelberg R, Andersen P. Adjuvant modulation of immune 
responses to tuberculosis subunit vaccines. Infect Immun. 1997;65(2):623–9.  
218.  Orme IM, Mcmurray DN, Belisle JT. Recent progress in TB vaccine development. 
2001;9(3):115–8.  
219.  Itos M, Lazo R, Mayhew E. Toxicity of Non-Drug-Containing Liposomes for Cultured Human 
Cells. Exp Cell Res. 1987;171:195–202.  
220.  Milicic A, Kaur R, Reyes-Sandoval A, Tang C-K, Honeycutt J, Perrie Y, et al. Small Cationic 
DDA:TDB Liposomes as Protein Vaccine Adjuvants Obviate the Need for TLR Agonists in 
Inducing Cellular and Humoral Responses. Cardona P-J, editor. PLoS One . 2012 Mar 
28;7(3):e34255.  
221.  Davis D, Gregoriadis G. Liposomes as adjuvants with immunopurified tetanus toxoid: influence 
of liposomal characteristics. Immunol Lett. 1987;61:229–34.  
222.  Brunel F, Darbouret A, Ronco J. Cationic lipid DC-Chol induces an improved and balanced 
immunity able to overcome the unresponsiveness to the hepatitis B vaccine. Vaccine. 
1999;17(17):2192–203.  
223.  Riese RJ, Chapman HA. Cathepsins and compartmentalization in antigen presentation. Curr 
Opin Immunol. 2000;12(1):107–13.  
224.  Wubbolts R, Fernandez-Borja M, Oomen L, Verwoerd D, Janssen H, Calafat J, et al. Direct 
vesicular transport of MHC class II molecules from lysosomal structures to the cell surface. J 
Cell Biol. 1996;135(3):611–22.  
225.  Kaur R, Bramwell VW, Kirby DJ, Perrie Y. Pegylation of DDA:TDB liposomal adjuvants 
reduces the vaccine depot effect and alters the Th1/Th2 immune responses. J Control 
Release . 2012;158(1):72–7.  
226.  Constant SL, Bottomly K.  INDUCTION OF TH1 AND TH2 CD4 + T CELL RESPONSES:The 
Alternative Approaches . Annu Rev Immunol. 2002;15(1):297–322.  
Page 206 of 212 
 
227.  Mosmann T. Th1 And Th2 Cells: Different Patterns Of Lymphokine Secretion Lead To 
Different Functional Properties. Annu Rev Immunol. 1989;7(1):145–73.  
228.  Infante-Duarte C. Th1/Th2 balance in infection. Springer Semin Immunopathol. 
1999;21(3):317–38.  
229.  Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 
paradigm. J Immunol . 2000;164(12):6166–73.  
230.  Hsieh CS, Macatonia SE, O’Garra A, Murphy KM. T cell genetic background determines 
default T helper phenotype development in vitro. J Exp Med . 1995 Feb 1;181(2):713–21.  
231.  Stewart D, Fulton WB, Wilson C, Monitto CL, Paidas CN, Reeves RH, et al. Genetic 
contribution to the septic response in a mouse model. Shock. 2002;18(4):342–7.  
232.  Hussain MJ, Wilkinson A, Bramwell VW, Christensen D, Perrie Y. Th1 immune responses can 
be modulated by varying dimethyldioctadecylammonium and distearoyl-sn-glycero-3-
phosphocholine content in liposomal adjuvants. J Pharm Pharmacol. 2014;66(3):358–66.  
233.  Kaur R, Henriksen-Lacey M, Wilkhu J, Devitt A, Christensen D, Perrie Y. Effect of 
incorporating cholesterol into DDA:TDB liposomal adjuvants on bilayer properties, 
biodistribution, and immune responses. Mol Pharm . 2014;11(1):197–207.  
234.  Hahn J, Euler M, Kilgus E, Kienhöfer D, Stoof J, Knopf J, et al. NOX2 mediates quiescent 
handling of dead cell remnants in phagocytes. Redox Biol. 2019;26(July):101279.  
235.  Carstens MG, Camps MGM, Henriksen-Lacey M, Franken K, Ottenhoff THM, Perrie Y, et al. 
Effect of vesicle size on tissue localization and immunogenicity of liposomal DNA vaccines. 
Vaccine . 2011;29(29–30):4761–70.  
236.  Christensen D, Foged C, Rosenkrands I, Lundberg C V., Andersen P, Agger EM, et al. CAF01 
liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations. Int J Pharm. 
2010;390(1):19–24.  
237.  Singla B, Ghoshal P, Lin H, Wei Q, Dong Z, Csányi G. PKCδ-mediated Nox2 activation 
promotes fluid-phase pinocytosis of antigens by immature dendritic cells. Front Immunol . 
2018;9(MAR).  
238.  Vasilevsky S, Liu Q, Koontz SM, Kastenmayer R, Shea K, Jackson SH. Role of p47phox in 
antigen-presenting cell-mediated regulation of humoral immunity in mice. Am J Pathol . 
2011;178(6):2774–82.  
239.  Allan ERO, Tailor P, Balce DR, Pirzadeh P, McKenna NT, Renaux B, et al. NADPH Oxidase 
Modifies Patterns of MHC Class II–Restricted Epitopic Repertoires through Redox Control of 
Page 207 of 212 
 
Antigen Processing. J Immunol. 2014;192(11):4989–5001.  
240.  Schnorrer P, Behrens GMN, Wilson NS, Pooley JL, Smith CM, El-Sukkari D, et al. The 
dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture. 
Proc Natl Acad Sci U S A . 2006 Jul 11;103(28):10729–34.  
241.  Liu Z, Roche PA. Macropinocytosis in phagocytes: Regulation of MHC class-II-restricted 
antigen presentation in dendritic cells. Front Physiol. 2015;6(JAN):1–6.  
242.  Nencioni A, Brossart P, Mantegazza A, Savina A, Vermeulen M, Perez L, et al. NADPH 
oxidase controls phagosomal pH and antigen cross-presentation in human dendritic cells. 
Commentary. Blood. 2008;112(12):4712–23.  
243.  Delamarre L, Pack M, Chang H, Mellman I, Trombetta ES. Differential lysosomal proteolysis in 
antigen-presenting cells determines antigen fate. Science (80- ). 2005;307(5715):1630–4.  
244.  Lanz E, Gregor M, Slavi?k J, Kotyk A. Use of FITC as a Fluorescent Probe for Intracellular pH 
Measurement. J Fluoresc . 1997;7(4):317–9.  
245.  Wieczorek M, Abualrous ET, Sticht J, Álvaro-Benito M, Stolzenberg S, Noé F, et al. Major 
histocompatibility complex (MHC) class I and MHC class II proteins: Conformational plasticity 
in antigen presentation. Front Immunol. 2017;8(MAR):1–16.  
246.  Klasen EA, Rigutti A, Bos A, Bernini LF. Development of a screening system for detection of 
somatic mutations. II. The use of peptides and insoluble protein fragments in a non-
competitive solid-phase enzyme immunoassay. J Immunol Methods. 1983;59(3):281–7.  
247.  Dwyer JM, Johnson C. The use of concanavalin A to study the immunoregulation of human T 
cells. Clin Exp Immunol . 1981;46(2):237–49.  
248.  Bemer V, Truffa-Bachi P. T cell activation by concanavalin A in the presence of cyclosporin A: 
Immunosuppressor withdrawal induces NFATp translocation and interleukin-2 gene 
transcription. Eur J Immunol. 1996;26(7):1481–8.  
249.  Tetsu K, Junqing C, Yasuhiko K, Isao T, Yoshikatsu K, Kazuhiro M, et al. CD1d-Restricted and 
TCR-Mediated Activation of Va14 NKT Cells by Glycosylceramides. Science (80- ) . 
1997;278(November):1626–9.  
250.  Palacios R. Concanavalin A triggers T lymphocytes by directly interacting with their receptors 
for activation. J Immunol . 1982 Jan;128(1):337–42. 
251.  Yagi J, Arimura Y, Takatori H, Nakajima H, Iwamoto I, Uchiyama T. Genetic background 
influences Th cell differentiation by controlling the capacity for IL-2-induced IL-4 production by 
naive CD4+ T cells. Int Immunol. 2006;18(12):1681–90.  
Page 208 of 212 
 
252.  O’Shea JJ, Gadina M, Siegel R. 9 - Cytokines and cytokine receptors. In: Rich RR, Fleisher 
TA, Shearer WT, Schroeder HW, Frew AJ, Weyand CM, editors. Clinical Immunology (Fourth 
Edition) . Fourth Edi. London: Content Repository Only!; 2013. p. 108–35. 
253.  Puglia CD, Powell SR. Inhibition of cellular antioxidants: a possible mechanism of toxic cell 
injury. Environ Health Perspect. 1984;57(7):307–11.  
254.  Cuff CA, Schwartz J, Bergman CM, Russell KS, Bender JR, Ruddle NH. Lymphotoxin alpha3 
induces chemokines and adhesion molecules: insight into the role of LT alpha in inflammation 
and lymphoid organ development. J Immunol. 1998;161(12):6853–68560.  
255.  Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev 
Immunol . 1997;15(1978):749–95.  
256.  Paludan SR. Interleukin-4 and interferon-γ: The quintessence of a mutual antagonistic 
relationship. Scand J Immunol. 1998;48(5):459–68.  
257.  Shibaki A, Si K. Induction of skewed Th1 / Th2 T differentiation via subcutaneous 
immunization with Freund ’ s adjuvant. Exp Dermatol. 2002;11(2):126–34.  
258.  Jackson SH, Devadas S, Kwon J, Pinto LA, Williams MS. T cells express a phagocyte-type 
NADPH oxidase that is activated after T cell receptor stimulation. Nat Immunol. 
2004;5(8):818–27.  
259.  Holmdahl R, Sareila O, Olsson LM, Bäckdahl L, Wing K. Ncf1 polymorphism reveals oxidative 
regulation of autoimmune chronic inflammation. Immunol Rev. 2016;269(1):228–47.  
260.  Hultqvist M, Olsson LM, Gelderman KA, Holmdahl R. The protective role of ROS in 
autoimmune disease. Vol. 30, Trends in Immunology. 2009. p. 201–8.  
261.  Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune 
system. Vol. 9, Nature Reviews Immunology. 2009. p. 162–74.  
262.  Lee K, Won HY, Bae MA, Hong J-H, Hwang ES. Spontaneous and aging-dependent 
development of arthritis in NADPH oxidase 2 deficiency through altered differentiation of 
CD11b+ and Th/Treg cells. Proc Natl Acad Sci. 2011;108(23):9548–53.  
263.  Garnero P. New biochemical markers of osteoarthritis . First Edit. Vol. 2, Aging Health. 
Elsevier Inc.; 2006. 639–647 p.  
264.  De Bri E, Reinholt FP, Heinegård D, Mengarelli-Widholm S, Norgård M, Svensson O. Bone 
sialoprotein and osteopontin distribution at the osteocartilaginous interface. Clin Orthop Relat 
Res. 1996;(330):251–60.  
Page 209 of 212 
 
265.  Mudgett JS, Hutchinson NI, Chartrain NA, Forsyth AJ, Mcdonnell J, Singer II, et al. 
Susceptibility of stromelysin 1-deficient mice to collagen-induced arthritis and cartilage 
destruction. Arthritis Rheum. 1998;41(1):110–21.  
266.  Yasuda Y, Kaleta J, Brömme D. The role of cathepsins in osteoporosis and arthritis: Rationale 
for the design of new therapeutics. Adv Drug Deliv Rev. 2005;57(7):973–93.  
267.  Garnero P, Borel O, Byrjalsen I, Ferreras M, Drake FH, McQueney MS, et al. The 
collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem. 
1999;273(48):32347–52.  
268.  Kafienah W, Brömme D, Buttle DJ, Croucher LJ, Hollander AP. Human cathepsin K cleaves 
native type I and II collagens at the N-terminal end of the triple helix. Biochem J . 1998 May 
1;331 ( Pt 3:727–32.  
269.  Hou WS, Li Z, Büttner FH, Bartnik E, Brömme D. Cleavage site specificity of cathepsin K 
toward cartilage proteoglycans and protease complex formation. Biol Chem. 2003;384(6):891–
7.  
270.  Gelderman KA, Hultqvist M, Pizzolla A, Zhao M, Nandakumar KS, Mattsson R, et al. 
Macrophages suppress T cell responses and arthritis development in mice by producing 
reactive oxygen species. 2007;117(10).  
271.  Burkholder T, Foltz C, Karlsson E, Linton CG, Joanne M. Health Evaluation of Experimental 
Laboratory Mice. Curr Protoc Mouse Biol 2012 Jun; 2 145–165. 2013;2(Jun):145–65.  
272.  Zhang X, Majlessi L, Deriaud E, Leclerc C, Lo-Man R. Coactivation of Syk Kinase and MyD88 
Adaptor Protein Pathways by Bacteria Promotes Regulatory Properties of Neutrophils. 
Immunity . 2009;31(5):761–71.  
273.  Hultqvist M, Olofsson P, Holmberg J, Bäckström BT, Tordsson J, Holmdahl R. Enhanced 
autoimmunity, arthritis, and encephalomyelitis in mice with a reduced oxidative burst due to a 
mutation in the Ncf1 gene. Proc Natl Acad Sci U S A. 2004;101(34):12646–51.  
274.  Pizzolla A, Wing K, Holmdahl R. A Glucose-6-Phosphate Isomerase Peptide Induces T and B 
Cell e Dependent Chronic Arthritis in C57BL / 10 Mice Arthritis without Reactive Oxygen 
Species and Complement. Am J Pathol . 2013;183(4):1144–55.  
275.  WHO guidance. The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the 
diagnosis and screening of active tuberculosis in people living with HIV. World Heal Organ. 
2015;(October).  
276.  Who. Global tuberculosis report 2018. WHO Press release. 2019;  
Page 210 of 212 
 
277.  Dutta NK, Karakousis PC. Latent Tuberculosis Infection: Myths, Models, and Molecular 
Mechanisms. Microbiol Mol Biol Rev. 2014;78(3):343–71.  
278.  Källenius G, Correia-Neves M, Buteme H, Hamasur B, Svenson SB. Lipoarabinomannan, and 
its related glycolipids, induce divergent and opposing immune responses to Mycobacterium 
tuberculosis depending on structural diversity and experimental variations. Tuberculosis. 
2016;96:120–30.  
279.  Karakousis PC, Bishal WR, Dorman SE. Mycobacterium tuberculosis cell envelope lipids and 
the host immune response. Cell Microbiol. 2004;6(2):105–16.  
280.  Saraav I, Singh S, Sharma S. Outcome of Mycobacterium tuberculosis and Toll-like receptor 
interaction: Immune response or immune evasion? Immunol Cell Biol. 2014;92(9):741–6.  
281.  Van Crevel R, Kleinnijenhuis J, Oosting M, Joosten LAB, Netea MG. Innate immune 
recognition of mycobacterium tuberculosis. Clin Dev Immunol. 2011;2011.  
282.  Kim KD, Lee HG, Kim JK, Park SN, Choe IS, Choe YK, et al. Enhanced antigen-presenting 
activity and tumour necrosis factor-α- independent activation of dendritic cells following 
treatment with Mycobacterium bovis bacillus Calmette-Guerin. Immunology. 1999;97(4):626–
33.  
283.  Nigou J, Gilleron M, Puzo G. Lipoarabinomannans: From structure to biosynthesis. Biochimie. 
2003;85(1–2):153–66.  
284.  Briken V, Porcelli SA, Besra GS, Kremer L. Mycobacterial lipoarabinomannan and related 
lipoglycans: From biogenesis to modulation of the immune response. Mol Microbiol. 
2004;53(2):391–403.  
285.  Choudhary A, PATEL D, Pinter A. Novel anti-lam and anti-pim6/lam monoclonal antibodies for 
diagnosis and treatment of mycobacterium tuberculosis infections. 2017;6(12).  
286.  Zhang S, Wu Q, Lei H, Zheng H, Zhou F, Sun Z, et al. Mannosylated structures of 
mycobacterial lipoarabinomannans facilitate the maturation and activation of dendritic cells. 
Cell Immunol . 2018;(November):0–1.  
287.  Cooper AM, Mayer-Barber KD, Sher A. Role of innate cytokines in mycobacterial infection. 
Mucosal Immunol . 2011;4(3):252–60.  
288.  Kimura A, Kishimoto T. IL-6: Regulator of Treg/Th17 balance. Eur J Immunol. 
2010;40(7):1830–5.  
289.  Paul WE.  Th1 Fate Determination in CD4 + T Cells: Notice Is Served of the Importance of IL-
12! . J Immunol. 2008;181(7):4435–6.  
Page 211 of 212 
 
290.  Harris JP, Lopman BA, O’Brien SJ. Infection control measures for norovirus: a systematic 
review of outbreaks in semi-enclosed settings. J Hosp Infect . 2010;74(1):1–9.  
291.  Champsi J, Young LS, Bermudez LE. Production of TNF-alpha, IL-6 and TGF-beta, and 
expression of receptors for TNF-alpha and IL-6, during murine Mycobacterium avium infection. 
Immunology . 1995;84(4):549–54.  
292.  Bean AG, Roach DR, Briscoe H, France MP, Korner H, Sedgwick JD, et al. Structural 
deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened 
susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by 
lymphotoxin. J Immunol . 1999 Mar 15;162(6):3504–11.  
293.  Feinberg H, Mitchell DA, Drickamer K, Weis WI. Structural basis for selective recognition of 
oligosaccharides by DC-SIGN and DC-SIGNR. Science (80- ). 2001;294(5549):2163–6.  
294.  Hunter SW, Brennan PJ. Evidence for the presence of a phosphatidylinositol anchor on the 
lipoarabinomannan and lipomannan of Mycobacterium tuberculosis. J Biol Chem . 1990 Jun 
5;265(16):9272–9. 
295.  Kaur D, Lowary TL, Vissa VD, Crick DC, Brennan PJ. Characterization of the epitope of anti-
lipoarabinomannan antibodies as the terminal hexaarabinofuranosyl motif of mycobacterial 
arabinans. Microbiology. 2002;148(10):3049–57.  
296.  Haji-Ghassemi O, Blackler RJ, Young NM, Evans S V. Antibody recognition of carbohydrate 
epitopes. Glycobiology. 2015;25(9):920–52.  
297.  McMichael AJ, Pilch JR, Fabre JW, Mason DY, Galfré G, Milstein C. A human thymocyte 
antigen defined by a hybrid myeloma monoclonal antibody. Eur J Immunol. 1979;9(3):205–10.  
298.  Gomez CR, Boehmer ED, Kovacs EJ. The aging innate immune system. Curr Opin Immunol. 
2005;17(5):457–62.  
299.  Stegmann M, Barclay AN, Metcalfe C. Reduction of leucocyte cell surface disulfide bonds 
during immune activation is dynamic as revealed by a quantitative proteomics workflow (SH-
IQ). Open Biol. 2018;8(9).  
300.  Svensson A, Sandberg T, Siesjö P, Eriksson H. Sequestering of damage-associated molecular 
patterns (DAMPs): a possible mechanism affecting the immune-stimulating properties of 
aluminium adjuvants. Immunol Res. 2017;65(6):1164–75.  
301.  Lotosh NY, Aliaseva SO, Malashenkova IK, Sorokoumova GM, Vasilov RG, Selischeva AA. 
Cationic Liposomes Cause ROS Generation and Release of Neutrophil Extracellular Traps. 
Biochem Suppl Ser A Membr Cell Biol. 2019;13(1):40–9.  
Page 212 of 212 
 
302.  van Dissel JT, Joosten S a, Hoff ST, Soonawala D, Prins C, Hokey D a, et al. A novel 
liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific 
T-cell responses in human. Vaccine . 2014;32(52):7098–107.  
303.  Yu B, Lee RJ, Lee LJ. Microfluidic Methods for Production of Liposomes. Methods Enzymol. 
2009;465(C):129–41.  
 
